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1 Introduction 
1.1 Trefoil factor family (TFF)  
1.1.1 TFF peptides 
The trefoil factor family (TFF) peptides belong to a family of mucin-associated small 
proteins containing seven conserved cysteine residues (Wright et al., 1997; Emami et 
al., 2004; Hoffmann, 2006). There are three members in the TFF family: TFF1, TFF2 
and TFF3. All three TFF genes are clustered on chromosome 21q22.3 in a head-to-tail 
arrangement within a 54.5 kb region in the order of “telomere-TFF1-TFF2-TFF3- 
centromere” and the transcription directed toward the centromere (Beck et al., 1996; 
Chinery et al., 1996; Gött et al., 1996; Seib et al., 1997; Hoffmann, 2013a; Figure 1).   
 
Figure 1: The region encoding human trefoil peptides on chromosome 21q22.3  
Genomic organization of the human TFF gene locus harboring the genes hTFF1, hTFF2 and 
hTFF3. The orientation of the telomere (tel) and the centromere (cen) as well as the nucleotide 
positions are indicated. The introns are shown as I1, I2 or I3 with corresponding size. The exons 
(E) encoding the signal peptide (typical precursors of secretory proteins) are marked by dots, the 
TFF domains are shown in black. The size bar refers to these coding regions. The figure is 
modified from Seib et al. (1997) and Hoffmann (2013a). 
All TFF peptides are synthesized via precursors containing a cleavable N-terminal 
signal sequence typical of secretory proteins. As a hallmark, they contain the unique 
TFF module comprised of about 42 amino acid residues and defining the TFF domain 
(formerly P-domain or trefoil domain; Thim, 1989; Hoffmann & Hauser, 1993; Wright et 
al., 1997; Thim & May, 2005; Hoffmann, 2013a). Intramolecular disulfide bridges are 
formed from six of the conserved cysteine residues in the order of C
1
–C
5
, C
2
–C
4
, C
3
–C
6
 
resulting in the characteristic three loop structure of the TFF domain (Thim & May, 
2005). A planar projection of this structure resembles a trefoil (Hoffmann, 2013a; 
Figure 2). The complex pattern of disulfide bridges is probably one reason for the 
remarkable resistance of TFFs against proteolytic degradation, particularly in the 
stomach (Thim & May, 2005; Kjellev, 2009). 
Not only the monomeric forms (Polshakov et al. 1997; Newton et al. 2000; Lemercinier 
et al. 2001; May et al. 2009) but also homodimeric and heterodimeric forms of TFF 
peptides have been detected in vivo (Gajhede et al., 1993; Chadwick et al., 1997; 
Newton et al., 2000; Thim & May, 2005; Kouznetsova et al., 2007b; May et al., 2009; 
Albert et al., 2010). The seventh free cysteine residue is essential for the formation of 
the dimeric forms of TFF1 and TFF3 (Chinery et al., 1995; Thim et al., 1995; Polshakov 
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et al., 1997; Williams et al., 2001; Muskett et al., 2003). In the human gastrointestinal 
(GI) tract, all TFFs are capable of forming heteromers with different partner proteins 
(Figure 2). 
A B 
  
 
Figure 2: Structure of a typical Trefoil domain and different forms 
of TFF peptides in the mammalian GI tract 
Schematically represented are: (A) typical disulphide-bond formation of 
the TFF domain (based on human TFF1). The conserved TFF domain 
(42 amino acids) is indicated in black with the proposed intradomain 
disulphide bonds; the amino acids outside of the trefoil domain are 
shown in grey; the seventh cysteine residue, at position 58, is shown in 
white (grey background) and in its reduced form; (B) the TFF1–GKN2 
heteromer, the monomeric form of TFF2 (including the additional 
disulfide bridge), the high molecular weight complex of TFF2 (partner X 
is not known thus far) and the TFF3–FCGBP heteromer. The TFF1 and 
TFF3 heteromers are disulfide-linked. The figures are modified from 
Chadwick et al. (1995) and Hoffmann (2013) 
The first discovered TFF member is TFF1 (formerly named pS2/BCEI/pNR-2/pNR-105/ 
Md2). It has been initially found in the MCF-7 human breast cancer cell line, described 
as an estrogen-responsive gene (Masiakowski et al., 1982; Jakowlew et al., 1984; 
Nunez et al., 1987). The human TFF1 gene codes for a small preprotein of 84 amino 
acids containing an amino terminal signal peptide characteristic of secreted proteins 
(Jakowlew et al., 1984; Rio et al., 1988b; Ribieras et al., 1998) . The secreted mature 
form of TFF1 contains 60 amino acids (MW: ~6.67 kDa), forming one trefoil domain 
(Jakowlew et al., 1984; Rio et al., 1988a; Thim, 1989). TFF2 (formerly named 
[P]SP/[pancreatic] spasmolytic polypeptide) has originally been detected in porcine 
pancreas during purification of insulin (Jørgensen et al. 1982; Tomasetto et al. 1990; 
De et al. 1994; Beck et al. 1996). It contains 106 amino acids (MW: ~12 kDa) and 
consists of two TFF domains (Thim, 1997; Thim & May, 2005). TFF3 (formerly named 
ITF/P1.B), the last known mammalian member of the trefoil family, was recognized 
originally in rat intestine (Suemori et al., 1991) and the human sequence was reported 
later (Hauser et al., 1993; Podolsky et al., 1993). It contains 59 amino acids (MW: ~6.6 
kDa) forming one trefoil domain.  
1.1.2 Expression of TFF peptides 
TFF peptides are mainly expressed by normal mucous epithelial cells, predominantly 
found in the GI tract as exocrine products (Wong et al., 1999; Hoffmann & Jagla, 2002; 
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Kjellev, 2009). They are also expressed in other parts of the human body, like the 
respiratory tract (Hoffmann, 2007), the salivary glands (Kouznetsova et al., 2010) and 
the pancreas (Guppy et al., 2012). Furthermore, TFF peptides are detectable in the 
human serum (Miyashita et al., 1994; Higashiyama et al., 1996; Grønbaek et al., 2006), 
urine (Rinnert et al., 2010) and are also found in minute amounts in the brain as 
neuropeptides (Hirota et al., 1994a, 1994b, 1995; Hinz et al., 2004). 
1.1.2.1 TFF peptides in the gastrointestinal (GI) tract  
TFF peptides are expressed in a tissue-specific manner within the GI tract (Table 1), 
which is the predominant expression site of all three TFF peptides (Madsen et al., 
2007; Hoffmann, 2013a) and are probably involved in various mucosal protection and 
repair processes. 
Table 1: TFF peptides and co-expressed secretory mucins in the human GI tract 
Organ Cell TFF Peptid Secretory mucin 
Stomach Cardiac and antral SMCs TFF1, TFF3 MUC5AC 
 Corpus SMCs 
(surface mucous cell) 
TFF1 MUC5AC 
 Mucous neck cells TFF2 MUC6 
 Antral gland cells TFF2 MUC6 
Intestine Brunner's glands TFF2, TFF3 MUC6 
 Goblet cells TFF3 MUC2 
The table is adapted from Hoffmann (2013a) 
The major expression site of TFF1 is the stomach. Tff1 is expressed predominantly by 
the surface mucous cells (SMCs) in the surface/foveolar epithelium (Rio et al., 1988a; 
Luqmani et al., 1989; Tomasetto et al., 1990; Hauser et al., 1993; Machado et al., 1996, 
2000; Karam et al., 2004; Ruchaud-Sparagano et al., 2004; Hoffmann, 2012). A 
relative high level of TFF1 expression has also been described in the upper ducts and 
surface cells of Brunner’s glands in the duodenum (Hanby et al., 1993). The 
expression of TFF1 has also been observed in the intestinal part of the GI tract, e.g. 
the small and large intestine and rectum (Singh et al., 1998; Madsen et al., 2007). 
TFF2 is mainly expressed in the stomach (Madsen et al., 2007) and secreted by gastric 
mucous neck cells and antral gland cells (Tomasetto et al. 1990; Hanby et al. 1993; 
Nogueira et al. 1999; Machado et al. 2000; Ota et al. 2006). In the duodenum, TFF2 
expression is detected in acini and distal ducts of Brunner’s glands (Piggott et al., 1991; 
Regalo et al., 2005). TFF2 expression was also shown in the mouse and rat antrum as 
well as in the intestine in only small amounts (Lefebvre et al., 1993; Cook et al., 1999). 
Additionally, Tff2 mRNA was reported to be expressed in the porcine ileum (Scholven 
et al., 2009). TFF3 secretion was demonstrated in deep laying SMCs of the antrum, the 
pyloric region and the proximal duodenum (Hoffmann & Jagla, 2002; Kouznetsova et 
al., 2004). The major expression sites of TFF3 are the goblet cells throughout the 
human and rodent intestine and also the gland acini and distal ducts of Brunner’s 
glands (Suemori et al., 1991; Hauser et al., 1993; Podolsky et al., 1993). 
In general, the multiple molecular functions of TFF peptides include (a) constituents of 
mucus barriers, (b) enhancement of rapid mucosal repair by cell migration 
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(“restitution”), (c) modulation of mucosal differentiation processes and (d) modulation 
of the mucosal immune response (Hoffmann, 2006, 2013b). Previous studies clearly 
demonstrated the protective and healing effects of all three TFF peptides after various 
mucosal damages (Hoffmann & Jagla, 2002; Zhang et al., 2003; Beck et al., 2004; 
FitzGerald et al., 2004; Poulsen et al., 2005; Hoffmann, 2006). TFFs support a variety 
of different mucosal defence and repair mechanisms, synergistically enhancing the 
surface integrity of the gastrointestinal mucosa and interact with mucins, influencing 
the rheological properties of viscoelastic mucous gels (Wong et al., 1999; Thim et al., 
2002; Hoffmann, 2004, 2013a). The protective effect of TFF1 is reported in the jejunum 
of a transgenic mouse over-expressing Tff1, where the extent of jejunal damage 
caused by indomethacin was markedly reduced when compared with control animals 
(Playford et al., 1996). Both Tff2 and Tff3 peptides were shown to enhance cell 
migration in the restitution phase of primary rabbit corneal epithelial cells in vitro (Göke 
et al., 2001). TFF3 is reported to protect the intestinal epithelial barrier function by 
interaction with mucins in human (Kindon et al., 1995) and to enhance the 
re-epithelialization of corneal wounds in the mouse (Paulsen et al., 2008). Moreover, 
all three lines of Tff-deficient mice showed mucosal abnormalities: Tff1-deficient mice 
developed obligatory antropyloric adenomas, 30% of which progressed to carcinomas 
(Lefebvre et al., 1996), Tff2-deficient mice had an increased number of parietal cells 
and showed increased susceptibility to gastric injury (Farrell et al., 2002), Tff3-deficient 
mice showed a decreased resistance to colonic damage by dextran sulfate sodium 
(DSS; Mashimo et al., 1996).  
Many studies demonstrated a motogenic effect of all three TFF peptides (Dignass et al., 
1994; Playford et al., 1995; Poulsom, 1996; Hoffmann & Jagla, 2002; Dürer et al., 2007; 
Hoffmann, 2009). Their enhancing effect on cell migratory processes has been shown 
in various epithelial cell lines (Hoffmann et al., 2001; Hoffmann & Jagla, 2002) pointing 
to a chemotactic but not a chemokinetic effect on cell migration (Chwieralski et al., 
2004; Hoffmann, 2009). There is increasing evidence indicating that TFF peptides 
modulate various mucosal differentiation processes that are crucial for the continuous 
regeneration of mucous epithelia from stem cells (Hoffmann, 2007, 2008), e.g., TFF1 is 
required for the commitment programme of mouse oxyntic epithelial progenitors 
(Karam et al., 2004). TFF1 expression is up-regulated after mucosal injury (Rio et al., 
1991; Wright et al., 1992; Taupin & Podolsky, 2003) and after total wounding (multi 
scratch assay) in the transformed human bronchial epithelial cell line (BEAS-2B) and 
human lung adenocarcinoma epithelial cell line (A549; Znalesniak, 2013).  
TFFs were also demonstrated to participate in immune responses and inflammatory 
processes (Poulsen et al., 2005; Hoffmann, 2009; McBerry et al., 2012). TFF2 
expression is found to be present in macrophages and lymphocytes (Göke et al., 2001; 
Kurt-Jones et al., 2007). The inflammatory and proliferative responses of these 
immune cells were shown to be dysregulated in TFF2-deficient mice (Kurt-Jones et al., 
2007). Not only TFF2 but also TFF3 expression has been observed in lymphoid tissues 
(e.g. spleen, lymph nodes and bone marrow; Cook et al., 1999). They both are shown 
to play a role in gastrointestinal inflammation and systemic immune responses 
(Baus-Loncar et al., 2005a; Poulsen et al., 2005; Kurt-Jones et al., 2007). A recent 
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study demonstrated that Tff2 suppresses Toxoplasma gondii driven type 1 
inflammation in mice (McBerry et al., 2012). 
1.1.2.2 TFF peptides in the central nervous system (CNS) 
The expression level of TFF peptides in the CNS is much lower when compared with 
the GI tract. Previous studies showed the expression of TFFs in the brain of human 
and mouse (Hirota et al., 1994a, 1994b, 1995; Probst et al., 1995, 1996; Schwarzberg 
et al., 1999; Reymond et al., 2002; Hinz et al., 2004). In human, both TFF3 mRNA and 
protein was found in the hypothalamus and pituitary (Probst et al., 1995, 1996; Jagla et 
al., 2000). TFF3 peptide was also detected in the posterior lobe of pituitary and 
postmortem cerebrospinal fluid (Jagla et al., 2000). 
In the mouse, Tff1 mRNA is weakly expressed throughout the brain (Hinz et al., 2004) 
and has been identified in cultured mouse astrocytes (Hirota et al., 1994a, 1994b). 
Biosynthesis of TFF2 in the CNS has rarely been described. Faint level of Tff2 
transcription has been reported in the mouse brain, with a higher concentration in the 
anterior but not the posterior lobe of the pituitary (Hinz et al., 2004). Recently, Tff2 
expression was found in the murine retina starting as early as embryonic day E15 and 
gradually increasing after postnatal day P5, with a high expression levels at P15 
(Paunel-Görgülü et al., 2011). In contrast, Tff3 expression is limited to the 
hippocampus, the temporal cortex and the cerebellum and the latter is the major site of 
expression (Hinz et al., 2004). Moreover, a maximum expression of Tff3 was shown in 
the mouse brain at P15 (Hinz et al., 2004). The high-resolution atlas of gene 
expression throughout the adult mouse brain (in situ hybridization (ISH) data) from the 
Allen Brain Atlas (http://mouse.brain-map.org/) shows that Tff1 positive cells are mainly 
found in the hippocampus and cerebellum, especially in the granular layer and Purkinje 
cells.  
In the rat, Tff1 is widely distributed throughout the adult rat brain and the pronounced 
expression was found in the hippocampus, frontal cortex and the cerebellum (Hirota et 
al., 1995). TFF1 expression was also detected in the substantia nigra pars compacta, 
the ventral tegmental area and in periaqueductal areas of adult rat midbrain, 
exclusively in neurons and not in astrocytes (Jensen et al., 2013). There is still no data 
published concerning Tff2 in the rat brain. TFF3 expression is found predominantly in 
the rat cerebellum, and also in hippocampus, amygdala and cortex, especially in 
magnocellular neurons of the hypothalamus (Probst et al., 1995).  
The role of TFF peptides in the CNS is probably diverse and has not yet been clarified. 
TFFs have been described as the factors influencing the development of the CNS; e.g., 
rat hippocampal Tff1 mRNA is restricted mainly to astrocytes and its expression 
decreases significantly during postnatal development at P7 (Hirota et al., 1995). Mouse 
Tff3 has been demonstrated as a typical neuropeptide of oxytocinergic neurons of the 
supraoptic and paraventricular nuclei (Hoffmann & Jagla, 2002) and improves learning 
and retention of novel object recognition memory in mice (Shi et al., 2012). Generally, 
TFF peptides are expected to act as neurotransmitters/neuromodulators (Hoffmann & 
Jagla, 2002). For example, injected TFF3 in the basolateral nucleus of rat amygdala 
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exhibits fear-modulating activities (Schwarzberg et al., 1999).  
Some in vitro studies show an anti-apoptotic effect of TFF peptides in different cell 
culture systems (e.g., gastric, intestinal, colorectal or breast cancer cell lines; Lalani et 
al., 1999; Chen et al., 2000; Kinoshita et al., 2000; Taupin et al., 2000; 
Bossenmeyer-Pourié et al., 2002; Siu et al., 2004). Interestingly, in contrast to the 
survival promoting and anti-apoptotic effects, also pro-apoptotic activity was reported. 
The application of recombinant TFF3 to cultured primary human chondrocytes caused 
increased apoptosis in vitro (Rösler et al., 2010). Moreover, the pro-proliferative and 
pro-apoptotic effects of Tff2 in the developing mouse retina cultured as organotypic 
whole mounts in vivo were demonstrated as well (Paunel-Görgülü et al., 2011). 
Nevertheless, there were no obvious neural abnormalities reported in Tff1-, Tff2-, or 
Tff3-deficient mice (Lefebvre et al., 1996; Mashimo et al., 1996; Farrell et al., 2002). 
However, from experiments with Tff3-deficient mice a participation of Tff3 in 
neurosensory signalling has been suggested (Lubka et al., 2008).  
1.1.2.3 Pathological expression of TFF peptides 
Generally, TFF peptides are aberrantly expressed in inflammatory diseases and in a 
variety of neoplastic disorders (Wong et al., 1999; Hoffmann et al., 2001; Emami et al., 
2004; Tomasetto & Rio, 2005; Kjellev, 2009; Hoffmann, 2013a).  
TFF expression is dysregulated during a wide range of inflammatory diseases, e.g. 
ileal Crohn's disease, ulcerative colitis, inflammatory bowel disease, gastric ulcer 
disease, acute cholecystitis, various types of metaplasia, different hyperplastic polyps, 
Barrett's oesophagus and pancreatitis (Hoffmann et al., 2001; Hoffmann & Jagla, 
2002). Furthermore, it was shown that the expression of TFFs is a typical response 
after gastric mucosal damage in various rat models of experimental ulceration (Alison 
et al., 1995; Hoffmann et al., 2001). Under these conditions, a unique glandular 
structure known as the ulcer-associated cell lineage (UACL) is a prominent site of TFF 
synthesis. The UACL delivers its secretion products, including EGF, to the lumen via 
excretory ducts and is thought to represent a natural repair kit activated after mucosal 
damage (Wong et al., 1999; Kjellev, 2009; Hoffmann, 2013a). Moreover, TFF genes 
are differentially expressed within the UACL, e.g., TFF1 (together with MUC5AC) and 
TFF2 (together with MUC6 and EGF) were detected respectively in the upper and 
lower parts of the structure (acinar and proximal ductular structures) and TFF3 
(together with MUC5B, TGF-α, and lysozyme) was infrequently detected in all parts of 
the UACL (Hoffmann & Jagla, 2002; Kjellev, 2009). TFF1 and TFF3 are considered to 
play an important role in the different responses of the stomach and the intestine to 
inflammation. An increased level of TFF1 expression was reported particularly during 
the healing of gastric ulcers (Saitoh et al., 2000) and TFF1 is also expressed during the 
acute phase of acid-induced colitis in the rat rectum (Itoh et al., 1996). Deregulation of 
TFFs is observed also after incisional wounds of GI tissue, in various induced gastric 
ulcerations as well as after irradiation and chemotherapy. Particularly, the late and 
sustained TFF1 and TFF3 responses are indicative for a role in late-stage repair 
processes (Hoffmann & Jagla, 2002). All the studies also provide the circumstantial 
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evidences that TFF peptides are differently involved in the mucosal epithelial 
regeneration (Hoffmann, 2013a). 
Inflammation is a critical component of tumour progression. Pathological expression of 
TFFs is also observed in premalignant conditions, e.g. Barrett’s metaplasia and 
metaplastic polyps, and dysregulated biosynthesis of TFFs is found in many epithelial 
tumours, e.g. in the esophagus, stomach, biliary tract, pancreas and intestine 
(Hoffmann & Jagla, 2002; Emami et al., 2004; Tomasetto & Rio, 2005). Moreover, 
aberrant expression of the TFFs has been reported for a variety of important solid 
tumours in humans, including gastric, intestinal, breast, prostate and lung cancers 
(Perry et al., 2008; Kjellev, 2009). Furthermore, unusual TFF plasma levels are 
indicative for the progression of certain cancers and can improve, for example, gastric 
cancer screening (Hoffmann, 2013a). All these data suggest a role of TFFs in the 
development and progression of human cancer. Particularly, expression of TFF1 is 
elevated in gastric mucosa with atypical hyperplasia and is not observed in poorly 
differentiated or intestinalized gastric cancer (Wong et al., 1999). Furthermore, the 
co-expression of TFF1 and GKN2 that normally form a heterodimer, is deregulated in 
gastric cancer (May et al., 2009). TFF3 is a marker for bad prognosis of both stomach 
and colon carcinomas and formation of the TFF3–FCGBP heteromer seems to be 
deregulated during colon carcinogenesis (Albert et al., 2010; Hoffmann, 2013a). 
In conclusion, TFF peptides are considered to play important roles not only in the 
physiological wound healing but also in the inflammatory processes, carcinogenesis, 
and metastasis. 
1.2 Mucosal protection and repair 
The large surface of the GI tract is exposed to numerous noxious agents and is vital for 
the complex communication with the environment. The protective mechanisms of the 
intestinal epithelium can be divided into three key components: (1) stratified mucus 
layer together with the glycocalyx of the epithelial cells, which provides a physical 
protection; (2) the single layer of epithelial cells forming a continuous cell sheet 
interconnected with tight junctions, which is characterized by self-renewal and 
restitution; (3) resident macrophages and dendritic cells (DCs) of the intestinal stroma 
completing the elements of the innate immune system. Furthermore, the adaptive 
immune system builds the fourth defence line both as master regulator and as an 
inducible system to remove microbiota that have sidestepped earlier defence lines 
(Sonnemann & Bement, 2011; Hansson, 2012). 
1.2.1 Mucus 
Mucus is an adhesive mixture of approximately 95% water, 5% mucin glycoprotein 
molecules, salts, immunoglobulins, cellular and serum macromolecules, as well as the 
mucin-associated TFF peptides, forming a continuous gel layer (Allen & Pearson, 
1993; Wong et al., 1999; Hoffmann & Jagla, 2002). This mucous gel layer covers the 
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mucosa throughout the GI tract and is, e.g., capable of withstanding the pH gradient in 
the stomach from acidic on its luminal side to near neutral at its apical cell membrane 
perimeter (Quigley & Turnberg, 1987). Generally, the mucus layer acts as a diffusion 
barrier against noxious agents, entraps microorganisms and interacts with the immune 
surveillance system (Allen & Pearson, 1993; Atuma, 2000). Moreover, it delivers also 
the tolerogenic signals to DCs influencing the function of intestinal antigen-presenting 
cells (e.g. DCs) and epithelial cells and thereby constrain the immunogenicity of gut 
antigens (Belkaid & Grainger, 2013; Shan et al., 2013).  
The gel-forming mucins such as MUC2, MUC5AC and MUC6 are secreted by 
gastrointestinal mucous cells (Matsuda et al., 2008; Johansson et al., 2011). The 
localization of the mucins varies throughout the GI tract (Table 1). In the stomach, 
MUC5AC together with TFF1 and MUC6 together with TFF2 are generally expressed 
in the surface epithelial cells and mucous neck cells, respectively. In the small intestine 
and colon, MUC2 is the one dominating mucin secreted from goblet cells together with 
TFF3 (Ho et al., 1995; Wong et al., 1999; Hoffmann & Jagla, 2002; Albert et al., 2010; 
Hoffmann, 2013a). Recently, different mucus structures in the GI tract have been 
revealed. The stomach and colon were reported to have a two-layered mucus 
structure, from which the inner mucus layer is firmly attached to the epithelium and the 
outer mucus layer is easily removed and has a less defined outer border. In contrast, 
the small intestine has only one layer of mucus (Hansson, 2012) suggesting different 
protective mechanisms in the stomach and intestine.  
1.2.2 Gastric self-renewal and restitution 
When the mucus layer is unable to inactivate the injurious components, the epithelial 
barrier acts as a second defence line (Tobey & Orlando, 1991; Orlando et al., 1992). 
This barrier is formed by epithelial cells linked together via cell-cell contacts (such as 
tight junctions, adherens junctions, and desmosomes; Balda & Matter, 2009).  
The repair of the epithelial barrier following injury is accomplished by two processes 
covering different time scales (Hoffmann, 2012). One process is the self-renewal 
(continuous regeneration). This is an essential component of the multiple protection 
and defence mechanisms maintaining the surface integrity. It takes several days to 
months to refresh the mucous epithelia throughout the adult life and is required for the 
repair of extensive and deep mucosal wounds (Hoffmann, 2008, 2013b). The typical 
feature of the gastric epithelial barrier is the continual bi-directional self-renewal 
occurring via differentiation of stem cells and progenitor cells within the isthmus 
followed by apoptosis of the mature cells at the end of their life cycles, respectively 
(Kouznetsova et al., 2011; Hoffmann, 2013b). Of note, the morphology and 
regeneration of the human stomach differ in some details from the rodent system 
(Hoffmann, 2008). The human stomach is divided histologically into three main regions: 
the fundus, corpus and pyloric antrum (Helander, 1981). The gastric epithelia, covered 
by surface mucous cells, differ much in their self-renewal rates and bidirectional 
renewal profiles. The antral units (combination of a pit [funnel-shaped faveolae] and a 
gland [divided into the isthmus, the neck, and the base region]) show a higher turnover 
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when compared with the corpus units (Figure 3; Hoffmann, 2008; Kouznetsova et al., 
2011). In addition to the isthmal somatic stem cells, at least a second stem cell 
population, defined by LGR5, is found at the bottom of the antral glands but not in 
fundic glands (Barker et al., 2010; Hoffmann, 2012). 
 
Figure 3: Schematic representation of the two gross types of human gastric units 
Two gross types of human gastric units: fundic- and antral unit, and their continual renewal from 
stem and transit amplifying cells. The major cell types and some of their characteristic secretory 
products are shown. MUC: mucin, GKN: gastrokine, LGR5: Leucine rich repeat containing G 
protein. This figure is reproduced from Kouznetsova et al. (2011). 
Nevertheless, minor disruptions of the surface layer of cells without damage of the 
basement membrane occur frequently, so speedy repair to restore epithelial continuity 
is essential. A sequence of events including epithelial cell dedifferentiation, forming of 
pseudopodia-like structures, reorganization of their cytoskeleton, migration into the site 
of defect to cover the exposed areas of the basement membrane and the 
redifferentiation after closure of the wound leading to a rapid epithelial repair has been 
referred as epithelial “restitution” (Silen & Ito, 1985; Taupin & Podolsky, 2003; 
Hoffmann, 2005; Sturm & Dignass, 2008). Restitution is a general phenomenon of 
mucous epithelia to superficial injury along the entire GI tract, as well as the respiratory 
tract, the urothelium, the oral epithelium, etc. (Hoffmann, 2005). It does not require cell 
proliferation and occurs within minutes to hours after the injury. Restitution is 
particularly well described to occur in the intestinal mucosa both in vivo (Feil et al., 
1989) and in vitro (Nusrat et al., 1992; Znalesniak & Hoffmann, 2010). In the stomach, 
surface mucous cells are the major players during restitution (Hoffmann, 2005). In vivo, 
epithelial cells undergo restitution converting from polarized epithelial cells (with 
apical-basal polarity) to polarized migrating cells (with planar polarity; 
Etienne-Manneville, 2008).  
Cell migration can be classified into single cell migration (amoeboid, mesenchymal) 
and collective migration modes (cell sheets, strands, tubes, clusters; Friedl, 2004; 
Friedl & Wolf, 2010). The collective cell migration as a cohesive group (maintaining 
cell–cell junctions) is typical of mucosal restitution (Znalesniak et al., 2009). The rat 
gastric cell line RGM-1 (Kobayashi et al., 1996) as an in vitro model for gastric 
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restitution (Nakamura et al., 1998; Osada et al., 1999; Ragasa et al., 2007) shows 
predominantly collective migration (Figure 4) and is appropriate for the investigation of 
wound healing. It is comparable to the best studied in vitro models of migrating 
intestinal IEC-6 and IEC-18 cells (McCormack et al., 1992; Znalesniak et al., 2009). As 
so far, the only known non-transformed gastric epithelial cell line RGM-1 is a promising 
tool for the study of the TFFs function during migration in vitro.  
 
 
 
Figure 4: Typical migratory RGM-1 cells after the wounding 
Under certain circumstances, epithelial cells may undergo an epithelial-mesenchymal 
transition (EMT) to become migratory (Hay, 1995; Savagner et al., 2005; 
Moreno-Bueno et al., 2008; Yang & Weinberg, 2008). The EMT is characterized by 
trans-differentiation of epithelial cells into fibroblastoid, motile cells, accompanied by 
changes in the gene expression program (Jechlinger et al., 2003; Huber et al., 2004; 
De Wever et al., 2008; Yang & Weinberg, 2008). The typical features for EMT are the 
down-regulation of epithelial-specific genes (e.g., tight- and adherens-junction proteins 
such as occludin and E-cadherin, respectively) and the induction of various 
mesenchymal genes (such as α-smooth muscle actin (α-SMA), vimentin and 
N-cadherin; Grünert et al., 2003; Lee et al., 2006; Znalesniak & Hoffmann, 2010). 
However, in vivo studies show that EMT is not complete in wound repair (Schäfer & 
Werner, 2008) and in vitro study shows that restitution is not fully accompanied by the 
unambiguous EMT (Znalesniak et al., 2009). 
The wound healing processe is modulated by numerous factors such as cytokines 
(Leaphart et al., 2007), growth factors (Sturm & Dignass, 2008), adhesion molecules 
(Ivanov et al., 2005), regulatory peptides (Moyer et al., 2007) including TFF peptides 
(Taupin & Podolsky, 2003; Hoffmann, 2005, 2008). TFFs contribute to mucosal 
defence and repair enhancement after various types of induced mucosal damage by 
modulation of cell-cell contacts, motogenic activity and synergy with epidermal growth 
factor (Hoffmann, 2005). 
1.2.3 Inflammatory process 
Inflammation is an adaptive and immediate response that is triggered by noxious stimuli 
and conditions, such as chemicals, infection or tissue injury (Cotran et al., 2004; 
Medzhitov, 2008; Weiss, 2008) and is mediated by tissue-resident leukocytes (e.g., 
macrophages), which can infiltrate the damaged region to remove the stimulus (Weiss, 
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2008; Sonnemann & Bement, 2011). The inflammatory response is regulated by 
various inflammatory mediators, like cytokines, chemokines, as well as small secreted 
proteins that are released by cells surrounding the damaged tissue and that act on 
immune system pathways leading to series of vascular and cellular reactions 
(Medzhitov, 2008). The vascular reactions resulting in the formation of inflammatory 
exudates include vasodilation with increased tissue perfusion and permeability. The 
cellular responses include the recruitment of leukocytes from the blood into the injured 
tissue by chemotaxis (margination and emigration) and the phagocytosis of invading 
microbes and apoptotic or necrotic cells (Böcker et al., 2008).  
Acute inflammation, as a component of wound healing, is a short-term response of the 
immune system to the damage. It usually limits the potential of infection and results in 
healing. A rapid repair of damaged mucosal epithelia is (therefore) essential for the 
prevention of chronic inflammation (Coussens & Werb, 2002). Furthermore, a 
prolonged, dysregulated and maladaptive response, which can be caused by the 
persistence of the initiating factors or a failure of mechanisms required for resolving the 
inflammatory reaction, as the hallmark of chronic inflammation (Coussens & Werb, 
2002; Weiss, 2008), plays a decisive role at different stages of tumour development and 
in gastric cancer (Houghton et al., 2004; Fox & Wang, 2007; Grivennikov et al., 2010; 
Hoffmann, 2013b). Dysregulated self-renewal in the course of chronic inflammation is 
the basis for the development of neoplasias (Radtke & Clevers, 2005; Vries et al., 
2010). Approximately 90% of all human cancers originate from abnormal epithelial cell 
proliferation (Nollet et al., 1999). There are studies reporting that TFFs, particularly 
TFF2 present in macrophages and lymphocytes (Kurt-Jones et al., 2007), can 
participate in and regulate the intestinal inflammatory processes and systemic immune 
responses (Baus-Loncar et al., 2005a, 2005b; Kurt-Jones et al., 2007) and also 
stimulate the migration of monocytes (Cook et al., 1999). 
1.3 Investigated projects 
TFF peptides are mainly expressed in the GI tract, where they not only play an 
important role in the wound healing of the gastrointestinal mucosa but also participate 
in the immune response. TFF peptides are also synthesized in the CNS. However, the 
function of TFF peptides in the CNS, especially in the immune response and during 
inflammatory processes is still unclear. In the context of the potential role of TFF 
peptides in wound healing and in the regulation of inflammatory processes of the GI 
tract and the CNS, four different model systems concerning various aspects of the 
synthesis and function of TFFs were investigated:  
(a) In vitro model for the restitution of gastric epithelial cells (RGM-1) including RNA 
interference (RNAi) to study the function of TFFs during this process (described in 
1.3.1). 
(b) Two in vivo mouse models of inflammatory diseases using Toxoplasma gondii (T. 
gondii) induced ileitis (oral infection) and encephalitis (i.p. infection) to study the 
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expression of TFFs during the immune responses and to examine the phenotype of 
Tff-deficient mice (described in 1.3.2; cooperation with Dr. I. Dunay [IMMB] and Prof. 
Dr. D. Schlüter / Dr. U. Händel [IMMB], Magdeburg). 
(c) In vitro study of the primary cell cultures of rat brain to study the cellular localization 
of TFFs in the rat brain (described in 1.3.3; cooperation with Prof. Dr. D. Dieterich / Dr. 
A. Stellmacher [IPT, Magdeburg]). 
1.3.1 Function of TFFs in an in vitro model of gastric restitution 
Here the non-transformed rat epithelial cell line RGM-1 (Kobayashi et al., 1996) was 
used as an in vitro restitution model. These cells are expected to show characteristics 
of surface mucous cells. An established technique to separate migratory and stationary 
cells in vitro allowed expression profiling of these cells (Znalesniak et al., 2009). 
Furthermore, RNAi was applied to investigate the function of TFFs for gastric 
restitution. 
RNA interference  
The mechanism of RNAi, discovered first in a worm (Fire et al., 1998) and then in 
mammalian cells (Elbashir et al., 2001), is a widely used method in biological and 
medical research. This RNA-dependent gene-specific silencing mechanism can be 
triggered both by endogenous and exogenous RNA and is used to drastically decrease 
the expression of a targeted gene (Hammond et al., 2000; Bartel, 2004). Since it may 
not totally abolish expression of the gene, this technique is sometimes referred as 
"knockdown", to distinguish it from "knockout" procedures in which expression of a 
gene is entirely eliminated.  
RNAi can be guided by small double-stranded RNA (dsRNA) including exogenous 
small interfering RNAs (siRNAs; Figure 5) or endogenous microRNAs (miRNAs). In the 
nucleus, endogenous dsRNAs with the imperfectly matched sequence to the target 
mRNA (Bernstein et al., 2001), in form of primary miRNAs (pri-miRNAs), are 
processed by Drosha to the precursor miRNAs (pre-miRNAs). Pre-miRNAs are 
subsequently transported to the cytoplasm (He & Hannon, 2004; Kim & Rossi, 2007). 
In the cytoplasm, the pre-miRNAs are shortened and processed by the endonuclease 
Dicer (RNAse III enzyme) to produce the mature miRNAs. Then, the mature miRNAs 
proceed with the RNAi process in the cytoplasm similar as the process of exogenous 
short hairpin RNAs (shRNAs) or dsRNA, which have perfectly complementary 
sequence to the target mRNA.  
In the cytoplasm, both the miRNA and shRNA are processed by Dicer to the siRNAs or 
miRNAs. They are 21-23 nucleotides (nt) -long with 2-base 3' overhangs. Afterward, 
the Ago2-RISC complex (Argonaute 2 - RNA-induced silencing complex) is activated 
by binding with the guide/antisense strand of siRNA or miRNA and meanwhile the 
passenger or sense strand is cleaved (siRNA) or released (miRNA; Matranga et al., 
2005). Subsequently, the activated Ago2-RISC complex binds to the mRNA bearing a 
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perfectly (siRNA) or not perfectly (miRNA) complementary sequence achieving the 
gene silencing.  
 
Figure 5: Mechanism of RNAi gene silencing in 
mammalian cells 
RNA interference pathway is initiated with the 
exogenous dsRNA/shRNA or endogenous 
pri-miRNA, followed by various processes, e.g., the 
Dicer cutting, RISC processing, passenger/ sense 
strand cleavage or release, and the targeting mRNA 
cleavage or degradation to achieve the silencing of 
the target gene. This figure is modified based from 
de Fougerolles et al. (2007).  
In the siRNA pathway, the silencing of gene expression is implemented by cleaving the 
mRNA strand between the nucleotides that are complementary to nucleotides 10 and 
11 of the guide strand relative to the 5’-end (de Fougerolles et al., 2007) The 
synthetically produced siRNAs are able to mediate gene silencing in mammalian 
system on any given target mRNA molecule (Caplen et al., 2001; Elbashir et al., 2001). 
The main advantage of using siRNAs is the ability to control the amount of transfected 
molecules and thereby their subsequent uptake into RISC. These characteristics might 
have a large impact on the putative off-target and anti-viral effects that partly depend 
on the siRNA concentration. In contrast, the relatively short duration of achieved gene 
silencing is the drawback of the siRNA usage. To target certain genes, siRNAs 
base-paired to mRNAs of the target genes must be designed following various rules 
(InvivoGen, 2003; LifeTechnologies, 2003). The designed siRNAs can be chemically 
synthesized and can be ordered from numerous commercial companies, sometimes 
with proprietary chemical modifications to ensure better RNAi results.  
1.3.2 Mouse models of inflammatory diseases after Toxoplasma 
gondii infection 
TFFs are known to be typically expressed during inflammatory conditions. Here, two 
mouse models for inflammatory diseases after T. gondii infection were investigated 
concerning the expression of TFFs and the influence of Tff-deficiency (Tff
KO
 mice): (i) 
mouse model of induced ileitis after oral T. gondii infection (Dunay et al., 2008) and   
(ii) mouse model of induced encephalitis after i.p. T. gondii infection (Händel et al., 
2012).  
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Life cycle of T. gondii 
T. gondii, first identified in Ctenodactylus gundi (Nicolle & Manceaux, 1908) and in 
rabbit (Splendore, 1908), is an obligate intracellular protozoan parasite that can invade 
and replicate in almost all nucleated cells in the host and causes toxoplasmosis 
(Dubey, 2008). Toxoplasmosis ranges from 15-85% in its worldwide prevalence and is 
estimated to be the third leading cause of food related deaths in the USA following 
salmonellosis and listeriosis (Mead et al., 1999). During disease progression after T. 
gondii infection, tissue cysts are formed followed by multiplication of the parasites 
within the host cell cytoplasm (Hutchison et al., 1970). There are three infectious 
stages including the tachyzoites (aggregate in any cell), the bradyzoites (in tissue 
cysts) and the sporozoites (in oocysts; Dubey et al., 1998). Infection with T. gondii can 
be acquired through different ways: congenital infection with tachyzoites (Wolf et al., 
1939), ingestion of tissue cysts (Sabin & Olitsky, 1937) or food/water contaminated 
with oocysts (Frenkel et al., 1970; Dubey et al., 1998). After infection in the host, T. 
gondii is able to cross the intestinal epithelial barrier (Bates, 2006), the placenta 
(Havelaar et al., 2007), as well as the blood–brain barrier (Feustel et al., 2012) and 
disseminate rapidly throughout the body (e.g., muscle, blood), and especially into the 
brain. 
The life cycle of T. gondii can be divided into feline (definitive host) and non-feline 
(intermediate host) infections, correlated with the sexual and asexual replication 
respectively (Figure 6). The sexual cycle of T. gondii begins when its definitive feline 
host ingests the T. gondii at any of the stages. After the ingestion, the parasites infect 
the epithelial cells in the ileum and then form zygotes fusing the extremely long-lived 
oocysts. Subsequently, oocysts are sporulated and shed from the feline intestines, 
whereby completing the sexual cycle (Dubey et al., 1970, 1998). The ingestion of 
sporulated oocysts by intermediate hosts starts the asexual lifecycle of T. gondii, which 
consists of two distinct stages depending on whether the infection is in the acute or 
chronic phase (Black et al., 2000). In the acute phase, the sporulated oocysts 
transform into the rapidly proliferating tachyzoites and can enter all nucleated cells. 
The tachyzoites replicate rapidly, ultimately lead to cell death, disseminate to 
neighboring cells and spread through all tissues of the intermediate host, establishing 
infection (Radke & White, 1998). The immune response of the host can facilitate the 
differentiation of the tachyzoite to the bradyzoite, the slow replicating form of the 
parasite (Weiss & Kim, 2000). Bradyzoites can cluster and form tissue cysts localized 
predominantly in the CNS and muscle tissue of the host. This development of tissue 
cysts defines the chronic stage of the asexual cycle. Bradyzoites can reside in tissue 
cysts for the lifetime and can also be released by a dropping in the immune pressure 
and redifferentiated back into tachyzoites, thereby completing the asexual cycle. The 
conversion from bradyzoites back to tachyzoites frequently happens in 
immunocompromised individuals (Luft et al., 1983; Wong, 1984) and can also happen 
when cysts are ingested through eating the infected or contaminated tissues and 
ruptured within the intestine of hosts. 
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Figure 6: Life cycle of T. gondii     
The sexual cycle is initiated when a member of the feline family ingests either oocysts or tissues 
that are infected with bradyzoite cysts. Following oocyst maturation (activated after being 
excreted from the cat), the oocysts become highly infectious and survive in the environment for 
months to years. Any warm-blooded animal that ingests these infectious oocysts becomes a host 
for the asexual cycle. Upon ingestion of these tissue cysts in raw or undercooked meat from a 
chronically infected host, the bradyzoites will infect the intestinal epithelium of the next 
susceptible host and differentiate back to the tachyzoite stage to complete the asexual cycle. If 
the ingesting animal is a cat, the bradyzoites can differentiate into the sexual stages, thereby 
completing the full lifecycle. The figure is modified based from Black & Boothroyd (2000). 
Mouse models to study the immune response to T. gondii infection 
As one of the most prevalent and successful parasite, T. gondii has been used as a 
model of intracellular pathogen to discover basic mechanisms of immune regulation 
and function in the host. Murine models of T. gondii infection, most often used for T. 
gondii studies, demonstrate the indispensability for the medical progress in the 
treatment of toxoplasmosis in human (Hunter et al., 1994; Liesenfeld, 2002; Dunay et 
al., 2010; Subauste, 2012). 
There are three clonal lineages of T. gondii, designated type I, II and III strains that 
predominate in North America and Europe (Dubey et al., 1970; Howe & Sibley, 1995; 
Sibley et al., 2002) covering approximately 90% of the T. gondii isolates (Peyron et al., 
2006). Each type shows a different virulence and epidemiological pattern of infection 
(Vaudaux et al., 2010). Type II strains (e.g., DX-strain, ME49-strain) are the 
predominant lineages causing toxoplasmosis in humans (Howe & Sibley, 1995) and 
are avirulent in murine infections. Type III strains are also avirulent, whereas the type I 
strains are highly virulent (uniformly lethal to mice; Howe & Sibley, 1995; Sibley et al., 
2002). Not only the strain of T. gondii but also the parasite stage, the genetic 
background of mice, the dose of inoculum and the inoculation route of infection are 
critical for the outcome of infection (Johnson, 1984; Blackwell et al., 1993). To mirror 
the course of natural infection in immunocompetent humans, commonly the 
mouse-avirulent (type II) strains with cysts number between 1 and 20 are used for the 
infection (Dunay et al., 2008; Munoz et al., 2011). The natural infection of T. gondii is 
through the oral route by ingestion of the undercooked meat containing cysts or 
water/food contaminated with cysts or oocysts. Thus the oral infection of susceptible 
mice with T. gondii is the approach closest to the actual situation and will result in 
Th1-type immunopathology in the ileum. Although the natural route of infection with T. 
gondii is not intraperitoneal, the i.p. infection model has the advantage of allowing 
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direct access to the site of primary infection. Thus i.p. infection is also wildly used in the 
mouse model of T. gondii infection.  
After T. gondii infection (either oral or i.p.), mice develop an acute infection (an acute 
phase, typically until 14 days after infection) followed by a chronic progressive infection 
(the chronic/latent stage), in which the parasites establish themselves in cysts, mainly 
in the CNS (Munoz et al., 2011). Both the acute and chronic infections stimulate 
production of high levels of IL-12 and IFN-γ by cells of the innate immune system (Yap 
& Sher, 1999; Waree, 2008; Miller et al., 2009; Dunay & Sibley, 2010; Figure 7). These 
two cytokines are essential for resistance to T. gondii infection and ultimately initiate 
the adaptive Th1 immune response (Denkers & Gazzinelli, 1998). Macrophages, 
neutrophils and DCs have been shown to produce IL-12 in response to parasites or 
antigens. DCs are the most significant source of IL-12 production after T. gondii 
infection (Liu et al., 2006). They play a central role in T-cells antigen presentation and 
direct polarisation towards the Th1 adaptive response, as well as the production of 
IFN-γ (Miller et al., 2009). Moreover, IL-1β is also required for IL-12 to stimulate natural 
killer (NK) cells to produce IFN-γ (Hunter et al., 1995), which is also secreted by CD4+ 
and CD8+ T-cells (Bliss et al., 2000; Dunay & Sibley, 2010). Thus, T. gondii-induced 
IFN-γ production is largely IL-12-dependent and plays an important role for the 
regulation of IL-2 and TNF-α as co-factors (Gazzinelli et al., 1993a, 1993b, 1994; 
Hunter et al., 1994; Tait & Hunter, 2009). IL-2 produced by CD4+ T-cells is an 
important T-cell mitogen and can enhance NK cell expansion (Kobayashi et al., 1989; 
D’Andrea et al., 1992; Denkers & Gazzinelli, 1998; Tait & Hunter, 2009). TNF-α is 
essential for the activation of macrophages and is released by monocytes, 
T-lymphocytes, as well as macrophages themselves (Stafford et al., 2002). The 
pro-inflammatory effects of the T. gondii induced Th1 cytokines (e.g. IFN-γ, IL-2 and 
TNFα) are eventually inhibited by the anti-inflammatory cytokines (e.g., IL-10 and 
TGF-β) that suppress the inflammatory damage from the T. gondii infection (Wilson et 
al., 2005; Miller et al., 2009; Saraiva & O’Garra, 2010).  
During the course of oral infection with T. gondii (Figure 7), bradyzoites are first 
released from the cysts in the intestine and then convert to tachyzoites, and move 
through the intestinal epithelium by infecting enterocytes. These enterocytes secrete 
chemokines and cytokines such as IL-12, chemokine (C-C motif) ligand (CCL) 3 and 
CCL4 that attract neutrophils, macrophages and help in DCs maturation, resulting in 
ileitis and ultimately initiating the Th1 immune response in the host (Miller et al., 2009). 
After having passed through the intestinal epithelium, the parasites proceed into the 
CNS, localize in the brain and finally initiate the encephalitis.  
In contrast to oral infection, i.p. infection-mediated encephalitis is caused without direct 
invasion of the intestinal epithelium but by spreading through blood vessels of the 
peritoneum. Thus, an ileitis is not arising in the early phase of i.p. infection.  
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Figure 7: Innate immune responses after T. gondii infection  
The immune responses of oral T. gondii infection start with the invasion of enterocytes in the 
intestinal epithelium and then followed by a series of Th1 immune responses. Of note, the 
intestinal epithelium is not involved after i.p. infection with T. gondii. After the i.p. infection, the 
parasites first activate the macrophage or DCs directly by spreading through blood vessels and 
induce the Th1 immunity. DCs: dendritic cells, NK cells: natural kill cells. This figure is modified 
from Waree (2008) and Miller et al. (2009). 
1.3.3 Expression of Tffs in primary cell cultures from rat brain 
Thus far, the cellular localization of TFFs in the brain is still unclear. In order to gain 
more insights which cells of the CNS express TFFs at least in vitro, different primary 
cell culture from rat brain were investigated by RT-PCR analysis and 
immunohistochemistry. First, neural cell cultures containing mix cell population of 
neuron and glial cells (Goslin et al., 1998) were analyzed. Second, a glial cell-enriched 
population (Guizzetti & Costa, 1996) was studied.  
1.4 Aims of this study 
Generally, this study was designed to gain insight into the expression and function of 
TFFs in the GI tract and CNS considering four different aspects. The aims of the four 
projects outlined in chapter 1.3 were as follows:  
(1) to gain new insights into the expression of TFFs after in vitro wounding of RGM-1 
cells and to analyze the expression profile of stationary and migratory cells and 
investigate the role of TFF1 by the help of RNAi; 
(2) to gain new insights into the expression of TFFs in the intestine during inflammatory 
conditions in a mouse model of induced ileitis after oral T. gondii infection and to 
investigate the phenotype of Tff3
KO
 mouse in this model; 
(3) to gain new insights into the expression of TFFs in the brain during inflammatory 
conditions in a mouse model of induced encephalitis after i.p. T. gondii infection and to 
investigate the phenotype of different Tff
KO
 mice in this model; 
(4) to gain new insights into which cell types cells (neurons, astrocytes, microglial cells) 
express TFFs in primary cell cultures from rat brain.  
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2 Materials 
2.1 Cell culture 
2.1.1 Materials 
Application Description Cat.-No. Producer 
    
CELLLSTAR
®
 6/24 well cell culture 
multiwell plates 
6xx160 
  
CELLLSTAR
®
 12/48/96 well cell 
culture multiwell plates 
6xx180 
  
CELLSTAR
®
 standard cell culture 
Flasks 50/250 ML, 25/75 cm² 
6xx170 
  
Cell cultivation 
CELLSTAR
®
 cell culture dishes,  
100 X 20 mm 
664160 
Greiner Bio-One, 
Frickenhausen 
    
 Corning
®
 cell lifter  3008 Corning
® 
Inc. Costar, 
MA, USA 
    
 Sterile glass cover slips, 22x22 mm BB02202
2A1 
 Microscope cover slip circles, 12 mm CB00120
RA1 
Gerhard Menzel, 
Braunschweig 
    
 BD falcon™ conical tubes, 15, 50 mL 352096 BD Biosciences, 
Heidelberg 
    
Pipettes and 
tips 
SafeSeal tips premium 1000/100/10 
µl, sterile 
692xxx Biozym Biotech 
Trading, Oldendorf 
    
 Serological pipettes 
1 mL, 2 mL, 5 mL, 10 mL, 25 ml 
612-12xx VWR International, 
Darmstadt 
    
 Tips 10 µL, 50 µL, 100 µL  0300  
xxx.xxx 
Eppendorf AG, 
Hamburg 
    
 Tips 2 µL, 200 µL, 1000 µL D10,200,
1000 
Gilson, Limburg 
2.1.2 Media and reagents 
Application Description Cat.-No. Producer 
    
DMEM high glucose (4.5 g/L )  E15-009   Media 
Leibovitz´s L-15 E15-020 
GE Healthcare Life 
Sciences/PAA GmbH, 
Cölbe 
    
 Neurobasal
®
 medium (1X), liquid 21103- 
049 
Life Technologies 
GmbH, Darmstadt 
    
Dulbecco's PBS (1x) H15-002   Reagents 
Fetal bovine serum gold (FBS) A15-151    
 MycoKill  (50x) P11-016 
GE Healthcare Life 
Sciences/PAA GmbH, 
Cölbe 
    
 G418-BC (100x) A 2912    
 NEA-Non essential amino acids(100x)  K 0293    
 Sodium pyruvate 1 mM L 0473 
Biochrom AG, Berlin 
    
 HBSS Hanks´s balanced salt solution  14170    
 L-glutamine (200 mM) 25030-081    
 BSA (Bovine Serum Albumin) 15561-020    
Life Technologies 
GmbH, Darmstadt 
    
 Opti-MEM
®
 I reduced serum medium 31985-047     
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Application Description Cat.-No. Producer 
    
Reagents B-27
®
 Serum-free supplement (50X) 17504-044    
 Lipofectamine
®
 2000 transfection 
teagent 
11668-027 
   
 0.25% Trypsin-EDTA (1X),PhenolRed 25200-056    
 0.05% Trypsin-EDTA (1X),PhenolRed  25300-054 
Life Technologies 
GmbH, Darmstadt 
    
 L-glutamine solution 59202C    
 Penicillin-streptomycin solution 
stabilized (100x) 
P 4333 
   
 Trypsin inhibitor from glycine max  T6522    
 Poly-D-lysine hydrobromide P7280    
 Deoxyribonuclease I  DN25 
Sigma-Aldrich Chemie 
GmbH, München 
2.2 Basic experiments 
2.2.1 Extraction 
Applications Description Cat.-No. Producer 
    
Tissue preparation Sterile disposable scalpel 
standard 
No. 10 FEATHER Safety Razor Co., 
Ltd. PFM, Köln 
    
TRIzol
® 
reagent 10296 
-028 
Life Technologies GmbH, 
Darmstadt 
   
RNA, DNA and 
protein Extraction 
ISOLATE RNA mini Kit BIO 
-52073 
Bioline GmbH, Luckenwalde 
    
 Complete protease inhibitor 
cocktail tablets 
0469311
6001 
Roche, Mannheim 
    
 Guanidine hydrochloride 0037.1 Carl Roth GmbH, Karlsruhe 
    
 Invisorb® spin tissue mini kit 1032100
300 
STRATEC Molecular GmbH, 
Berlin 
2.2.2 RT-PCR 
Applications Description Cat.-No. Producer 
    
Semi-micro plastic 
UV-cuvettes 
Y199.1 Carl Roth GmbH, Karlsruhe 
   
Concentration 
determination 
Cuvettes for absorption 
measurements 
6040-UV-
10-531 
Hellma GmbH & Co. KG, 
Müllheim 
    
 Bio-Rad protein assay dye 
reagent concentrate 
500-0006 Biorad, München 
    
 BCA (bicinchoninic acid) 
protein assay reagent 
23225 Thermo Fisher Scientific, 
Bonn 
    
RiboLock RNase-inhibitor EO0384   
DNase I, RNase-free EN0521   
RevertAid H minus reverse 
transcriptase 
EP0452 
  
dNTP set R0181   
Reverse  
transcription 
Oligo(dT)18 primer SO132 
Thermo Fisher Scientific, 
Bonn 
    
 Safe-lock tubes  
0,5/1.5/2 mL 
0030-120 Eppendorf AG, Hamburg 
    
 Safe-lock tubes, biopur, 
0,5/1,5 mL 
0030-121   
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Applications Description Cat.-No. Producer 
    
PCR-oligos (primers)  Metabion, Martinsried PCR 
   
 DreamTaq green DNA 
Polymerase 
EP0714 Thermo Fisher Scientific, 
Bonn 
    
 Mineral oil M5904 Sigma-Aldrich Chemie 
Gmbh, München  
    
 PCR- reaction tubes, 200 µL GS001- x Kisker Biotech GmbH & Co. 
KG, Steinfurt 
2.2.3 Western blotting 
Applications Description Cat.-No. Producer 
    
Western blotting Gel-blotting paper BF2 FT-2-519 
-580600N 
Sartorius AG, Göttingen 
    
 Luminol 123072    
 p-Cumaric acid 537-98-4  
Sigma-Aldrich Chemie 
Gmbh, München 
    
 Protein-marker I 27-1010 Peqlab Biotechnologie 
GmbH, Erlangen 
    
 Whatman PROTRAN BA79 
nitrocellulose transfer membrane 
10402096 Whatman, Dassel 
   
 Ponceau S 
1142750
010 Merck, Darmstadt 
    
Agarose gel for DNA 
electrophoresis research  
11404.05 Serva, Heidelberg Gel 
electrophoresis 
   
 1% Ethidium bromide 
solution (10 mg/mL) 
331564 Merck, Darmstadt 
    
 GeneRuler™ 1kb Plus DNA 
ladder, ready-to-use  
SM1333 
   
 6x Loading dye  
Thermo Fisher Scientific, 
Bonn 
    
 Rotiphorese
®
 Gel 30  
(30% acrylamide/ 
bisacrylamide = 37.5:1.) 
3029.1 
   
 TEMED 2367.3    
 APS (Ammonium persulfate) 9592.3 
Carl Roth GmbH, Karlsruhe 
2.2.4 Immunostaining 
Description Cat.-No. Producer 
   
Goat serum B15-035 PAA GmbH, Cölbe 
   
Dako fluorescent mounting medium  S 3023 Dako GmbH, Hamburg 
   
Triton™ X-100 100-155   
Sodium azide (NaN3) S 2002   
Horse serum H0146   
HEPES (4-(2-hydroxyethyl)piperazine- 
1-ethanesulfonic acid) 
H3375 
  
Saponin 47036   
BSA (bovine serum albumin) A7888   
DPX mountant 44581 
Sigma-Aldrich Chemie Gmbh, München 
   
Tris ultrapure A1086 AppliChem GmbH, Darmstadt 
   
EDTA (ethylenediamine tetraacetic 
acid · Na2-salt) 
11280 SERVA Electrophoresis GmbH, 
Heidelberg 
   
PFA (paraformaldehyde) 0335.2   Carl Roth GmbH, Karlsruhe    
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Description Cat.-No. Producer 
   
D(+)-saccharose/sucrose 4621.1 Carl Roth GmbH, Karlsruhe    
Sodium periodate 2603.2     
Boric acid 5935  
   
Gelatine 4274.1  
   
L-Lysine hydrochloride 1700.2     
Methanol P717.2     
Ethanol 0342.2  
   
Mowiol 4-88 0713.2  
   
VECTASTAIN
®
 Elite ABC Kit PK-6100 BIOZOL Diagnostica Vertrieb GmbH, 
Eching 
   
Tissue-Tek
®
 O.C.T™ Compound 4583 Sakura Finetek GmbH, Staufen 
2.3 Peptides and antibodies 
2.3.1 Synthetic peptides and antiserum 
Two antisera (anti-mTff1-1 and anti-rTff3-2) raised against synthetic peptides were 
used in this study. The peptides were both provided by Dr. H. Kalbacher and they 
present partial sequences of mouse Tff1 (Karam et al., 2004) or rat Tff3 (GenBank
®
 
accession No.: NP_037174.2; see below). The peptides were purified using reversed 
phase-HPLC and their identities were confirmed by MALDI-MS (matrix-assisted laser 
desorption/ionization mass spectrometry), then coupled to KLH (keyhole limpet 
hemocyanin) via glutaraldehyde and used to immunize rabbits (Charles River 
Laboratories, Sulzfeld).  
Affinity purification of anti-mTff1-1 was performed as described previously (Wiede et al., 
1999). Briefly, the mTff1 peptide was coupled to BSA via glutaraldehyde, diluted to 20 
mg/mL with PBS and loaded onto nitrocellulose membranes for 5 h at room 
temperature. The membranes were washed with PBS and residual protein binding 
capacity was blocked by incubation with 5% normal goat serum in PBS for 30 min. 
Then, loaded membranes were incubated with antiserum anti-mTff1-1 diluted 1:50 in 
5% normal goat serum in PBS supplemented with 0.1% sodium azide overnight at 
room temperature. After a washing with PBS, bound antibodies on the membranes 
were eluted with 0.2 M glycine–HCl buffer/pH 2.5 (containing 150 mM NaCl and 1 
mg/mL BSA) for 30 min. Eluted antibodies were neutralized by adding 1/10 of volume 2 
M Tris-base/pH 8.0 and dialyzed against PBS overnight at 4°C. Finally, purified 
antibodies were concentrated by ultrafiltration using Vivaspin tubes (GE Healthcare 
Europe GmbH, Freiburg). The affinity-purified antiserum anti-mTff1-1 was tested via 
ELISA for reactivity against the BSA conjugate or synthetic peptide. 
Description Sequences Source 
   
Tff1 peptide, representing the 
C-terminus of mouse Tff1 
FHPMAIENTQEEECPF (1-16) H. Kalbacher 
(Karam et al., 2004) 
   
Tff3 peptide, representing rat 
Tff3 
Whole rat Tff3 peptide sequence 
(1-59) 
H. Kalbacher  
(GenBank
®
 accession 
No.: NP037174.2) 
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2.3.2 Primary antibodies 
Antiserum Description 
Size 
kDa 
Origin Dilution 
Species 
Reactivity 
Source 
/Cat. Nr 
       
anti- 
Actin 
(20-33) 
N-terminal region 
universal for all 
actins 
42 rabbit 
polyclonal 
WB: 
1:50 - 200 
IF: --- 
Human, 
Rat, 
Mouse 
Sigma-Aldrich, 
München 
/A5060 
       
anti- 
Human 
beta Actin 
(N-21) 
N-terminal region 42 rabbit 
polyclonal 
WB: 1:200 
IF: --- 
Human, 
Mouse 
Santa Cruz, 
Heidelberg / 
sc-130656 
       
anti- 
mTff1-1 
against sequence: 
FHPMAIENTQEEE
CPF 
6.7 rabbit 
polyclonal 
WB: 1:1000 
IF: 1:500 
Mouse 
Rat 
Fu et al. 
(2013)  
       
anti- 
rTff3-2 
against sequence: 
rat Tff3 protein 
sequence 1-59 
6.6 rabbit 
polyclonal 
WB: 1:2000 
IF: 1:500 
Rat 
Mouse 
IMMC 
       
anti- 
MAP2 
specific for all forms 
of MAP2 (a, b, c) 
280 mouse 
monoclonal 
IF: 1:500 Human 
Rat 
Mouse, etc. 
Sigma-Aldrich, 
München 
/M4403 
       
anti- 
GFAP 
against full length 
native protein 
~50 chicken 
polyclonal 
IF: 1:1000 Human 
Rat 
Mouse, etc. 
      
anti- 
Iba-1 
against sequence: 
CTGPPAKKAISELP 
(135-147) 
17 goat 
polyclonal 
WB: 1:1000 
IF: 1:500 
Human 
Rat 
Mouse, etc. 
Abcam, 
Cambridge, 
UK 
ab4674 
ab5076 
       
anti- 
Iba-1 
against Iba1 
C-terminal 
sequence 
17 rabbit 
polyclonal 
WB: 1:1500 
IF: 1:1000 
Human 
Rat 
Mouse 
Wako 
Chemicals 
GmbH,Neuss 
019-19741 
       
anti- 
Toxoplasma 
gondii 
stains Toxoplasma 
gondii by 
immunohistoemical 
techniques 
--- rabbit 
polyclonal 
WB: --- 
IF: 1:1000 
Human 
Rat 
Mouse, etc. 
BioGenex, 
CA, USA 
PU125-UP 
2.3.3 Secondary antibodies 
Antiserum Origin Dilution Cat. Nr Producer 
     
Biotinylated goat anti-rabbit 
IgG antibody 
 WB: 1:2000 BA-1000  
    
Peroxidase anti-rabbit 
IgG(H+L) 
goat WB: 1:4000 PI-1000 
Biozol Diagnostica 
Vertrieb GmbH, 
Eching 
     
Alexa Fluor
®
 488 anti-rabbit 
IgG (H+L) 
goat IF: 1:1000 A-11008 Invitrogen, Life 
Technologies GmbH, 
Darmstadt 
     
anti-goat IgG (H+L)-Cy3 donkey IF: 1:500 705-165-003 Dianova, Hamburg      
DyLight™ 649 anti-chicken donkey IF: 1:1000 703-496-155       
anti-chicken IgG (H+L)-Cy3  donkey F: 1:1000 703-165-155       
anti-mouse IgG (H+L)-Cy3 donkey IF: 1:1000 715-165-150  
     
anti-rabbit IgG whole 
molecule F(ab´)2 fragment-Cy3 
goat   IF: 
1:100-200 
C2306 
    
DAPI (4',6-Diamidino-2- 
Phenylindole Dihydrochloride) 
 IF: 1:1000 D9542 
Sigma-Aldrich, 
München 
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2.4 Animals 
2.4.1 Transgenic mice  
Three different transgenic mice were used in this study, i.e., Tff1-deficient mice (Tff1
KO
 
mice), Tff2-deficient mice (Tff2
KO
 mice) and Tff3-deficient mice (Tff3
KO
 mice). The 
result for the weight control experiment is present in the Appendix I (on page i). 
2.4.1.1 Tff1-deficient mice (Tff1KO mice) 
Tff1-deficient mice were generated by Lefebvre et al. (1996) and kindly provided by Dr. 
M.-C. Rio: To inactivate the mouse Tff1 gene, a targeting vector was constructed by 
inserting the neomycin resistance gene (neo) cassette into exon 2 of mTFF1 to 
achieve the disruption (Figure 8) and was electroporated into D3 embryonic stem (ES) 
cells (129S2/SvPas). C57BL/6J blastocysts microinjected with one positive clone were 
reimplanted in pseudo gestante females to generate the chimeric male. Then the 
mutant allele was transmitted to offspring by mating the generated chimeric male with 
129/Svj females, yielding Tff1
+/-
 heterozygotes. These mice were subsequently mated 
to yield Tff1
-/-
 homozygous (Tff1
KO
), as well as Tff1
+/+
 homozygous (wild type). They 
were used as Tff1-deficient mice and wild type mice, respectively, in this study.  
 
 
 
Figure 8: Targeting strategy of the mTFF1 gene (Lefebvre et al. 1996) 
2.4.1.2 Tff2-deficient mice (Tff2KO mice) 
Tff2-deficient mice were generated by Baus-Loncar et al. (2005b) and kindly provided 
by Prof. N. Blin: To inactivate the mouse Tff2 gene, targeting vector was constructed by 
replacing exon 1 and exon 2 of mTFF2 (encoding one functional Tff2 domains) with 
neo gene cassette (Figure 9) and electroporated into AB2.2 (129SvEv) ES cells. After 
microinjection of the positive clone into blastocysts from C57BL/6, high percentage 
chimaeric mice were obtained. Subsequently, germline transmission of the disrupted 
Tff2 allele was generated and confirmed. Without adverse effects on ability of 
reproduction, the Tff2
-/-
 homozygous (Tff2
KO
) were subsequently reproducted and also 
used for this study. 
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Figure 9: Targeting strategy of the mTFF2 gene (Baus-Loncar et al., 2005b) 
2.4.1.3 Tff3-deficient mice (Tff3KO mice) 
Tff3-deficient mice were generated by Mashimo et al. (1996): The targeting vector, in 
which the entire exon 2 of mTff3 gene (encoding most of the TFF domain) was 
replaced with the neo gene cassette (Figure 10), was homologous recombinated in J1 
ES cells (129/Sv-Aguti). The original strain of the Tff3
-/-
 mice (Tff3
KO
) was kindly 
provided by Prof. D.K. Podolsky (Harvard Medical School), which have a mixed 
background of 129/Sv and C57BL/6 (Lubka et al., 2008; Blaschke, 2010). After 
backcrossing these Tff3
+/-
 heterozygotes (homozygous sister lines) for more than 10 
generations, Tff3
+/+
 mice (wild type strain) as well as Tff3
-/-
 mice (TFF3
KO
) were 
obtained with the same genetic background and were used for this study. The pedigree 
for the backcrossing culture is presented in the Appendix II (on page ii). 
 
 
 
Figure 10: Targeting strategy of the mTFF3 gene (Mashimo et al., 1996) 
2.4.2 Materials  
Description Cat.-No. Producer 
   
Normal saline, 0.9% NaCl 89167-772   
Tweezers and scissors  ----- 
VWR International, Darmstadt 
   
BD butterfly needles 367344 
  
BD Falcon
®
 cell strainers 3523x0 
BD Biosciences, Heidelberg 
   
Sterile disposable scalpel standard No. 10 FEATHER Safety Razor Co., Ltd. PFM, 
Köln 
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2.5 Transformation and transfection 
Description Cat.-No. Producer 
   
Competent cells E. coli TOP10 5-1600-020 IBA GmbH, Göttingen, Germany 
   
pGEM
®
-T easy vector system I A1360 Promega GmbH, Mannheim, 
Germany 
   
HotStar HiFidelity polymerase kit 202602   
QIAquick gel extraction kit 28706 
Qiagen, Hilden, Germany 
   
pIRES vector 631605 Takara Bio Europe/Clontech 
Saint-Germain-en-Laye, France 
   
JetStar
® 
plasmid mini prep kit 200200 Genomed GmbH, Löhne 
   
BD Falcon™ round bottom tubes,  
5 mL PS with cap 
352003 BD Biosciences, Heidelberg 
   
LB broth (lennox) L7275   
LB broth with agar (lennox) L7025   
IPTG (isopropyl 
β-D-1-thiogalactopyranoside) 
16758 
  
Ampicillin sodium salt A9518 
Sigma-Aldrich Chemie Gmbh, 
München 
   
SOC medium BIO-86033 Bioline GmbH, Luckenwalde 
   
Glycerol from plant (glycerin) 23176 SERVA Electrophoresis GmbH, 
Heidelberg 
   
Calcium chloride/CaCl2 CN93.2 Carl Roth GmbH, Karlsruhe 
   
X-gal (5-Bromo-4-chloro-3-indolyl-beta 
-D-galactopyranoside, light prevented) 
203782 Merck Chemicals GmbH, Schwalbach 
   
T4 DNA ligase M0202S 
  
Restriction enzymes RxxxxS 
New England Biolabs GmbH, 
Frankfurt am Main 
   
Sterile plastic loop 510-1001-STR Elkay Products, Inc., Massachusetts, 
USA 
2.6 Stealth RNAi duplexes 
Stealth RNAi™ compounds, provided from Invitrogen, are 25-mer dsRNA molecules 
containing proprietary chemical modifications that enhance nuclease stability and 
reduce off-target effects by limiting sense strand activity (Carstea et al., 2005). The 
three rat Tff1 stealth RNAi™ and the negative control duplexes used in this study had 
the following sequences: 
Name Cat. No.  Sequence Nucleotide positions GC% 
      
sense CAUGGUGCUUCCGACCUCUGGUCAU 218-242 56.01% rTff1- 
siRNA1 
Tff RSS 
350528 anti-sense AUGACCAGAGGUCGGAAGCACCAUG  Hi GC 
      
sense CCAGAACCAGGAAGAAACAUGUGCC 93-117 52.00% rTff1- 
siRNA2 
Tff RSS 
350530 anti-sense GGCACAUGUUUCUUCCUGGUUCUGG  Hi GC 
      
sense GCAAGAAGAAGAAUGUCCCUUCUAA 252-276 40.00% rTff1- 
siRNA3 
Tff RSS 
350529 anti-sense UUAGAAGGGACAUUCUUCUUCUUGC  Low GC 
      
sense GGUAGGUGAGUGUACAGACGCAAUA  50.00% Negative 
Control 
12935- 
114 anti-sense UAUUGCGUCUGUACACUCACCUACC  Hi GC 
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2.7 Equipment and software 
Devices/Function Description Producer/Distributor 
   
Homogenization Precellys 24 Peqlab Biotechnologie GmbH, 
Erlangen 
   
 Ultraturrax T25 basic IKA Werke GmbH, Staufen 
   
Thermomixer Eppendorf AG, Hamburg 
  
Heating/shaking/ 
stirring 
IKA magnetic stirrer COMBIMAG REO 
  
 Magnetic stirrer RCT bank 
IKA Werke GmbH, Staufen 
   
 Innova® 4200 incubator shaker New Brunswick Scientific, 
Edison, NJ, USA 
   
NanoDrop ND-1000 
Spectrophotometer 
Thermo Fisher Scientific, Bonn 
  
Concentration 
measurement 
Libra S12 spectrophotometer Biochrom Ltd.,Omnilab, Bremen 
   
Agagel maxi  Gel 
electrophoresis Casting system compact L/XL 
Biometra, Göttingen  
   
 Electrophoresis supplier EPS 3500 Amersham Pharmacia Biotech, 
Freiburg 
   
 Heinzinger economy line LNG350 06 Herolab, Wiesloch 
   
 Mini-protean   
 PowerPac™ basic power supply 
Biorad, München 
   
Microtome Leica Jung CM3000 cryostat 
microtome 
Leica Mikrosysteme Vertrieb 
GmbH, Wetzlar  
   
Microwave Micromat Txp EEH8733 AEG-Elektrolux, Nürnberg 
   
Microscope Axiovert 40, 135   
 Axiophot/axiocam HRC   
 Axio observer.Z1/AxioCamMRm 
Carl Zeiss Microscopy GmbH, 
Göttingen 
   
 BZ-8000 Keyence, Frankfurt 
   
Filterset 01, BP 365 nm +/- 12 nm,  
FT 395 nm, LP 420 nm   
Objectives and 
filter 
Filterset 10, BP 450-490 nm,  
FT 395 nm, LP 397 nm   
 Filterset 15, BP 546 nm +/- 12 nm,  
FT 580 nm, LP 590 nm   
Ph1 Plan-NEOFLUAR 10x/0,30   
Ph2 Plan-NEOFLUAR 20x/0,50   
Ph3 Plan-APOCHROMAT 63x/1,40   
Plan-NEOFLUAR 40x/0,75 
Carl Zeiss Microscopy GmbH, 
Göttingen 
   
PCR/RT  Robocycler gradient 96 Stratagene,Heidelberg 
   
Protein Transfer Heidolph polymax 1040 Carl Roth GmbH, Karlsruhe 
   
 Heinzinger economy line 
LNG 350 06 
Amersham Pharmacia Biotech, 
Freiburg 
   
 Semi dry blotter 20 x 20 Biostep, Jahnsdorf 
   
Incubators Hera cell 150 Haereus, Hanau 
   
 US autoflow Nuaire, Integra Biosciences 
GmbH, Fernwald  
   
Biological safety cabinets 
class II 
Nuaire, Integra Biosciences 
GmbH, Fernwald 
  
Safety bench/ 
laminar flow 
Hera safe Haereus, Hannau 
   
Balance Sartorius analytic A2000S Sartorius, Göttingen 
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Devices/Function Description Producer/Distributor 
   
GeneGnome  Syngene Bioimaging Synoptics 
Ltd., Cambridge, England   
Documentation & 
semi-quantitative 
analysis 
Herolab E.A.S.Y RH3 Amersham Pharmacia Biotech, 
Freiburg 
   
Vortex Vortex-Genie 2 Carl Roth GmbH, Karlsruhe 
      
Centrifugation Biofuge primo R Haereus, Hanau 
   
 Micro centrifuge Carl Roth GmbH, Karlsruhe 
   
Mikro 200R  
Universal 30RF 
 
 
 Universal 329R 
Hettich Lab Technology, 
Tuttlingen 
   
   
AxioVision 3.1 Software  
 AxioVision release 4.8  
Carl Carl Zeiss Microscopy 
GmbH, Göttingen  
   
 Adobe® photoshop 7.0 Adobe System GmbH, 
München    
 Adobe® Reader® XI  
   
 GeneTools Syngene Bioimaging, Synoptics 
Ltd., Cambridge, UK 
   
 BZ observation application Keyence, Frankfurt 
   
 Herolab E.A.S.Y Win32 Amersham Pharmacia Biotech, 
Freiburg 
   
 Microsoft® Office 2003 Microsoft Corporation, 
Redmond, WA, USA 
2.8 Oligodeoxynucleotides List 
Table 2: RT-PCR analyses of RGM-1 cells (Rattus norvegicus) 
Genes  Accession No.  Primer Primer Pairs nucleotide Tm Size 
  No.  positions (°C) (bp) 
       
Tff1 NM_057129.1 MB1547 CCCAGAACCAGGAAGAAACA 92-111 60 206 
Trefoil factor family 1 MB1548 ACCAGTTCTCTCGGATGGAC 297-278   
       
Acta2 NM_031004 MB671 CGATAGAACACGGCATCATCAC 257-278 60 457 
Actin, alpha 2 (aortic smooth muscle) MB672 TCCAGAGCGACATAGCACAG 713-694   
       
Ccna2 NM_053702.3 MB661 TGTCTGTGTTAAGAGGAAAGC 796-816 57 449 
Cyclin A2 MB662 GTGAAGGTCCATGAGACAAG 1244-1225   
       
Birc5 M_022274.1 MB2270 ACCACCGGATCTACACCTTC 51-70 60 513 
Survivin/Baculoviral IAP repeat-containing 5 MB2271 GTGAAGGTCCATGAGACAAG 563-544   
       
Vim NM_031140.1 MB673 TTTCCAAGCCTGACCTCAC 859-877 60 459 
Vimentin MB674 GAGAAATCCTGCTCTCCTCC 1317-1298   
       
ß-Actin NM_031144.3 MB2158 AAGTACCCCATTGAACACGG 280-299 60 946 
Actin, beta MB2159 CAGCTCAGTAACAGTCCGC 1225-1207   
       
Pgc NM_133284.2 MB1169 TGGGTGTCTTCTGTCTACTGC 361-381 60 565 
Pepsinogen C MB1170 GCATGACGAGCAGAGAGGT 925-907   
       
Gkn2 NM_001039686.1 MB2164 ATGCTCTTCCACCACCATTT 202-221 60 367 
Gastrokine 2 MB2165 GCAGATAGAGATCCCCAGGA 568-549   
       
Muc16 XM_235886.7 MB2242 CCCCTAGTGGCTATGTACCG 314-333 60 453 
Mucin 16 MB2243 AGGGTAGGTTGGTGATGGTG 766-747   
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Genes  Accession No.  Primer Primer Pairs nucleotide Tm Size 
  No.  positions (°C) (bp) 
       
Cxcl2/Sdf-1 NM_022177.3 MB2298 CAGAGCCAACGTCAAACATC 201-220 60 712 
chemokine (C-X-C motif) ligand 12 MB2299 ACTGGAAAAAGGAGCCTCTG 912-893   
       
Lgr5 NM_001106784.1 MB1151 ACTGGAGCAAAGATCTCGTC 1006-1025 57 221 
Leucine rich repeat containing G protein MB1152 TTATTCCGGGCTAAGTTCAG 1226-1207   
       
Tff3 NM_013042.1   MB1551 GACTCCAGCATCCCAAATGT 198-217 60 152 
Trefoil factor 3 MB1552 GCAGATCAGGGGTGAGTGTT 349-330    
Table 3: RT-PCR analyses of mouse tissue (Mus musculus) 
Genes Accession No. Primer Primer Pairs nucleotide Tm Size 
  No.  positions (°C) (bp) 
      
ß-Actin NM_007393.3 MB1912 CCCTCACGCCATCCTGCGTC 592-611 60 638 
Actin, beta MB1913 ACGCAGCTCAGTAACAGTCCGC 1208-1229   
      
Tff1 NM_009362.2 MD7 ATCTGTGTCCTCGCTGTGGT 128-145 57 323 
Trefoil factor family 1 MD8 GGGGAAGCCACAATTTATCC 450-429   
      
Tff2 NM_009363.3 MD5 TTCCACCCACTTCCAAAC 242-259 57 310 
Trefoil factor family 2 MD6 AATGCTGTGTCTAGCCACTG 532-551   
      
Tff3 NM_011575.2  MB1847 TCTGGCTAATGCTGTTGGTG  60 392 
Trefoil factor family 3 MB1848 TCAGATCAGCCTTGTGTTGG 443-424   
      
Ifnγ NM_008337.3 MB2054 TCCTCCTGCGGCCTAGCTCTG 83-103 60 412 
Interferon gamma MB2055 TGGCGCTGGACCTGTGGGTT 494-475   
      
Il-12αp35-2 NM_008351.2 MB2133 CACAGTCCTGGGAAAGTCCTG 9-029 60 402 
Interleukin 12 subunit alpha isoform 2 MB2134 TAGCCAGGCAACTCTCGTTC 410-391   
      
Il-1β NM_008361.3 MB2038 GTGGCTGTGGAGAAGCTGTGGC 270-291 60 390 
Interleukin 1 beta MB2039 CAGGGTGGGTGTGCCGTCTT 659-640   
      
Il-10 NM_010548.2 MB2154 CTGCTCTTACTGACTGGCAT 95-114 60 180 
Interleukin 10 MB2155 GGAGTCGGTTAGCAGTATGT 274-255   
      
Tnfα NM_013693.2 MB2052 GCAGCCAACCAGGCAGGTTCT 83-103 60 592 
Tumour necrosis factor α MB2053 ACGTAGTCGGGGCAGCCTTGT 611-591   
      
T529 AF487550.1 (T.g./RHrep)  MB2066 ACTACAGACGCGATGCCGCTC 107-127 60 222 
Toxoplasma gondii strain RH repeat region MB2067 CTCTCCGCCATCACCACGAGGAA 328-306   
      
Iba1 NM_019467 MB1727 GGATTTGCAGGGAGGAAAAG 329-349 60 215 
Ionized calcium binding adapter molecule 1 MB1728 GCCACTGGACACCTCTCTAA 523-243   
      
Cd4 NM_013488.2 MB2117 ACCCCTTGACAGAGTGCAAA 630-649 60 472 
T-cell surface glycoprotein CD4 antigen MB2118 TCCTGATGCAGTGTCCCTTT 1101-1082   
      
Cd8 NM_001081110.2 MB2119 CCCGAACTCCGAATCTTTCC 200-239 60 587 
T-cell surface glycoprotein CD8 antigen MB2120 CAAACACGCTTTCGGCTC 806-789   
Table 4: RT-PCR analyses of rat primary cell cultures (Rattus norvegicus) 
Genes Accession No. Primer Primer Pairs nucleotide Tm Size 
  No.  positions (°C) (bp) 
      
Tff1 NM_057129.1 MB1547 CCCAGAACCAGGAAGAAACA 92-111 60 206 
Trefoil factor family 1 MB1548 ACCAGTTCTCTCGGATGGAC 297-278   
      
Tff2 NM_053844.1 MB45 GCAGAACACCCAGGTCCAG  001-19 60 556 
Trefoil factor family 2 MB46 CTTGGAAAGACACTGTGTC 556-538   
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Genes Accession No. Primer Primer Pairs nucleotide Tm Size 
  No.  positions (°C) (bp) 
      
Tff3 NM_013042.1   MB1551 GACTCCAGCATCCCAAATGT 198-217 60 152 
Trefoil factor family 3 MB1552 GCAGATCAGGGGTGAGTGTT 349-330    
      
Map2 NM_013066.1 MB2143 CATCATTCGCACTCCTCCAA MB2143 60 462 
Microtubule-associated protein 2 MB2144 GAGGAGACATTGCTGAGTCG MB2144   
      
Gfap NM_017009.2 MB2145 AGGGACAATCTCACACAGGA 416-435 60 439 
Glial fibrillary acidic protein MB2146 GGCGATAGTCATTAGCCTCG 854-835   
      
Iba1 NM_017196.3 MB2141 TTGGATGGGATCAACAAGCA 168-187 60 274 
Ionized calcium binding adapter molecule 1 MB2142 ATCTCTTGCCCAGCATCATT 441-422   
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3 Methods 
3.1 Cell culture 
3.1.1 RGM-1 cells 
The non-transformed rat gastric epithelial cell line RGM-1 (Kobayashi et al., 1996), 
kindly provided by Dr. S. J. Hagen (Boston, USA), was maintained in 75 cm
2
 cell 
culture flasks with filter caps at 37°C in a humidified atmosphere with 5% (v/v) CO2. 
DMEM (Dulbecco’s modified Eagles medium) with 4.5 g/L glucose was routinely used 
as cell culture medium and was supplemented with 1% (v/v) 100x non-essential amino 
acids, 1 mM sodium pyruvate, 2 mM glutamine (see below), and 10% (v/v) FBS (fetal 
bovine serum). For the migration experiments, cells between the 10th and 20th 
sub-cultivation were used. Before scratch-wounding, cultures were incubated in serum 
free, full supplemented growth medium (see below) for 12-15 h.  
Full supplemented medium 
Non-essential amino acids 100x 1% (v/v) 
Sodium pyruvate 1 mM 
Glutamine 2 mM 
10% (v/v) FBS was added if needed 
3.1.2 Primary cell cultures 
3.1.2.1 Neural cell cultures 
Primary hippocampal and cortical cultures were prepared by Dr. A. Stellmacher (IPT, 
Magdeburg) according to Goslin et al. (1998) from hippocampi and cortices, 
respectively, of E18 rat embryos (Sprague Dawley; Harlan, Rossdorf, Germany). 
Briefly, hippocampi or cortices were carefully dissected from rats on embryonic day 18 
respectively and treated with 0.05% trypsin for 20 min at 37°C. After an incubation with 
trypsin inhibitor (0.5 mg/mL trypsin inhibitor with 0.24 mg/mL DNase I (Dn25)), 
hippocampi and cortices were triturated respectively in HBSS plus 3 mg/mL BSA with 
needles of decreasing diameters and cell strainers until cells were fully suspended. 
Then 20,000 to 40,000 cells were plated on prepared poly-D-lysine coated cover slips 
(diameter 12 mm) and cultivated in Neurobasal
®
 medium supplemented with 0.8 mM 
glutamine and 1x B-27
®
 serum-free supplement at 37°C with 5% CO2 (v/v). Cells were 
feed with 1/10 of fresh culture medium every week, i.e. 50 µL fresh medium was added 
to each well of 24-well plate every week. 
3.1.2.2 Glial cell-enriched cultures 
Glial cell-enriched cultures were prepared by Dr. A. Stellmacher (IPT, Magdeburg) 
according to Guizzetti & Costa (1996). In brief, cortices of P2 rats (Sprague-Dawley; 
Harlan, Rossdorf, Germany) were dissected and trypsinized (0.25% v/v trypsin, 20 min 
at 37°C). Trituration was performed with needles and cell strainers as described in 
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chapter 3.1.2.1. Cells were cultivated in flasks in DMEM supplemented with 2 mM 
glutamine and 1x penicillin/streptomycin (100 U/mL). Medium was changed every 3-4 
days. After the cells reached confluency, they were detached with trypsin/EDTA and 
collected from the culture flask and plated onto cover slips (diameter 12 mm, placed in 
24-well plate) at a dilution of 1:12 with the same supplemented DMEM medium. 
3.2 In vitro scratch wound assays and RNA interference 
3.2.1 In vitro wounding of RGM-1 cells 
For the further use for immunocytochemistry, sterile glass cover slips (22 x 22 mm) 
were first placed in 6-well plate. RGM-1 cells were suspended in fully supplemented 
growth medium (see chapter 3.1.1) with 10% v/v FBS, seeded at a density of 4.5 x 10
5
 
in each well and cultured with 2.5 mL same medium. When cells were confluent, this 
medium was replaced by 2.5 mL serum free medium. After 12 h incubation, the cell 
monolayer was scratched under sterile conditions with a cell lifter (19 mm blade). 
Routinely, 2 wound sides (~18-19 mm) were created on each cover slip. The wounded 
cell cultures were carefully rinsed with serum free medium to remove residual cell 
debris. Cells were further incubated in 2.5 mL fresh serum free medium for 24 h and 
were then used for immunocytochemistry (see chapter 3.7.1.1).  
The cells used for RT-PCR analysis were prepared with a similar procedure as for 
immunocytochemistry. Instead of cover slips, cells were seeded in 100 mm cell culture 
dishes at a density of 2 x 10
6
 in fully supplemented growth medium with 10% v/v FBS. 
After reaching the cell confluence and following a 12 h serum free medium incubation, 
the cell monolayer was scratched under sterile conditions with a cell lifter (19 mm 
blade). Routinely, 5 rectangular wound zones (~5 x 40-80 mm) were created on each 
100 mm culture dish according to the pattern marked on the outer bottom surface of 
the cell culture dishes. The wounded cells were then carefully rinsed with 37°C serum 
free medium, further incubated in fresh serum free medium for 24 h at 37°C and then 
sorted as stationary and migratory cells (Figure 12, on page 33) for further 
experiments. 
3.2.2 siRNA and transfection 
Three non-overlapping stealth RNAi™ duplexes were designed to rat Tff1 
(NM_057129.1): site 1 (Tff1-siRNA1), site 2 (Tff1-siRNA2), and site 3 (Tff1-siRNA3). 
Sequence information for the three stealth RNAi™ duplexes as well as the stealth 
RNAi™ negative control used is provided in chapter 2.6. 
One day before transfection, RGM-1 cells were seeded in 100 mm cell culture dishes 
at 2 x 10
6
 cell density in fully supplemented growth medium with 10% v/v FBS. This 
medium was replaced by 15 mL Opti-MEM
®
 I reduced serum medium 4 h before 
transfection. Then cells were transfected with 125 nM stealth RNAi™ for Tff1 or stealth 
RNAi™ negative control, respectively, using the cationic lipid-based transfection 
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reagent Lipofectamine 2000 at 1 µg/mL according to the manufacturer’s instructions. 
Shortly, for each cell culture dish, 120 µL stealth RNAi™ duplexes (20 µM) was diluted 
and gently mixed with 1.5 mL Opti-MEM
®
 I reduced serum medium. Meanwhile 30 µL 
Lipofectamine
®
 2000 was gently mixed with 1.5 mL Opti-MEM
®
 I reduced serum 
medium, then incubated for 5 min at room temperature. All these steps were finished 
within 25 min. Then the diluted RNA oligomer and the diluted Lipofectamine
®
 2000 
were gently mixed and incubated for another 15 min at room temperature. At the end, 
RNA oligomer-Lipofectamine
®
 2000 complexes was added to the culture dish 
containing cells and 15 mL Opti-MEM
®
 I reduced serum. The medium was then mixed 
gently by rocking forth and back. 
After 8 hours, 10% FBS was added to the transfection mix. At 24 hours after 
transfection, the medium was replaced with normal growth medium, fully 
supplemented including 10% (v/v) FBS. Cells were cultured for another 48-72 h. When 
cells were confluent, this medium was replaced by 15 mL of serum free medium. After 
12 h incubation, the cell monolayers were scratched under sterile conditions with a cell 
lifter (19 mm blade). 
3.2.3 Scratch wounding of cells after transfection 
In the process of scratch wounding, 5 rectangular wound zones (~5 x 40-80 mm) were 
created as described in chapter 3.2.1 (also see Figure 12a).  
The wound areas were photographed immediately (0 h) and 24 h after the scratch at 
exactly the same positions according to the pattern on the outer bottom (Figure 11a). 
The growth area between the two time points (0 h and 24 h) was then analyzed by 
Adobe Photoshop 7.0 by counting the pixel numbers (Figure 11b, c).  
a
0h
  
b
0h
  
c
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24h
 
 
b
24h
 
 
 
Figure 11: Photograph and analysis process of the growth area after wound healing 
a: cell photos, made at exactly the same positions 0 h and 24 h after the scratch. b: cell edges 
(black line) as determined from the corresponding photos (the area with cells were marked with 
slashes) c: growth area of cells (marked in black) after 24 h wound healing 
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3.2.4 Isolation of stationary and migratory cells 
After the scratch wound assays (either from normal or siRNA transfected RGM-1 cells ) 
“stationary cells” and then the “migratory cells” were isolated (Znalesniak et al., 2009) 
for further analysis. Cell isolation begins with collection of the “stationary cells”. In this 
step, only cells that did not have direct contact with the border zone (i.e., cells from one 
half of the culture dish which has not been scratch wounded; see Figure 12a) were 
harvested with a plastic cell scraper.  
Then, all remaining stationary cells as well as the migratory cells close to the stationary 
cells were removed with 4-5 mm fragments of double edge stainless-steel razor blades 
as described previously (Dürer et al., 2007; Znalesniak et al., 2009). The remaining 
migratory cells were rinsed gently with 37°C serum free medium (~5 times), so that 
only a population of “pioneer” cells were left over (i.e., about 10 rows of cells directly 
behind the migratory front) and collected (Figure 12b, c, d). All procedures of cell 
wounding and cell sorting were controlled with a microscope.  
After a short rinse with PBS/pH 7.4 at 20°C, total RNA was isolated from the separated 
“migratory cells” and “stationary cells” respectively. RNA isolation was preceded with 
450 µL lysis buffer of ISOLATE RNA mini kit (Bioline GmbH) or 1 mL TRIzol
® 
reagent 
according to the manufacturer's protocol (see chapter 3.4.2). 
a b   
 
c d  
 
Figure 12: Scratch wound assay and 
isolation of stationary and migratory cells 
(a) Five rectangular wound zones were 
created on the right side of 100 mm culture 
dish according to the pattern marked on the 
outer bottom surface, i.e. all cells in the white 
area were carfully removed. Cells on the 
unwounded left side were used as stationary 
cells. (b) Cell growth pattern in one of the five 
wound zones, 24h after the scratch 
wounding. (c) Stationary cells were collected 
from left side of the dish. After having 
removed the other cells, only a population of 
pioneer cells were left over and collected as 
migratory cells (10 narrow rows of cells on 
right side of the dish). (d) “Pioneer” cells, left 
over in the wound zone and collected as the 
migratory cells. 
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3.3 Animal experiments 
3.3.1 Animal maintenance and genotyping 
Animal care and experimental procedures were performed according to legal 
regulations, and experiments with T. gondii infection were approved by state 
authorities (Landesverwaltungsamt, Saxony-Anhalt, Halle, Germany; AZ: 
IMMC/G/01-1004/10, 2-1174 Uni MD). Tff-deficient mice Tff1
KO
, Tff2
KO
, Tff3
KO
 and the 
corresponding wild type mice were used for the study (see chapter 2.4.1). Animals 
were kept at the animal facility of the Medical Faculty, housed in standard cages at a 
steady room temperature (22°C), maintained under controlled conditions with a 
regulated twelve hour light cycle (lights was available at 7 a.m.) and provided with food 
and water ad libitum.  
Genomic DNA used for genotyping was isolated from tail clippings taken at weaning 
and purified with Invisorb
®
 spin tissue mini kit (STRATEC GmbH) following the 
manufacturer’s instruction (see also in chapter 3.4.4). All primer sequences and 
corresponding gene maps are listed in Table 5. For Tff1
KO
 mice, the reverse primer 
MB990 annealed within the intron after exon2 of mTFF1 recognized both the knock out 
and wild type alleles. Paired with MB990, forward primer MB989 annealed to the intron 
before exon2 giving rise to a 215 bp amplicon, whereas forward primer MB988 
annealed within the targeted deletion neomycin cassette producing a 505 bp amplicon. 
For Tff2
KO
 mice, the reverse primer MB820 annealed within intron after exon4 
recognized both the null and wild type alleles. Paired with MB820, forward primer 
MB821 annealed within exon2 giving rise to a ~2.65kb amplicon, whereas forward 
primer MB819 annealed within the targeting vector producing a ~2.4kb amplicon. For 
Tff3
KO
 mice, to recognize the wild type alleles, forward primer MB1871 annealed within 
exon2 and reverse primer MB98 annealed intron after exon2 giving rise to a 291 bp 
amplicon, whereas to recognize the knock out alleles, primer pair MB1920 and 
MB1921 annealed within the targeted deletion neomycin cassette producing a 637 bp 
amplicon.  
Table 5: Primer list for genotyping 
Genes Primer 
No. 
Sequence Nucleotide 
positions 
Size 
(bp) 
     
Tff1 forward MB989 CCATGACTCACCCTGCTTTT intron before exon 2 215 
Tff1 reverse MB990 CCCCTACTGTGCTGAGAGATG intron after exon 2  
      
     
Neo forward MB988 AGGATCTCCTGTCATCTCACCT targeting vector 505 
Tff1 reverse MB990 CCCCTACTGTGCTGAGAGATG intron after exon 2  
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Genes Primer 
No. 
Sequence Nucleotide 
positions 
Size 
(bp) 
     
Tff2 forward MB821 GTCCCTTGGTGTTTCCACCC exon2 ~2.65k 
Tff2 reverse MB820 ACTGTGATCAGCAGTCATGCG intron after exon4  
      
     
Neo/Tff2 forward MB819 GGTACCCCGGGTTCGAAATC targeting vector ~2.4k 
Tff2 reverse MB820 ACTGTGATCAGCAGTCATGCG intron after exon4  
      
     
Tff3 forward MB1871 CTGTCACATCGGAGCAGTGT exon 2 291 
Tff3 reverse MB98 TGACCCTGTGTCATCACCCT intron after exon 2  
      
     
Neo forward MB1920 TGCTCTGATGCCGCCGTGTT targeting vector 637 
Neo reverse MB1921 GCACGAGGAAGCGGTCAGCC targeting vector  
      
3.3.2 Toxoplasma gondii infection 
Mice used for T. gondii infection were kept under specific-pathogen free (spf) 
conditions. To obtain T. gondii cysts for in vivo experiments, NMRI mice 
(Harlan-Winkelmann, Borchen, Germany) were orally infected with 5 cysts of a type II 
strain of T. gondii (DX or ME49) at the age of 2 to 3 months, as described (Deckert et al. 
2006; Dunay et al. 2008; Händel et al. 2012; performed and provided by IMMB, 
Magdeburg). Cysts formed in the brain of these mice and were then used for the 
experimental infection. These chronically T. gondii infected mice were sacrificed 3 to 5 
months after infection to obtain the cysts produced (approximately 50 cysts per total 
mouse brain). The mice were deeply anesthesized with isoflurane and decapitated. 
Brain tissues were removed and dispersed in 2 mL 0.1 M PBS/pH 7.4 using button 
needles and injection needles. Then 20 µL of this suspension was spread on a 
microscope slide, covered with a cover slip. The number of cysts was counted under 
the microscope with magnification of 10 and was then adjusted to a concentration of 25 
cysts / mL in 0.1 M PBS. The adjusted suspension was administered (i.p. or p.o.) to the 
experimental mice (Tff1
KO
, Tff2
KO
 and Tff3
KO
 mice). DX-strain suspension (200 µL) was 
intraperitoneally injected (i.e., 5 T. gondii cysts per mouse) by Dr. U. Händel (IMMB, 
Magdeburg) and ME49-strain suspension (120 µL) was orally administered (i.e., 3 
cysts pro mouse) by Dr. I. Dunay (IMMB, Magdeburg). 
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3.3.3 Perfusion, organ collection and tissue processing 
Four weeks after the i.p. infection (performed by Dr. U. Händel, IMMB, Magdeburg) or 
7 days after the oral infection (performed by Dr. I. Dunay, IMMB, Magdeburg), organs 
of the experimental mice were harvested. Animals were deeply anaesthetized with 
isoflurane and perfused transcardially with 50 mL saline to remove contaminating 
intravascular leukocytes from the brains and other organs and then decapitated. The 
skull bone was carefully removed to obtain an injury-free brain. The brain was then 
sagittally cutted through the midline of the brain into two parts. The left half of the brain 
was used for immunohistochemistry (see chapter 3.7.2), and the right half of the brain 
was used for RNA and protein extraction and proceeded for further processing of 
experiments (see chapter 3.4.2). Ileum (only from orally infected mice), colon and 
stomach were also collected. 
3.4 Extraction from Tissue and Cells 
3.4.1 Preparation of tissue and cells 
Fresh tissue or tissue kept at -80°C was cooled on ice, cut with a scalpel into small 
pieces (0.2-0.5 g) and filled in a 2 mL tube added with corresponding buffer for 
RNA/protein extraction. After cooling in liquid nitrogen for 10 s, the suspension was 
homogenized with the Precellys 24 (2 x 20 s, 6800 rpm, 30 s pause). After 
centrifugation at 16,000 g for 5-10 min at 4°C, the supernatants were transferred to 
new tubes and used for RNA/protein extraction. 
Collected cells were washed 3 times with 1x PBS and added with corresponding buffer 
for extraction, then homogenized by pipetting up and down. Suspensions were 
centrifuged at 16,000 g for 5-10 min at 4°C when needed. The supernatants were 
transferred to new tubes for RNA/protein extraction. 
3.4.2 Total RNA extraction 
Total RNA of tissues and cells was isolated and purified using TRIzol
® 
reagent or 
ISOLATE RNA mini kit, according to the manufacturer's protocol. 
When using the ISOLATE RNA mini kit, the chaotropic lysis buffer was used to lyse the 
cells and inactivate RNases. After homogenizing, the sample lysate was applied to a 
spin column to selectively remove genomic DNA. RNA was then bound to a silica 
membrane. Remaining cell debris was removed by subsequent wash steps. Pure RNA 
was eluted in the final step with RNase-free water.  
Sample lysate was centrifuged at maximum speed for 1 min and was carefully 
transferred to spin column R1 placed in a 2 mL collection tube. After 2 min 
centrifugation at 10,000 g, spin column R1 was discarded, and 1 volume (usually 
400µL) of 70% ethanol was added to the filtrate and well mixed by pipetting. The 
mixture was then transferred to spin column R2 placed in a new collection tube and 
centrifuged at 10,000 g for 2 min. The filtrate was discarded. Spin column R2 was 
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placed in a new collection tube, filled with 500 µL wash buffer “AR” and centrifuged at 
10,000 g for 1 min. Then the filtrate was discarded. Spin column R2 was placed in a 
new collection tube, filled with 700 µL wash buffer BR and centrifuged at 10,000 g for 1 
min. The filtrate was discarded and spin column R2 was placed in a new collection 
tube centrifuged at 10,000 g for another 2 min to remove all traces of ethanol. Then the 
spin column R2 was placed in an elution tube and 30 µL RNase-free water was directly 
added to spin column membrane. After 1 min incubation at room temperature, the 
elution tube was centrifuged at 6000 g for 1 min to elute the RNA. 
The extraction with TRIzol
® 
Reagent uses the acid guanidinium thiocyanate-phenol- 
chloroform method (Chomczynski & Sacchi, 1987). Under acidic conditions (pH 4-6), 
proteins and DNA partitioned into the organic phase, while RNA remained in the 
aqueous phase. RNA is then recovered from the aqueous phase by precipitation with 
isopropanol or ethanol.  
The supernatant (1 mL) of TRIzol
® 
Reagent was first incubated for 5 min at room 
temperature to permit complete dissociation of the nucleoprotein complex, and then 
200 µL chloroform were added and shaked vigorously by hand for 15 seconds. After 
2-3 min incubation at room temperature, the mixture was centrifuged at 12,000 g, 4°C 
for 15 min. Three phases were formed: a lower red phenol chloroform phase, an 
interphase, and a colourless upper aqueous phase. The aqueous phase was carefully 
aspirated into a new tube to precede the procedure for RNA extraction. The interphase 
and organic phenol-chloroform phase were saved for the protein extraction. For 1 mL 
of TRIzol
®
 Reagent 0.5 mL of 100% isopropanol was added to the aqueous phase. 
After 10 min incubation at room temperature, the mixture was centrifuged at 12,000 g, 
4°C for 10 min. After 2 times wash with 1 mL of 75% ethanol, the RNA pellet was air 
dried for 5-10min. The RNA pellet was then resuspended in RNase-free water and 
incubated at 60°C for 10 min. The isolated RNA was used for further studies or frozen 
at -80°C for long-term storage. 
3.4.3 Total protein extraction 
Total protein of cells and tissues was isolated using either protein extraction buffer 
(self-configured, see below) or the TRIzol
® 
reagent according to the manufacturer's 
protocol.  
When using the protein extraction buffer (see below), 4-fold volume of buffer (0.8 - 2 
mL) with 50 mg/mL protease inhibitor was added to tissue (0.2 – 0.5 g); alternatively 
150 µL extraction buffer was added to the cells. The supernatant was added to the 
same volume of chloroform (0.8 - 2 mL) and incubated for 30 min at 4°C to remove 
non-polar interfering substances. The mixture was then centrifuged at 16,000 g for 10 
min at 4°C. Supernatant was used for further experiments or frozen at -20°C for 
long-term storage. 
When using the TRIzol
® 
Reagent, the interphase and the organic phenol-chloroform 
phase left from TRIzol
® 
Reagent RNA extraction were used for protein extraction. The 
proteins were denatured by this chaotropic agent (guanidinium thiocyanate) in the 
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organic phase. For 1 mL TRIzol
® 
Reagent used in the initial homogenization, 1.5 mL of 
isopropanol was added to the phenol-ethanol supernatant. After 10 min incubation at 
room temperature, the mixture was centrifuged at 12,000 g, 4°C for 10 min. The protein 
pellet was then washed three times with 2 mL 0.3 M guanidine hydrochloride in 95% 
ethanol and once with 2 mL of 100% ethanol for 20 min each at room temperature and 
centrifuged at 7500 g for 5 min at 4°C after every wash step. Supernatant was 
discarded and the protein pellet was air dried for 5-10min and dissolved in 1% SDS 
(sodium dodecyl sulfate) solution. For long-term storage, protein was frozen at -20°C. 
Protein extraction buffer (500mL) 
1 M Tris/HCl, pH 8.0 10 mL 
4 M NaCl 3.75 mL 
deionized water add to 500 mL 
3.4.4 Genomic DNA extraction 
Genomic DNA for genotyping was isolated from tail clippings taken at weaning and 
further purified with Invisorb
®
 Spin Tissue Mini Kit following the manufacturer’s 
instruction. Briefly, tail clippings were digested in 400 µL lysis buffer G with protein 
kinase K, shaked at 52°C for 2 h. After 1 min centrifugation, the suspension was 
transferred to a new tube and filled with 200 µL binding buffer T. The mixture was 
mixed thoroughly and transferred to the column set in a 2 mL tube. The tube was 
centrifuged 1 min and filtration was discarded. The column was then washed two times 
with wash buffer and centrifuged 1 min, and then the column was centrifuged for 
another 2 min to remove the remaining buffer. The elution buffer E was applied to the 
centre of the membrane in column and centrifuged for 2 min. The eluted DNA can be 
directly used for PCR for genotyping. 
3.5 RT-PCR analysis 
3.5.1 RNA quantification  
RNA (DNA) concentration was calculated from the absorption measured at a 
wavelength of 260 nm as well as 280nm by NanoDrop ND-1000 spectrophotometer 
following the instruction. RNA solution (1-2 µL) was applied to the sensor of the 
spectrophotometer and the concentration was determined directly from the 
measurement. 
3.5.2 Removal of genomic DNA and reverse transcription 
Before reverse transcription, total RNA (normally 2 µg RNA for tissues and 0.5 µg RNA 
for cells) from each sample was first digested with DNase I to eliminate the rest of 
genomic DNA. According to the manufacturer's instructions, RNA was incubated with 
the enzyme at 37°C for 45 min (see below), and DNase I was then inactivated by 10 
min incubation with EDTA at 65°C.  
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Digestion of RNA 
RNA 0.5-2 µg  x µL 
10x Reaction buffer with MgCl2 1 µL 
DNase I, RNase-free (1 u) 1 µL 
RiboLock
TM
 RNase inhibitor (40 u) 1 µL 
DEPC-treated water to 10 µL 
After the DNA digestion, RNA was used for the first strand cDNA (complementary 
DNA) synthesis. The reaction was primed with oligo(dT)18 using RevertAid H Minus 
reverse transcriptase according to the manufacturer’s protocol. RNA was incubated 
with oligo(dT)18 primer at 65°C for 5 min to allow denaturation and then was chilled 
immediately on ice for 3 min to prevent renaturation. After a gentle mix and a brief 
centrifugation, RNA was incubated with reverse transcriptase, mixed with 5x reaction 
buffer, RNase inhibitor and dNTP, at 42°C for 60 min. The reaction was terminated by 
heating at 70°C for 10 min (see below). The mix was subsequently diluted to 100 µL 
with sterile deionized water. After a brief centrifugation, the cDNA was used for further 
studies or frozen at -20°C for long-term storage. 
Reverse transcript reaction (20 µL reaction) 
Total RNA after DNA digestion (with EDTA) 11 µL 
Oligo(dT)18 primer 1 µL 
 5 min, 65°C 
  
5x Reaction buffer 4 µL 
RiboLock RNase inhibitor (40 u) 0.5 µL 
dNTP Mix, 10 mM each 2 µL 
RevertAid H Minus reverse transcriptase (200 u) 1 µL 
 60 min, 42°C, then 10min, 70°C 
3.5.3 PCR 
The relative expression level of selected genes was monitored by RT-PCR analysis. 
DreamTaq Green DNA Polymerase was used for amplification. The reaction mix was 
prepared (see below) and overlaid with light mineral oil. PCR amplification was then 
performed in the programmed (see below) thermo Robocycler. Beta-actin transcripts 
were amplified in parallel reactions as an internal control for the integrity of the cDNA 
preparations. The cDNA was also checked for contaminating chromosomal DNA by 
amplification of a promoter sequence (from the beta-actin gene). All the specific primer 
pairs used in this study are listed at chapter 2.8. 
RT-PCR reaction (10 µL reaction) 
cDNA (equivalent of 2 mg/L RNA) 1-4 µL 
10x DreamTaqGreen buffer* 1 µL 
dNTP Mix, 2 mM each 1 µL 
7.5 µM primer-mix (forward + reverse) 1 µL 
DreamTaq DNA polymerase 0.1 µL 
autoclaved deionized water to 10 µL 
*10x DreamTaq Green Buffer contains 20 mM MgCl2 and loading dye 
Thermal cycling programs for RT-PCR reaction 
Step Temperature Time  Number of cycles 
initial denaturation 95°C 3 min 1 
denaturation 95°C 45 s 
annealing 57/60°C 45 s 
extension 72°C 45 s 
24-40 
final extension 72°C 5 min 1 
Methods 
 40 
3.5.4 Electrophoresis 
After PCR, the size of the products was confirmed by electrophoresis on a 1.5% 
agarose gel. For preparation of the gel, 8 g agarose were dispersed in 500 mL 1x TBE 
buffer (see below) and heated in a microwave oven until completely dissolved. Before 
casting the gel, 10 mg/L ethidium bromide was added to the dissolved agarose. Then 
the horizontal agarose gel was casted in the leveled casting chamber with comb teeth. 
Comb teeth were slowly removed once the gel solidified. Each amplification reaction 
(8.5 µL from the 10 µL reaction) was loaded into the gel slots. The electrophoresis was 
run using power supply system (Heinzinger Economy Line LNG 350 06) at 150 V in 1x 
TBE buffer. The PCR products resolved in the gel were visualized (exposure at 254 nm 
UV light) and documented by the Herolab E.A.S.Y system.  
1x TBE buffer (1L) 
Tris 10.8 g 
H3BO3 (solid) 5.5 g 
0.5 M EDTA, pH 8 4.0 mL 
deionized water to 1 L 
3.5.5 Semi-quantitative analysis 
All relative expression levels of selected genes were determined by semi-quantitative 
analysis of the DNA bands with the GeneTools software. As a control gene β-actin was 
amplified in parallel reactions. All data were then analyzed with Excel 2003. 
3.6 Western blotting 
3.6.1 Protein quantification 
Total protein concentration of cell or tissue extracts were determined using two protein 
quantitation methods: BCA (bicinchoninic acid) method and Bio-Rad Protein Assay 
method.  
The BCA method is a quick and highly accurate protein quantitation method. The BCA 
reagent reacts with protein and changes color from light blue to purple. The intensity of 
purple color is based on the amount of total protein concentration in the sample. Total 
protein concentration of the sample was determined by comparing absorbance (562 
nm) readings to serially diluted BSA standards. The BCA protein assay reagent was 
used following the manufacturer's instructions. All samples were prepared in duplicate 
and incubated for 30 min at 37°C. Absorbance was measured with the NanoDrop 
ND-1000 spectrophotometer following the instructions. The protein concentrations of 
the sample were calculated out automatically from the standard curve. 
The Bio-Rad protein assay is based on the reaction of proteins with an alkaline copper 
tartrate solution and Folin reagent. It was also used for protein quantitation following 
the manufacturer's instructions. The BSA standards were the same as for the BCA 
method. All standards and samples were prepared in duplicate. The Bio-Rad assay 
dye was diluted 1:5 with deionized water and well mixed. For each measurement 1 mL 
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diluted dye with 1 µL standard or sample was mixed thoroughly and then transferred to 
a disposable plastic cuvette. The absorbance was read at 595 nm by Libra S12 
spectrophotometer. The concentration was then determined using the standard curve 
equation in Excel 2003. 
3.6.2 SDS-PAGE (sodium dodecyl sulfate- polyacrylamide gel 
electrophoresis) 
Proteins were separated by SDS-PAGE based on molecular weight. The SDS-PAGE 
gel consists of two sections: the upper stacking gel (see below) focused the proteins 
and the running gel (see below). The two sections were prepared from different buffers, 
and combined with different pH values. Protein samples were mixed (3:1) with 
corresponding 4x loading buffer (reducing or non-reducing, see below) and boiled for 5 
min. Then samples were immediately cooled in ice for 5 min to prevent renaturation, 
and were briefly centrifuged.  
Samples with equal amounts of proteins (10 or 20 µg) were loaded in each lane. 
Protein-Marker I (7 µL) was loaded into one lane in order to provide a reference. The 
gel was run in electrophoresis buffer Laemmli (see below) at 75 mA until the protein 
samples entered the running gel, then the current was raised to 100 mA until desired 
protein separation was achieved. 
6% Stacking gels for Western blot (for 2 gels) 
4x stacking gel buffer 3.125 mL 
30% acrylamide/bisacrylamide (37.5:1) 3.125 mL 
20% SDS (w/v) 0.125 mL 
TEMED 12.5 µL 
20% APS (w/v) 125 µL 
deionized water 9mL 
4x Stacking gel buffer (500 mL): 60.57 g Tris (1 M), adjusted to pH 6.8 with HCl 
15% Running gels for Western blot (for 2 gels) 
4 x running gel buffer 3.8 mL 
30% acrylamide/bisacrylamide (37.5:1)  10.0 mL 
TEMED 8 µL 
20% APS (w/v) 80 µL 
deionized water 6.2 mL 
4x Running gel buffer (500 mL): 90.86 g Tris (1.5 M) + 10 mL SDS (10% (w/v)),  
adjusted to pH 6.8 with HCl; add APS and TEMED shortly before overlaying 
4x Reducing loading buffer (10 mL) 
0.5 M Tris/HCl, pH 6.8 2.5 mL 
glycerol 2.0 mL 
10% SDS (w/v) 4.0 mL 
0.1% bromophenol blue (w/v) 0.5 mL 
2-mercaptoethanol 0.5 mL 
deionized water 0.5 mL 
For non-reducing buffer, use 0.5 mL deionized water  instead of 2-mercaptoethanol 
Electrophoresis buffer Laemmli (500 mL) 
Tris  1.52 g 
glycine 7.13 g 
20% SDS (w/v) 2.5 mL 
deionized water add to 500 mL 
pH approx. 8.8 
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3.6.3 Western blot 
After the protein separation, the SDS-PAGE gel was carefully removed from the 
chamber. Protein transfer (from the polyacrylamide gel to the nitrocellulose membrane) 
was carried out with a 20x20 cm semi dry blotter. The gel was carefully placed on the 
top of the membrane to avoid any air bubble. The membrane was placed on three 
layers of filter papers (gel-blotting-paper BF2) on the anode side of the semi dry blotter, 
and the gel was covered with another three layers of filter papers to form a 
sandwich-structure. All materials in this step were pre-wetted in transfer buffer (see 
below). After covering the cathode on this sandwich-structure, the transfer was for 70 
min at 0.8 mA /cm
2
 (approx. 90 mA for each membrane). To control the transmission 
efficiency, the membrane was shortly treated with Ponceau S solution (see below), a 
negatively charged stain that can bind to positively charged amino groups of the 
blotted polypeptides. 
Transfer buffer for electro-blot (1000 mL) 
Tris 5.81 g 
glycine 2.93 g 
20% SDS 1.85 mL 
methanol 200 mL 
deionized water add to 1000 mL 
pH approx. 8.8 
Ponceau S solution (500 mL) 
Ponceau S 1.0 g 
Trichloroacetic acid 15 g 
deionized water add to 500 mL 
3.6.4 Immunological detection of proteins 
In order to detect the protein of interest, mono- or polyclonal antibodies can be used. 
The membrane needs first to be blocked with a blocking solution to prevent 
non-specific antibody binding, and then be incubated with primary antibodies which 
bind the protein of interest. After extensive washing, the membrane is incubated with 
the appropriate secondary antibody that binds the primary antibody. Usually the 
secondary antibody is conjugated to an enzyme, for instance horseradish peroxidase, 
which aids in visualization (Alberts et al., 2002). After the enhanced 
chemiluminescence (ECL) treatment, the oxidized form of luminol from horseradish 
peroxidase (HRP) produces chemiluminescence, which can be detected at 428 nm.  
For this purpose, the transferred protein on nitrocellulose membrane was fixed by 
treating with 0.2% glutaraldehyde in 1x PBS (see below) for 30 min. After washing two 
times with 1x PBS-T (see below) and once with 1x TBS-T (see below) for 5 min each, 
the unspecific binding sites on the membrane were blocked with blocking buffer 
(consisting of 1% BSA and 1% dry milk in 1x TBS-T) for 60 min. Then the membrane 
was incubated with primary antibody diluted in 1x TBS-T (see chapter 2.3.2) at 4°C 
overnight or at room temperature for 60-120 min. After three times 5 min washing with 
1x TBS-T, the membrane was incubated with the corresponding secondary antibody 
conjugated with HRP (see chapter 2.3.3) at room temperature for 45-60 min. Dilution 
was with 1x TBS-T diluted. Then the membrane was washed two times, 10 min each 
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with 1x TBS-T. The ECL solution (see below) was prepared during this washing step. 
For one membrane, 2.5 mL of each fresh ECL solution were mixed and the mixture 
was pipetted onto the membrane. After 2 min incubation, the membrane was visualized 
with Gene Gnome. The exposure times of each membrane differed from 5 x 2 min to 5 
x 3 min depending on the signal strength. 
1x PBS (2000 mL) 
Na2HPO4  2.3 g 
KH2PO4  0.5 g 
NaCl  18.0 g 
deionized water add to 2000 mL 
KH2PO4 dissolves at last, adjust to pH 7.4 with NaOH before making up to 2000 mL 
1x PBS-T (1000 mL) 
1x PBS 999 mL 
Tween 20 1 mL 
1x TBS-T (2000 mL) 
Tris 4.84 g 
NaCl 17.52 g 
Tween 20 2 mL 
deionized water add to 2000 mL 
ECL solution (10 mL) 
solution A 250 mM luminol (44.29 g/L) 100 µL 
 90 mM p-coumaric acid (14.77 g/L) 44 µL 
 1 M Tris/HCl, pH 8.5 1000 µL 
 deionized water 8856 µL 
solution B 30% H2O2 (w/v) 6.1 µL 
 1 M Tris/HCl, pH 8.5 1000 µL 
 deionized water 8993.9 µL 
mix solution A and B (1:1) shortly before use 
3.6.5 Competitive inhibition 
The specificity of the staining with anti-mTff1-1 and anti-rTff3-2, respectively, was 
tested by competition with the corresponding synthetic peptides (see chapter 2.3.3). 
One mL antiserum (anti-mTff1-1 or anti-rTff3-2, diluted in 1x TBS-T buffer, 1:500) was 
pre-adsorbed with 10 µg corresponding synthetic peptide by shaking at 4°C overnight 
and then used for Western blot analysis. 
3.7 Immunohistochemistry 
3.7.1 Cell cultures 
3.7.1.1 RGM-1 cells (after in vitro wounding) 
Cells on glass cover slips (22 x 22 mm, see chapter 3.2.1) were fixed with cold 
methanol at -20°C for 5 min and then washed 3 times for 5 min each with PBS/pH 7.4 
at room temperature. Non-specific antibody binding sites were blocked with blocking 
buffer (see below) at room temperature for 1 h. The primary antibody anti-mTff1-1 (see 
chapter 2.3.2) was 1:500 diluted with blocking buffer. The incubation with the primary 
antibody was at 4°C overnight. The cover slips were rinsed with PBS/pH 7.4 3 times 5 
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min each at room temperature, and then incubated with the secondary antibody, 
Cy3-labeled anti-rabbit-IgG F(ab’)2 fragment from sheep antiserum (see chapter 
2.3.3), 1:200 diluted in blocking buffer at room temperature for 1 h (from this step, the 
incubation and all following steps were carried out in the dark) and rinsed again with 
PBS/pH 7.4 2 times 5 min each at room temperature. 
Blocking buffer (10 mL) 
goat serum 1 mL (final conc. 10%) 
10% NaN3 100 µL (final conc. 0.1%) 
10% Triton™ X-100 300 µL (final conc. 0.3%) 
1x PBS/pH 7.4 add to 10 mL 
The cell nuclei were stained with DAPI (4',6-diamidino-2-phenylindole dihydrochloride) 
at room temperature for 5 min using a 1:1000 diluted DAPI stock solution (0.1 mg/mL 
in PBS/pH 7.4). Subsequently, the cover slips were rinsed twice with PBS/pH 7.4 at 
room temperature for 5 min and once with deionized water for 5 min. The cover slips 
were embedded on the microscope slides using DAKO fluorescent mounting medium. 
The slides were photographed with an Axiophot microscope equipped with an 
AxioCam digital camera. The following filter sets were used: filterset 01 for DAPI and 
filterset 15 for Cy3 (see chapter 2.7). The images were processed with the AxioVision 
3.1 software. 
3.7.1.2 Primary rat brain cells 
All procedures were performed at room temperature. After 20–22 DIV (days in vitro), 
primary culture cells (provided from Dr. Stellmacher, IPT, Magdeburg) grown on glass 
cover slips were fixed with periodate-lysine-paraformaldehyde (PLP) fix (see below) for 
30 min. Cells were washed with PBS 3 times and blocked with blocking solution (see 
below) for 1 h. Subsequently, cells were incubated with primary antibody (see chapter 
2.3.2) diluted in blocking solution for 1 h. After 3 times washing with PBS, cells were 
incubated with secondary antibodies (see chapter 2.3.3) diluted in block solution for 1 h. 
Cells were incubated with DAPI for 3 min to stain the cell nuclei. Subsequently, cells 
were washed 2 times with PBS, once with water, and mounted with Mowiol 4-88 onto 
the slide. The following antibodies were used (see also in chapter 2.3): primary 
antibodies: goat anti-Iba-1, rabbit anti-Iba-1, chicken anti-GFAP, mouse anti-MAP2, 
and rabbit anti-rTff3-2 antiserum; secondary antibodies: donkey anti-goat Cy3, Alexa 
Fluor™ 488 goat anti–rabbit, donkey anti-chicken Cy3, DyLight™ 649 donkey 
anti–chicken, donkey anti-mouse Cy3, goat anti-rabbit Cy3.  
PLP fix 
PFA (paraformaldehyde) 4% 
sucrose 5.4% 
NaIO4 0.01 M 
lysine HCl 0.1M 
dissolved in 0.1M sodium phosphate buffer/pH 7.4 
Blocking solution 
horse serum 10% 
sucrose 5% 
BSA 0.01 M 
saponin 0.2 mg/mL 
dissolved in PBS buffer, pH 7.4 
Methods 
 45 
Cells were viewed and recorded digitally using the Zeiss microscope Axio Observer.Z1 
equipped with a camera AxioCam MRm and the AxioVision Release 4.8 software. The 
excitation and emission spectra of the fluorescent markers for all the 
immunofluorescence staining are listed below. Images were processed using Adobe 
Photoshop 7.0. 
Excitation and emission spectra of the fluorescent markers 
Fluorescence Marker Excitation (nm) Emission (nm) Colour/Spectrum 
Alexa Fluor 488 499 519 green 
Cy3 552 565 red 
Alexa Fluor 647 652 668 infrared 
DyLight 649 654 673 infrared 
DAPI 345 455 blue 
3.7.1.3 Quantitative analysis 
Photos of the RGM-1 cells after in vitro wounding were captured in such way that both 
stationary and migratory cell regions were visible. All photos had the same frame size. 
For each photo, the total Tff1 immunofluorescence signal was analyzed within a 
normalized area of stationary and migratory cells, respectively, with GeneTools (Figure 
13). This signal was divided by the number of cells in order to obtain the Tff1 staining 
per cell. All data were then analyzed with Excel 2003. 
   
Figure 13: Schematic presentation of total Tff1 immunofluorescence signal analysis  
The rectangular standardized zones (stationary (s) and migratory (m)) were marked by a red line. 
The scratch wound is indicated by the white dotted line. (A) Using GeneTools software, total Tff1 
immunofluorescence was measured within a pair of rectangular standardized zones (s and m).  
(B) The cell number within the corresponding areas was counted after staining the nuclei with 
DAPI. Scale bar: 20µm. 
3.7.2 Tissues 
3.7.2.1 Tissue preparation 
Mouse brains were carefully dissected (see chapter 3.3.3). The right half used for 
freeze sections was immediately fixed in 4% PFA (in 50 mM HEPES-Puffer/pH 7.4) 
overnight at 4°C, and then transferred to 1 M sucrose (dissolved in 1x PBS/pH 7.4) 
overnight at 4°C. Subsequently, the tissues were embedded in OCT compound 
(Tissue-Tek
®
), frozen in 2-methylbutane (pre-frozen at -60°C) for 2 min, and then 
stored at -80°C. To prepare sagittal sections for free floating immunohistochemical 
staining, the frozen half hemisphere was cut using Leica Jung CM3000 Cryostat 
Microtome at -20°C. The 25 µm sagittal sections were cut and carefully collected into 
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24-well plate containing 1x PBS and used for further experiments. For long-term 
storage, sections were frozen in 1 M sucrose at -20°C. 
3.7.2.2 Free floating immunohistochemistry 
Free-floating sections were washed 3 times for 10 min each with PBS/pH 7.4 at room 
temperature. Sections were then incubated in 50% (v/v) methanol solution in 1x 
PBS/pH 7.4 with 1% (v/v) H2O2 (fresh made) at room temperature for 10 min to block 
the endogenous peroxidase activity. Then sections were washed again 3 times for 10 
min each with PBS/pH 7.4 at room temperature. The non-specific background staining 
of sections were blocked with freshly made blocking buffer I (see below) at room 
temperature for 60 min. Then, sections were incubated with the primary antibodies 
mTff1-1 and Iba-1 (see chapter 2.3.2), diluted in blocking buffer I, for 1-3 days at 4°C. 
Sections were then washed 3 times for 10 min each with PBS/pH 7.4 at room 
temperature and blocked again with blocking buffer II (see below) for 60 min at room 
temperature. Sections were incubated with the secondary antibody (biotinylated goat 
anti-rabbit IgG antibody, see chapter 2.3.3) diluted in blocking buffer II at room 
temperature overnight. After that, sections were washed 3 times for 10 min each with 
PBS/pH 7.4 at room temperature.  
The avidin-biotin peroxidase complex (ABC) method (VECTASTAIN
®
 Elite ABC Kit, 
BIOZOL GmbH) was used following the manufacturer's instructions. First, sections 
were blocked with 1x BSA (0.2%) solution at room temperature for 60 min. During this 
time, solution A and solution B from the VECTASTAIN
®
 Elite ABC Kit were both 1:1000 
diluted in 1x BSA solution (see below) and incubated at room temperature for 30 min. 
After the blocking, sections were further incubated with this mixture, overnight at 4°C or 
more than 4 h at room temperature. Then, sections were washed two times with 1x 
PBS/pH 7.4 and once with 1x Tris-buffer/pH 7.6 (0.05 M) for 10 min each at room 
temperature. During this washing step, 0.5 g/L DAB (diaminobenzidine) solution (in 1x 
Tris-buffer/pH 7.6) as chromogen was freshly made and 0.5 mL DAB solution was 
added to each well of the 24-well plate containing sections. To start the staining 
reaction, 20 µL 3% H2O2 was added to each well and incubated for 2-4 minutes under 
visual control to avoid strong background. The reaction was stopped with PBS washing 
for three times and then mounted onto gelatine-coated slides (pretreated with 0.5% 
gelatine; air dried and stored at 4°C). After being air-dried, the slides with mounted 
sections were progressively dehydrated: first with series of ethanol (concentration 
elevated from 70% to 100%), 2 min each; then with xylol (two times, for 2 min and 5 
min). At the end, cover slips were mounted with DPX mounting medium on the slides. 
After air drying overnight, the slides were examined under the microscope BZ-8000 
(Keyence) and then processed with the BZ observation application software 
(Keyence). 
Blocking buffer I for immunohistochemical staining (10 mL) 
goat serum 1 mL (final conc. 10%) 
10% NaN3 100 µL (final conc. 0.1%) 
10% Triton™ X-100 300 µL (final conc. 0.3%) 
1x PBS/pH 7.4 add to 10 mL 
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Blocking buffer II for immunohistochemical staining (10 mL) 
goat serum 1 mL (final conc. 10%) 
10% NaN3 100 µL (final conc. 0.1%) 
10% Triton™ X-100 100 µL (final conc. 0.1%) 
1x PBS/pH 7.4 add to 10 mL 
Mixture from VECTASTAIN
®
 Elite ABC Kit (10 mL) 
2% BSA 1 mL (final conc. 0.2%) 
solution A from ABC Kit 10 µL 
solution B from ABC Kit 10 µL 
1x PBS/pH 7.4 add to 10 mL 
3.7.3 Competitive inhibition 
The specificity of the staining with anti-mTff1-1 and anti-rTff3-2, respectively, was 
tested by competition with the corresponding synthetic peptides, i.e., 1 mL antiserum 
(anti-mTff1-1 or anti-rTff3-2, diluted in blocking buffer) was pre-adsorbed with 10 µg 
corresponding synthetic peptide by shaking at 4°C overnight and then used for 
immunohistochemistry. 
3.8 Stable transfection of RGM-1 cells 
3.8.1 Construction of plasmid 
3.8.1.1 Primer construction and reliable RT-PCR 
The primers for the corresponding genes (human TFF1-3, GKN2) were designed for 
the complete coding sequences (CDs). Corresponding restriction sites were added to 
the 5’-end of both primers (forward and reverse). The primer pairs used in this study 
are listed in chapter 2.8. The PCR reaction was performed with HotStar HiFidelity DNA 
Polymerase Kit (Qiagen). HotStar HiFidelity DNA Polymerase possesses a 3'→5' 
exonuclease activity generally referred to as proofreading activity. It has been 
chemically modified to temporarily inactivate the polymerase activity, as well as the 
3'→5' exonuclease activity of the enzyme. This prevents excessive degradation of both 
primers and template during PCR setup and the initial PCR cycles, providing highly 
sensitive and reliable high-fidelity PCR. The products generated using HotStar 
HiFidelity DNA Polymerase can be used directly in TA- or UA- cloning procedures. 
Following the manufacturer's instructions, 2 µL cDNA from human tissue (stomach for 
TFF1, TFF2 and GKN2; colon for TFF3) was used in a 20 µL PCR reaction. After 
shortly mixing and brief centrifugation, PCR amplification without mineral oil was then 
performed in the programmable thermo Robocycler with lid heating.  
Reliable RT-PCR reaction (20 µL) 
cDNA (equivalent of 2mg/L RNA) 2 µL 
5x HotStar HiFidelity PCR buffer* 4 µL 
7.5 µM primer-mix (forward + reverse) 2 µL 
HotStar HiFidelity DNA Polymerase (2.5 units/µL) 0.5 µL 
RNase-free water to 20 µL 
*Contains 1.5 mM dNTPs and 7.5 mM MgSO4. 
Methods 
 48 
Thermal cycling programs of reliable RT-PCR reaction 
Step Temperature (°C) Time  Number of cycles 
initial denaturation 95 5 min 1 
denaturation 94 30 s 
annealing 60 45 s 
extension 72 60 s 
35 
final extension 72 10 min 1 
3.8.1.2 TA cloning with pGEM®-T Easy Vector System I 
Before cloning, 10 µL of each reliable RT-PCR amplicons were mixed with 1.8 µL 6x 
loading dye and analyzed by gel electrophoresis (see chapter 3.5.4). The remaining 
amplicons were then ligated into the pGEM-T
®
 Easy Vector, a linearized vector with a 
single 3´-terminal thymidine at both strands. The T-overhangs at the insertion site of 
this vector greatly improve the efficiency of ligation of PCR products by preventing 
recircularization of the vector and providing a compatible overhang for PCR products 
generated by certain thermostable polymerases. Following the manufacturer's 
instructions of pGEM-T
®
 Easy Vector System I kit (Promega GmbH), the 2x rapid 
ligation buffer, the pGEM-T
®
 Easy vector, the T4 DNA Ligase and the PCR production 
were mixed (see below) and incubated for 15-30 min at room temperature, and 
competent E. coli cells were transformed with the ligation mix. 
Ligation reaction (10 µL) 
2x rapid ligation buffer 5 µL 
pGEM
®
-T or pGEM
®
-T Easy Vector (50ng) 1 µL 
T4 DNA ligase (400 units/µL) 1 µL 
PCR product 2 µL 
nuclease-free water to 10 µL 
3.8.1.3 Transformation of E. coli and white-blue screening 
Preparation of competent E. coli cells (centrifuge Universal 30RF was used): 
a) In a 5 mL centrifuge tube, 100 µL E. coli cells were added into 2 mL LB medium 
and shaked at 180 rev /min, 37°C, over night. 
b) The overnight culture was transferred to 100 mL LB medium in an Erlenmeyer flask 
and shaked at 180 rev / min, 37°C for 1-2 h until the OD600 nm ~ 0.45-0.55. 
c) The sample was centrifuged at 3000 rpm at 4°C for 10 min. The cell pellet was 
resuspended in 10 mL 0.1 M CaCl2 and kept on ice for 30 min. 
d) After 5 min centrifugation at 1500 rpm 4°C, the cell pellet was resuspended in 5 mL 
ice cold 10% glycerol with 0.1 M CaCl2. 
e) The suspension was then aliquoted (100 µL each) in 1.5 ml eppendorf tube and 
kept at -80°C. 
Transformation of competent E. coli cells consisted of following steps (plasmids carried 
the gene for ß-galactosidase, so the selection was done with help of the white-blue 
screening; centrifuge Universal 30RF was used): 
a) During the incubation of the ligation, 100µL competent E. coli cells kept at -80°C 
were thawed on ice. 
b) 10 µL ligation mixtures was added to 100 µL competent E. coli cells and gently 
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mixed, then incubated on ice for 10 min following a “heat-shock” for exactly 45 sec 
at 42°C in water bath. 
c) The transformation mixture was kept on ice for another 10 min and then 
transferred into a 5 mL centrifuge tube with 1 mL SOC medium. The pipette tip was 
left in the tube.  
d) The transformation mixture was shaked at 180 rev/min, 37°C for 1 h (tube cap was 
slightly opened). 
e) Shortly before the next step, 40µl 5-Bromo-4-chloro-3-indolyl-beta-D- 
galactopyranoside (X-gal; light prevented) and 40µl Isopropyl β-D-1- 
thiogalactopyranoside (IPTG) was pipetted onto the LB agar containing plate, well 
mixed, spread with a sterile plastic loop and dried in air slightly. 
f) After 1 h incubation, the ligation mixture was spread over tow LB agar containing 
plate from step (e). The LB agar plates were incubated at 37°C, overnight. 
g) The positive clones (white colour, not blue) were picked with a pipette tip and each 
transferred to a 5 mL tube containing 2 mL LB medium with 100 µg / mL ampicillin. 
h) The LB-ampicillin medium was incubated in the Innova
®
 4200 Incubator Shaker at 
180 rev/min, 37°C, overnight.  
i) The transformed colonies were identified by a colony PCR with a crude bacterial 
lysate serving as a template. 
3.8.1.4 Plasmid DNA extraction from cell culture 
From positively identified clonies, plasmid DNA was isolated with JetStar
®
 plasmid mini 
prep kit (Genomed GmbH) following the manufacturer's instructions (centrifuge 
Universal 30RF was used) as following. The extracted plasmid DNA was used for 
either restriction digestion or cell transfection. 
a) Each transformation mixture was transferred into a 2 mL Eppendorf tube and 
centrifuged at 4000 rpm for 10 min at room temperature. 
b) The supernatant was discarded. 300 µL cell resuspending buffer E1 was added to 
each pellet and resuspended immediately with pipette. 
c) Then, 300 µL lysis buffer E2 was added to the suspension, mixed and incubated for 
5 min at room temperature. 
d) 300 µL precipitation buffer E3 was added to the suspension, mixed and centrifuged 
at 13000 rpm for 5 min at room temperature. 
e) The supernatant was transferred to a new 1.5 mL Eppendorf tube and 540µL 
isopropanol were added, shake briefly. 
f) After centrifugation at 15000 rpm for 30 min at 4°C, the supernatant was discarded, 
200 µL 70% ethanol (-20°C) was added to the pellet and vortexed. 
g) After centrifugation at 15000 rpm for 5 min at 4°C, the supernatant was discarded. 
The plasmid pellet was air dried for approx. 30 min at room temperature and then 
dissolved in 30-50 µL distilled water. 
3.8.1.5 DNA extraction from gel 
The DNA band was excised with a clean sharp scalpel from the agarose gel and then 
extracted with QIAquick Gel Extraction Kit (Qiagen) following the manufacturer's 
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instructions (centrifuge Universal 30RF was used). Shortly, the excised DNA fragment 
was incubated with 3 volumes of buffer QG to 1 volume of gel (100 mg ~ 100 µL) at 
50°C for ~10 min until the gel slice has completely dissolved. The colour of the mixture 
was yellow, indicating that pH was ≤7.5, which is the efficient range for the QIAquick 
membrane. One gel volume of isopropanol was added and mixed. The mixture was 
applied to the QIAquick column placed in a 2 mL collection tube to bind DNA. The 
flow-through was discarded and column was washed with 0.75 mL of buffer PE and 
centrifuged for 1 min at 15,000 rpm. The flow-through was discarded and column was 
centrifuged for an additional 1 min at 15,000 rpm to remove residual ethanol. Then the 
QIAquick column was placed into a clean 1.5 mL tube and 30 µL of buffer EB was 
dispensed directly onto the QIAquick membrane to completely elute the bound DNA.  
The concentration of plasmid DNA after every isolation procedure was measured by 
NanoDrop ND-1000 spectrophotometer (see chapter 3.5.1). 
3.8.1.6 Restriction digestion and ligation 
Different restriction enzymes were used in this study. As a general rule, the restriction 
digestion was carried out in 25 µL volume, using between 3-6 µL of the DNA (either the 
target fragments or vector plasmid). For each restriction enzyme the corresponding 
buffer was used. The concentration was of 1 unit per 1µg of target DNA. All restriction 
digestions were performed at 37°C for 2 h. The digested DNA were confirmed by gel 
electrophoresis with 5 µL 6x loading dye and the fragment of interest was excised from 
the agarose gel with a clean sharp scalpel, purified and isolated using QIAquick Gel 
Extraction Kit (see chapter 3.8.1.5), then used in the corresponding ligation reaction. 
Restrictions digest (25µL) 
10x buffer (corresponding to restriction enzyme) 2.5 µL 
restriction enzyme (20 units/µL) 1 µL 
target DNA (appro. 1-3 µg/µL)  3 - 6 µL 
aqua dest. water to 25 µL 
 
In the ligation reaction, digested DNA fragment and vector plasmid were adjusted to 
the same concentration and incubated together in the presence of T4 DNA ligase (see 
below) at 4°C overnight. The ligation product was used for transformation of E. coli. 
Ligation reaction (10 µL) 
2x rapid ligation buffer 5 µL 
digested DNA (target fragment; 0.1-1 µM) 1 µL 
digested DNA (vector plasmid; 0.1-1 µM) 1 µL 
T4 DNA ligase (400 units/µL) 1 µL 
nuclease-free water to 10 µL 
3.8.2 Transfection of RGM-1 cells 
The stable transfection of the RGM-1 cell line with the corresponding plasmid 
construction was performed using Lipofectamine
®
 2000 Transfection Reagent with a 
similar protocol as the siRNA transfection (chapter 3.2.2). Shortly, one day before 
transfection, RGM-1 cells were seeded in the 6-well plate at 2 x 10
6
 cell density in 3 mL 
fully supplemented growth medium (plus 10% v/v FBS). This medium was replaced by 
3 mL Opti-MEM
®
 I reduced serum medium 4 h before transfection. Then cells were 
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transfected with 4 µg corresponding plasmid, respectively, using Lipofectamine® 2000 
at 1 µg/mL. Different with siRNA transfection, after 4 hours, 10% v/v FBS was added to 
the transfection mix. At 8 hours after transfection, cells were washed replaced with the 
selective medium: fully supplemented including 10% v/v FBS and 0.5 mM 
G418-optimized selective antibiotic concentration. Cells were cultured for another 
24-72 h with this selective medium until cell islets were formed. Cell islets were 
monitored under the microscope every day. The most distinctly separated cell isles 
were carefully separately trypsinized and transferred to separate wells of a 48-well 
plate using a 10 µL tip. With the selective medium, they were allowed to grow to 
confluence and those populations forming monolayers were transferred to 6-well plate, 
and then to a flask. After reaching confluence, the colony cells were analyzed by 
RT-PCR and Western blot. The primers and antibodies used are shown in chapter 2. 
3.9 Statistical analyses 
The statistical analyses were performed with the Excel 2003 programme using the 
Student's t-test. The error bars in the figures represent ± SD. Significant differences 
between the mean values of the different experimental groups are indicated by 
asterisks (P ≤ 0.05: significance, one asterisk; P ≤ 0.01: highly significance, two 
asterisks; P ≤ 0.001: extremely high significance, three asterisks).  
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4 Results 
This chapter presents the results of four connected projects all concerned with the 
functional aspects of TFFs in vivo and in vitro. As model systems, the GI tract and the 
CNS were used:  
(a) studies of the gastric epithelial cell line RGM-1 (in vitro; 4.1.1);  
(b) studies of a mouse model of ileitis after oral T. gondii infection (in vivo; 4.1.2);  
(c) studies of a mouse model for encephalitis after i.p. T.gondii infection (in vivo; 4.2.1); 
(d) studies of primary cell cultures from rat brain (in vitro; 4.2.2).  
4.1 TFF analysis in the GI system 
4.1.1 Analysis of gastric epithelial RGM-1 cells after in vitro wounding 
4.1.1.1 Expression profiling of stationary and migratory RGM-1 cells 
Expression profiles of migratory and stationary cells after in vitro wounding were 
analyzed in RGM-1 cells, a non-transformed gastric epithelial cell line well-established 
as an in vitro model for gastric restitution (Nakamura et al., 1998; Osada et al., 1999; 
Ragasa et al., 2007).  
In in vitro wounding experiments, the stationary and migratory cells were isolated 
respectively as described in chapter 3.2.4. Subsequently both cell populations were 
used for RT-PCR analysis (Figure 14A). The expression profiles of selected genes 
revealed differences between the migratory and stationary cells. β-actin used as an 
internal control for the integrity of the cDNA showed comparable expression in all 
samples. The corresponding semi-quantitative analysis (normalized against β-actin) is 
shown in Figure 14B.  
As a gene representing the terminal differentiation of gastric surface mucous cells 
(Karam et al., 2004; Hoffmann, 2012, 2013b), Tff1 was significantly up-regulated in 
migratory cells when compared with stationary cells. A significant up-regulation in 
migratory cells was also observed for the expression of Acta2/α-Sma, Ccna2 and 
Survivin/Birc5. 
In contrast, the expression of Gkn2, Pgc, Muc16, Sdf-1/Cxcl12 and Lgr5 was 
significantly down-regulated in migratory cells; whereas Tff3 expression was variable 
with a tendency to be reduced in migratory cells.  
Vim and β-actin showed comparable expression in stationary and migratory cells.  
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Figure 14: Expression profiling of stationary and migratory RGM-1 cells (RT-PCR analyses) 
(A) Tff1, Acta2/α-Sma, cyclin A2 (Ccna2), survivin/Birc5, Vimentin (Vim), gastrokine 2 (Gkn2), Tff3, 
pepsinogen C (Pgc), mucin 16 (Muc16), stromal cell-derived factor-1 (Sdf1/Cxcl12) and leucine rich 
repeat containing G protein coupled receptor 5 (Lgr5) expression was monitored in RGM-1 cells 48 
h after scratch wounding (three independent experiments). Both stationary (s) and migratory (m) 
cells were isolated and analyzed separately. The integrity of the cDNAs was tested by monitoring 
the transcripts for β-actin. The number of amplification cycles is given in parentheses. (B) The 
semi-quantitative evaluation of the corresponding transcript levels was normalized against β-actin
(relative gene expression levels). The significance of the differences between stationary and 
migratory cells is indicated by asterisks. 
Based on the elevated Tff1 transcript levels in the migratory RGM-1 cells, the 
expression of TFF1 peptide was also compared in stationary and migratory cells by 
immunofluorescence analysis. The repopulated zone of migratory cells and the zone of 
stationary cells were analyzed 24 h after scratch wounding (Figure 15A). Generally, 
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strongly Tff1 positive cells were mainly detected in the migratory zone. A 
semi-quantitative analysis of the relative Tff1 immunoreactivity per cell (for details of 
analysis, see chapter 3.7.1.3) clearly revealed that TFF1 staining is predominantly 
localized in migratory RGM-1 cells and that the difference is highly significant when 
compared with stationary cells (Figure 15B). The Tff1 immunofluorescence in the 
migratory cells is shown in Figure 15C, which indicates that TFF1 is probably localized 
in secretory granules. 
The specificity of the antiserum anti-mTff1-1 was tested by Western blot analysis, 
which revealed that the antiserum detected Tff1 from both the mouse and the rat 
stomach and the immunoreactivity could be competitively inhibited by the synthetic 
peptide used for immunization (Figure 16). 
A  B 
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Figure 15: TFF1 peptide expression in the RGM-1 cells after 24 
h wound healing 
Scratch-wounded RGM-1 cells were allowed to migrate for 24 h. 
Immunofluorescence staining was performed with anti-mTff1-1 
antiserum and Cy3-labeled secondary antibody (red); nuclei were 
counterstained with DAPI (blue). (A) Both the stationary (s) and the 
migratory (m) zones were imaged in one photo. The scratch wound 
is indicated by the white dotted line. (B) The relative Tff1 staining 
per cell is shown in stationary (s) and migratory cells (m). For each 
group 16 photographs from 5 different cover slips were analyzed. 
The difference between stationary and migratory cells is highly 
significant (p<1x10
-6
). (C) Typical Tff1 immunofluorescence in 
migratory cells (Cy3 label, red). Nuclei appear in blue (DAPI). 
Scale bars: 20 µm  
 
 
Figure 16: Western blot analysis 
for specificity test of 
anti-mTff1-1 
SDS-PAGE under reducing 
conditions, subsequent Western 
blot analysis.  (A) Extracts of the 
gastric corpus (c)  and antrum (a) 
from  the  rat  and  the mouse, 
respectively, were analyzed using the affinity-purified anti-mTff1-1 antiserum. (B) Analysis after 
competition with the synthetic peptide FHPMAIENTQEEECPF. The molecular weight standard is 
shown on the left. 
Results 
 55 
4.1.1.2 RNAi targeting Tff1 negatively influences migration of RGM-1 cells 
Based on the clear differences in Tff1 expression levels between migratory and 
stationary RGM-1 cells (chapter 4.1.1.1), the further investigations were focussed on 
the function of TFF1 during the wound healing processes. The expression of Tff1 was 
mainly restricted to migratory RGM-1 cells (Figure 14, Figure 15) indicating that Tff1 
may play a role in the cell migration. Moreover, a motogenic effect of TFF1 in vitro was 
reported previously (Marchbank et al., 1998; Prest et al., 2002; Buache et al., 2011). 
Thus, it was tempting to test whether inhibition of Tff1 expression would affect 
migration of RGM-1 cells. Thus, Tff1 transcripts in RGM-1 cells were knocked down 
during the wound healing by siRNA. 
RNAi experiments were carried out with three different RNAi duplexes targeting Tff1 
(Tff1-siRNA1, Tff1-siRNA2, Tff1-siRNA3, see chapter 2.6). Following transfection with 
the siRNA duplexes or the negative control siRNA, respectively, RGM-1 cells were 
analyzed after in vitro scratch wounding by calculating the repopulated area after 24 h. 
The effects of three non-overlapping Tff1-siRNAs were tested with different 
concentrations, e.g. 62.5 nM and 125 nM (Figure 17).  
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Figure 17: Concentration dependent siRNA duplexes efficiency test 
RGM-1 cells treated either with stealth RNAi
TM
 negative control or Tff1-siRNA1, 2, 3 were scratched 
and allowed to migrate in serum-free medium for 24 h. The wound areas of both the negative 
control group and the Tff1-siRNAs group were photographed 0 h and 24 h after the scratch at the 
exact same positions. Two concentrations of siRNA were tested: 62.5 nM and 125 nM. The 
re-populated areas calculated by their pixel numbers are shown. (A) Tff1-siRNA efficiency 
compared between Tff1-siRNA1 and Tff1-siRNA2. (B) Tff1-siRNA efficiency compared between 
Tff1-siRNA1 and Tff1-siRNA3.  
All three siRNAs showed positive RNAi effects and the strongest knock-down effect 
was obtained with Tff1-siRNA2 at the concentration of 125 nM, which was further used 
for the subsequent wound healing experiments. 
In the following studies, RGM-1 cells transfected with 125 nM Tff1-siRNA2 showed 
diminished migratory activity resulting in a smaller repopulated area when compared 
with the negative control and this effect was highly significant (Figure 18).  
Furthermore, the cells transfected with 125 nM Tff1-siRNA2 were also analyzed by 
expression profiling of stationary and migratory cells (Figure 19).  β-actin used as an 
internal control for the integrity of the cDNA showed comparable expression in all 
samples. The corresponding semi-quantitative analysis (normalized against β-actin) is 
shown in Figure 19B. As expected, Tff1 expression was suppressed in RGM-1 cells 
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transfected with Tff1-siRNA2 when compared with cells transfected with the negative 
control siRNA. Moreover, the expression level of Gkn2 was elevated in RGM-1 cells 
transfected with Tff1-siRNA2; whereas Acta2/α-SMA expression was reduced in these 
cells. Expression of β-actin was comparable in all samples. 
A B 
 
Figure 18: RNA interference and analysis of cell migration rates 
RGM-1 cells treated either with 125 nM stealth RNAi
TM
 negative control or 125 nM Tff1-siRNA2 were 
scratched and allowed to migrate in serum-free medium for 24 h. The wound areas of both the 
negative control group and the Tff1-siRNA2 group were photographed 0 h and 24 h after the scratch 
at the exact same positions. (A) In a typical experiment, the area of the re-populated zone covered 
with cells is schematically marked in black (24 h); whereas the stationary cells’ zone is hatched (0 h); 
the non-populated area is shown in white. (B) The re-populated areas calculated by their pixel 
numbers are shown (for each group 46 photographs from 3 different experiments were analyzed). 
The difference between the negative control and Tff1-siRNA2 is highly significant (P= 3.62 x 10
-6
). 
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Figure 19: Expression profiling of stationary and migratory RGM-1 cells (RT-PCR analyses 
of RNAi experiment) 
(A) RGM-1 cells were pre-treated with the stealth RNAi
TM
 negative control or Tff1-siRNA2. Then, 
Tff1, gastrokine 2, and Acta2/α-Sma expression was monitored 24 h after scratch wounding (3 
independent experiments). Both the stationary (s) and migratory (m) cells were isolated and 
analyzed separately. The integrity of the cDNAs was tested by monitoring the transcripts for 
β-actin. The number of amplification cycles is given in parentheses. (B) The semi-quantitative 
analysis of the corresponding transcript levels were normalized against β-actin (relative gene 
expression levels). The significance of the differences between stationary and migratory cells is 
indicated by asterisks.  
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4.1.2 Analysis of the mouse ileum after oral T. gondii infection (murine 
ileitis model) 
4.1.2.1 Genotyping and infection of the mice 
The role of TFF3 in the ileum during the inflammation and immune response was 
investigated here by studying Tff3
KO
 mice and their wild-type counterparts after oral 
infection with a type II strain of T. gondii (ME49).  
Genotyping of mice used for the experiment was performed via tail blot (Figure 20). 
The corresponding primers were described before (see chapter 3.3.1). As expected, 
Tff3 expression was not detectable in Tff3
KO
 mice and the expression of the inserted 
neo gene was detected. 
 
Figure 20: Tail blot analysis  
The genotype of the experimental mice was determined by PCR analysis of the genomic DNA 
isolated from the tail of each mouse (both control and orally T. gondii infected group, respectively). 
The number of amplification cycles is given in parentheses. 
Infection of the mice was as follows: 18 mice were divided into two groups: 8 mice (4x 
wild type and 4x Tff3
KO
) for the uninfected control group and 10 mice (5x wild type and 
5x Tff3
KO
) for the T. gondii infected group. In the latter, 3 T. gondii cysts (ME49, type II 
strain) were orally administered per mouse (infection was performed by Dr. I. Dunay, 
IMMB, Magdeburg). The experimental infection was for 7 days and the mouse ileum 
was then obtained and analyzed. 
4.1.2.2 Tff3KO mice have a different immune response in the ileum after oral T. 
gondii infection 
The gene expression profile of mouse ileum (after oral infection, with 3 T. gondii cysts 
for 7 days) was tested by RT-PCR (Figure 21A). β-actin used as an internal control for 
the integrity of the cDNA showed comparable expression in all samples. The 
corresponding semi-quantitative analysis (normalized against β-actin) is shown in 
Figure 21B.  
Tff1 expression was hardly detectable in the ileum of uninfected mice; whereas there 
was an elevated expression after T. gondii infection (5/10 mice). In contrast, Tff3 was 
stably expressed in the wild type ileum of both control and infected groups. Tff2 was 
also found mainly in the uninfected control group. Interestingly, its expression level was 
decreased in Tff3
KO
 mice.  
As typical Th1-associated cytokines after T. gondii infection, Ifnγ, Il-12αp35-2, Il-1β, 
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Il-10 and Tnfα were all induced in the infected group. Surprisingly, the up-regulation of 
these genes was significantly decreased in Tff3
KO
 mice with exception of interleukin 10 
(Il-10). This result indicates that the Tff3
KO
 mice may have a different immune response 
in the ileum during the early stage of oral infection with T. gondii. 
A 
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Figure 21: Expression profiling of the mouse ileum (RT-PCR analyses) 
(A) Tff1, Tff2, Tff3, interferon gamma (Ifnγ), interleukin-12 subunit alpha isoform 2 (Il-12αp35-2), 
interleukin 1b (Il-1β), interleukin 10 (Il-10) and tumour necrosis factor α (Tnfα) expression was 
monitored in the ileum of mice with or without oral T. gondii infection (3 cysts for 7 days). The 
integrity of the cDNAs was tested by monitoring the transcripts for β-actin. The number of 
amplification cycles is given in parentheses. (B) The semi-quantitative analysis of the 
corresponding transcript levels (relative gene expression levels normalized against β-actin). The 
significance of the differences among groups is indicated by asterisks.  
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4.2 TFF expression in the CNS 
4.2.1 Cerebral TFF expression after intraperitoneal T. gondii infection 
(murine Toxoplasma encephalitis model) 
4.2.1.1 Genotyping and infection of the mice, infection efficiency test 
Here, TFF expression was monitored in a mouse model of experimental Toxoplasma 
encephalitis (TE). Intraperitoneal infection with type II strain of T. gondii (DX) was 
performed with both Tff1
KO
 and Tff2
KO
 mice as well as their wild-type counterparts.  
Genotyping of the mice used for the experiment was performed via tail blot (Figure 22). 
The corresponding primers were described before (see chapter 3.3.1). As expected, 
Tff1 expression was not detectable in Tff1
KO
 mice and the expression of the inserted 
neo gene was detected. Similarly in Tff2
KO
 mice, Tff2 expression was not detectable; 
instead, the inserted neo gene was detected.  
 
Figure 22: Tail blot analysis 
The genotype of the experimental mice was determined by PCR analysis of the genomic DNA 
isolated from the tail of each mouse (both control and T. gondii infected (i.p.) group, respectively). 
The number of amplification cycles is given in parentheses.  
Infection of the mice was as follows: 30 mice were divided into two groups: 15 mice (5x 
wild type, 5x Tff1
KO
 and 5x Tff2
KO
) for the uninfected control group and 15 mice (5x wild 
type, 5x Tff1
KO
 and 5x Tff2
KO
) for the T. gondii infected group. In the latter, 5 T. gondii 
cysts (DX, type II strain) were administered intraperitoneally per mouse (infection was 
performed by Dr. U. Händel, IMMB, Magdeburg). The experimental infection was for 4 
weeks. 
Invasion of the parasite was determined by PCR using the genomic DNA isolated from 
the heart of the experimental mice (Figure 23). The parasite DNA was detected 
targeting the T. gondii strain RH repeat region (Patrat-Delon et al., 2010; GenBank
®
 
accession no. AF487550.1, corresponding primer pair: T.g/RHrep, see chapter 2.8). As 
expected, T. gondii DNA was detectable in the T. gondii infected mice only and not in 
the uninfected control mice.  
Furthermore, the presence of parasites in the brain was also detected by 
immunohistochemistry (Figure 24) using an anti-T. gondii antibody (see chapter 2.3.2). 
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All sections from infected brains showed positive T. gondii staining (Figure 24B, D, F), 
whereas all sections from uninfected brains were negative (Figure 24A, C, E).  
 
Figure 23: Parasite DNA test 
The expression of T. gondii strain RH repeat region (T.g./RHrep) was tested by PCR. Genomic DNA 
was isolated from the heart of the mice (both control and T. gondii infected groups). The number of 
amplification cycles is given in parentheses.  
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Figure 24: T. gondii localization in mouse brain (ABC stain) 
Free floating staining of T. gondii in control (A: wild type, C: Tff1
KO
, E: Tff2
KO
) and infected (B: wild
type, D: Tff1
KO
, F: Tff2
KO
) mice brain (i.p. infection with 5 T. gondii cysts for 11 days). Each overview 
presents a merge of about 300 single photos. All sections were stained and photographed under the 
same conditions. The staining in the meninges region was non-specific. Scale bars: 500 µm 
 
4.2.1.2 TFF expression profiling in mouse brain after T. gondii infection: 
up-regulation of TFF1 
The expression profiles for Tff1, Tff2 and Tff3 in different tissues were monitored via 
RT-PCR (Figure 25, on page 62). The brain was divided into the cerebellum and the 
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remaining brain (brain without cerebellum). The stomach was used as the internal 
control because of its well known Tff expression profile. β-actin used as an internal 
control for the integrity of the cDNA showed comparable expression levels in all 
samples. The corresponding semi-quantitative analysis (normalized against β-actin) is 
shown in Figure 25B. Generally, Tff1, Tff2 and Tff3 were detectable in stomach and 
differently expressed in brain.  
In the uninfected control group, Tff1 was strongly expressed in the stomach as 
expected (except in Tff1
KO
 mice). Trace amounts of Tff1 were also detectable in the 
cerebellum and in the remaining brain (35 amplification cycles, data not shown). After 
T. gondii infection, Tff1 expression level in the infected group showed almost no 
change in the stomach but was significantly induced in the cerebellum and the 
remaining brain. Moreover, the up-regulation of Tff1 expression in the Tff2
KO
 mouse 
cerebellum and remaining brain was significantly higher than in wild type mice.  
Aside from the expected expression of Tff2 in the stomach (except in Tff2
KO
 mice), Tff2 
was also found in the brain with a significant up-regulation in Tff1
KO
 mice. However, 
Tff2 expression was not changed after T. gondii infection in both the brain and the the 
stomach. Of note, trace amounts of Tff2 were also detectable in the remaining brain 
with 35 amplification cycles (data not shown). 
Tff3 expression was also detectable in both the stomach and the brain of all mice. In 
the brain, Tff3 was found to be expressed mainly in cerebellum and only in trace 
amounts in the remaining brain (signal was clearly detectable after 35 amplification 
cycles, data not shown). Interestingly, in the stomach the Tff3 expression level was 
higher in Tff2
KO
 mice when compared with the wild type mice. However, Tff3 
expression was not affected by T. gondii infection in both the brain and the stomach 
(Figure 25B).  
Following the up-regulation of Tff1 transcript levels in the brain (in wild type and Tff2
KO
 
mice) after T. gondii infection (Figure 25), the TFF1 peptide was also localized by 
immunohistochemistry in the brain of wild type and Tff2
KO
 mice (Figure 26, on page 
63). The section overview shows a relatively weak expression of the TFF1 peptide in 
brain sections of uninfected mice (wild type and Tff2
KO
; Figure 26A, C), and a higher 
expression level in infected brain sections (Figure 26B, D).  
Furthermore, the specificity of the immunostaining with anti-m-Tff1-1 antiserum was 
tested by competitive inhibition. In the uninfected wild type mouse brain, anti-m-Tff1-1 
detected TFF1 peptide (Figure 27A, on page 63) and this staining could be 
competitively inhibited by the synthetic peptide used for immunization (Figure 27B). 
The correctives of the RT-PCR products for Tff1 and Tff2 from mouse brain have been 
proven by cloning and sequencing. The results are presented in the Appendix III (on 
page iii). 
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Figure 25: Tff expression profiling of the mouse brain and stomach, respectively (RT-PCR 
analyses) 
(A) Tff1, Tff2 and Tff3 expression was monitored in the mouse cerebellum, remaining brain and 
stomach with or without i.p. T. gondii infection (5 cysts, for 4 weeks). The integrity of the cDNAs 
was tested by monitoring the transcripts for β-actin. The number of amplification cycles is given in 
parentheses. (B) The semi-quantitative analysis of the corresponding transcript level was 
normalized against β-actin (relative gene expression levels). The significance of the differences 
among groups is indicated by asterisks. 
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Figure 26: Localization of TFF1 peptide in the mouse brain (IHC, ABC staining) 
Brain sections from control (A: wild type, C: Tff2
KO
) and T. gondii infected (B: wild type, D: Tff2
KO
) 
mice (i.p., 5 cysts, for 4 weeks) were analyzed with affinity-purified anti-mTff1-1 antiserum. A-D: 
Each overview represents a merge of about 300 single photos. a-d: corresponding single photos of 
the cerebellum (a-A, b-B, c-C, d-D). All sections were stained and photographed under the same 
conditions. Scale bars: A-D: 500 µm, a-d: 150 µm. 
 
A (anti-mTff1-1) B (competitive inhibition) 
  
Figure 27: Specificity of the immunostaining with anti-m-Tff1-1 anti-serum (ABC staining) 
Parallel brain sections from uninfected wild type mice were either stained with affinity-purified 
anti-mTff1-1 antiserum (A) or, after competition, with the synthetic peptide FHPMAIENTQEEECPF 
(B). Each overview represents a merge of about 300 photos. All sections were stained and 
photographed under the same conditions. Scale bars: 500 µm. 
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4.2.1.3 Expression profiling in the cerebellum after T. gondii infection 
RT-PCR and immunohistochemistry staining in the mouse brain showed that the Tffs 
were mainly expressed in the cerebellum. Thus this brain region was further 
investigated by systematic RT-PCR analyses.  
The expression of the following cytokines involved in the immune response was 
analyzed: Iba1, Ifnγ, Tnfα, Il-12αp35-2, Il-1β, Il-2, Il-10 as well as two markers for 
T-cells, i.e., Cd4, Cd8 (Figure 28A, on page 65). β-actin used as an internal control for 
the integrity of the cDNA showed comparable expression in all samples. The 
expression of all studied genes was significantly up-regulated in the infected group, 
compared with the uninfected control group (p<0.001). The corresponding 
semi-quantitative evaluation (normalized against β-actin) is shown in Figure 28B (on 
page 65).  
The expression of Iba-1, the typical marker for microglial cells particularly elevated in 
the activated status during the immune response (Ito et al., 1998), was significantly 
induced after the infection. Interestingly, in the uninfected control group, Iba-1 
expression was somewhat higher in Tff2
KO
 mice when compared with both wild type 
and Tff1
KO
 mice.  
Cytokines involved in Th1 inflammation (Ifnγ, Tnfα, Il-12, Il-1β, Il2, and Il-10) and T-cell 
markers (Cd4, Cd8) were all significantly induced after T. gondii infection. Of note, 
expression of most cytokines is not significantly different when compared between wild 
type, Tff1
KO
 and Tff2
KO
 mice. Only Ifnγ showed a significantly higher expression of Ifnγ 
in the infected Tff2
KO
 mice when compared with both infected wild type and Tff1
KO
 
mice. Furthermore, in the infected group, Cd8 also has a slightly higher expression 
level in the Tff2
KO
 mice when compared with both the wild type and the Tff1
KO
 mice. 
According to the elevation of Iba1 transcript levels in the infected mouse brain (Figure 
28), immunohistochemistry analysis of IBA-1 peptide was also performed in the wild 
type and Tff2
KO
 mouse brain (Figure 29, on page 66). Consistent with the RT-PCR 
results, the section overview showed a weak IBA-1 expression in uninfected brain 
sections (Figure 29A, C) but a much higher expression level in the infected brain 
sections (Figure 29B, D). The induction of IBA1 indicates an activation of microglial 
cells after T. gondii infection. However, the distribution of the IBA-1 and TFF1 peptides 
in the mouse brain is different (Figure 26, on page 63; Figure 29), which implies that 
TFF1 peptide is not expressed in microglial cells. 
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Figure 28: Expression of inflammatory genes in the mouse cerebellum (RT-PCR analyses) 
(A) Ionized calcium binding adapter molecule 1 (Iba1), interferon gamma (Ifnγ), tumour necrosis 
factor α (Tnfα), interleukin-12 subunit alpha isoform 2 (Il-12αp35-2), interleukin 1b (Il-1β), interleukin 
2 (Il-2), interleukin 10 (Il-10), Cd4 and Cd8 expression was monitored in the cerebellum (wild type, 
Tff1
KO
 and Tff2
KO
 mice) with or without i.p. T. gondii infection (5 cysts, for 4 weeks). The integrity of 
the cDNAs was tested by monitoring the transcripts for β-actin. The number of amplification cycles 
is given in parentheses. (B) The semi-quantitative analysis of the corresponding transcript levels 
was normalized against β-actin (relative gene expression levels). The significance of the differences 
is indicated by asterisks. The expression levels of all genes are significantly higher in the T. gondii 
infected mice when compared with the uninfected control group (p<0.001; this is not indicated with 
asterisks). 
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Figure 29: Localization of IBA-1 in mouse brain (IHC, ABC staining) 
Brain sections from control (A: wild type, C: Tff2
KO
) and T. gondii infected (B: wild type, D: Tff2
KO
) 
mice were analyzed with anti-IBA-1 antibody. A-D: Each overview represents a merge of about 300 
single photos. a-d: corresponding single photos of the cerebellum (a: from A; b: from B; c: from C;
d: from D). All sections were stained and photographed under the same condition. Scale bars: A-D: 
500 µm, a-d: 150 µm. 
4.2.2 TFF expression in primary cell cultures from rat brain 
The neural cell cultures from rat hippocampus or cortex and glial cell-enriched cultures 
from rat cortex (all cultures were provided by Dr. Stellmacher, IPT, Magdeburg), 
respectively, were tested for Tff expression. The following markers for the different cell 
types were used:  IBA1 (Ito et al., 1998) for microglial cells, GFAP for astrocytes (Eng 
et al., 1971) and MAP2 for neurons (specifically in the perikarya and dendrites; Matus, 
1991).  
The RT-PCR expression profiles of these cell cultures are shown in Figure 30. β-actin 
used as an internal control for the integrity of the cDNA showed comparable 
expression in all samples. Tff1 and Tff2 expression was not detectable in all three cell 
cultures. The corrective of these two primer pairs were proved in chapter 3.1.1 (for Tff1) 
and by Znalesniak & Hoffmann (2010; for Tff2). In contrast, Tff3 was stably expressed. 
As expected, the expression of Gfap was detectable in all three cell cultures. Map2 
expression was detectable in both of the neural cell cultures, but could hardly be found 
in the glial cell-enriched culture. The expression of Iba1 was much weaker in both of 
the neural cell cultures when compared with the glial cell-enriched culture.  
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Figure 30: RT-PCR analyses of various primary cell cultures 
Tff1, Tff2, Tff3, microtubule-associated protein 2 (Map2), glial fibrillary acidic protein (Gfap) and 
ionized calcium binding adaptor molecule 1 (Iba1) expression was monitored in rat primary cell 
cultures. Both neural (respectively from cortex and hippocampus) and glial cell-enriched cell 
cultures were isolated and analyzed separately. The integrity of the cDNAs was tested by monitoring 
the transcripts for β-actin. The number of amplification cycles is given in parentheses. 
4.2.2.1 Localization of TFF3 peptide in neural cell cultures from the cortex or 
hippocampus 
Based on the stable expression of TFF3 transcripts, the TFF3 peptide was also 
localized in the different cell cultures by immunofluorescence studies (Figure 31, on 
page 68; Figure 32, on page 69; Figure 34. on page 70).  
In neural cell cultures from both cortex and hippocampus TFF3 was mainly detected in 
the neurons expressing MAP2 (Figure 31, Figure 34), but not in astrocytes marked by 
GFAP (Figure 32, Figure 34).  
The double immunofluorescence staining in neural cell cultures of both the cortex and 
the hippocampus indicates that MAP2-positive neurons are also positively stained by 
TFF3 (Figure 31). However, some of the TFF3-positive cells were not found positively 
stained for Map2. These cells may represent glial cells. Thus, double 
immunofluorescence staining was performed with TFF3 and the astrocyte marker 
GFAP (Figure 32). The results clearly show that TFF3 is not localized in astrocytes 
(GFAP-positive cells). 
Furthermore, a triple immunofluorescence staining of both cortex and hippocampus 
neural cell cultures was performed (Figure 34, on page 69). Here again, TFF3 is not 
expressed in astrocytes (GFAP positive cells). However, TFF3 is co-localized with IBA1 
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(typical of microglial cells) indicating that Tff3 may be expressed not only in neurons but 
also in microglial cells (Figure 34). 
The specificity of the antiserum anti-r-Tff3-2 was also tested by immunofluorescence 
staining. In the neural cell cultures from both the cortex and hippocampus, anti-r-Tff3-2 
could be competitively inhibited by the synthetic peptide used for immunization (Figure 
33, on page 69). 
4.2.2.2 Localization of Tff3 peptide in glial cell-enriched cultures from the cortex 
To further investigate TFF3 expression in different glial cells, corresponding glial 
cell-enriched cultures were analyzed (Figure 35, on page 71). The antibodies 
anti-GFAP and anti-IBA1 clearly detected astrocytes and microglial cells, respectively, 
without any cross reactivity (Figure 35A). Tff3 was clearly expressed in microglial cells 
(IBA1 positive cells; Figure 35C) and no localization of TFF3 in astrocytes (GFAP 
positive cells) was found (Figure 35B, C). These results clearly indicate that in the glial 
cell-enriched cultures TFF3 is expressed in microglial cells but not in astrocytes. 
 A     
 B   
 
 
Figure 31: Double immunofluorescence studies of neural cell cultures (MAP2/red, TFF3/green) 
Primary cell cultures from the cortex (A) or hippocampus (B), respectively, were stained with 
anti-rTff3-2 antiserum and Alexa Fluor
®
 488-labeled secondary antibody (green, exposure time 7500 
ms). Co-staining was with anti-MAP2 antibody and Cy3-labeled secondary antibody (red, exposure 
time 500 ms); nuclei were counter-stained with DAPI (blue). Scale bars: 20 µm.  
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Figure 32: Double immunofluorescence studies of neural cell cultures (GFAP/red, 
TFF3/green) 
Primary cell cultures from the cortex (A) or hippocampus (B), respectively, were stained with 
anti-rTff3-2 antiserum and Alexa Fluor
®
 488-labeled secondary antibody (green, exposure time 
7500 ms). Co-staining was with anti-GFAP antibody and Cy3-labeled secondary antibody (red, 
exposure time 500 ms); nuclei were counter-stained with DAPI (blue). Scale bars: 20 µm.    
 
A:                  cortex B:               hippocampus 
  
Figure 33: Specificity of immunofluorescence staining with anti-r-Tff3-2 antiserum
(TFF3/green)  
Cell cultures from the rat cortex (A) and hippocampus (B), respectively, were either stained with 
anti-rTff3-2 antiserum or after competitive inhibition with the synthetic Tff3 peptide (whole rat Tff3 
peptide sequence (1-59)), and then labeled with Alexa Fluor
®
 488-labeled secondary antibody 
(green, exposure time 7500 ms); nuclei were counter-stained with DAPI (blue). Scale bars: 20 µm.  
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Figure 34: Triple immunofluorescence studies of neural cell cultures (IBA1/red, TFF3/green, 
GFAP/violet)  
Primary cell cultures from the cortex (A) or hippocampus (B), respectively, were stained with 
anti-rTff3-2 antiserum and Alexa Fluor
®
 488-labeled secondary antibody (green, exposure time 7500 
ms). Co-staining was with anti-IBA1 and Cy3-labeled secondary antibody (red, exposure time 8000 
ms), as well as anti-GFAP anti-body and DyLight™ 649-labeled secondary antibody (violet, exposure 
time 3000 ms). Nuclei were counterstained with DAPI (blue). Scale bars: 20 µm. 
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Figure 35: Immunofluorescence studies of glial cell-enriched cultures 
Primary glial cell-enriched primary cultures from the cortex: (A) double staining with 
rabbit-anti-IBA1 anti-serum and Alexa Fluor
®
 488-labeled secondary antibody (green, exposure 
time 200 ms). Co-staining was with anti-GFAP antibody and Cy3-labeled secondary antibody (red, 
exposure time 500 ms); (B) double staining with anti-rTff3-2 antiserum and Alexa Fluor
®
 
488-labeled secondary antibody (green, exposure time 2500 ms). Co-staining with anti-GFAP 
antibody and Cy3-labeled secondary antibody (red, exposure time 500 ms); (C) Triple staining 
with anti-rTff3-2 antiserum and Alexa Fluor
®
488-labeled secondary antibody (green, exposure 
time 3500 ms). Co-staining was with anti-IBA1 and Cy3-labeled secondary antibody (red, 
exposure time 3500 ms), as well as anti-GFAP antibody and DyLight™649-labeled secondary 
antibody (violet, exposure time 10000 ms). Nuclei were counterstained with DAPI (blue). Scale 
bars: 20 µm. 
 
Discussion 
 72 
5 Discussion 
5.1 TFFs in the GI system 
5.1.1 TFF expression and function in RGM-1 cells (in vitro) 
5.1.1.1 Increased Tff1 synthesis in migratory cells during wound healing 
processes 
The migration of epithelial cells is the major component of the mucosal restitution 
occurring in the early phase of the mucosal repair (Silen & Ito, 1985; Hoffmann, 
2013b). The enhancing effect of the TFF1 peptide on cell migration has been shown in 
various gastric-, intestinal-, oral-, bronchial-, and corneal-epithelial cells (Playford et al., 
1995; Hoffmann et al., 2001; Hoffmann & Jagla, 2002; Prest et al., 2002). Previous 
studies demonstrated that TFF1 expression is up-regulated after the mucosal injury 
(Rio et al., 1991; Wright et al., 1992; Taupin & Podolsky, 2003), and after the total 
wounding (multi scratch assay) in the transformed human bronchial epithelial cell line 
(BEAS-2B) and human lung adenocarcinoma epithelial cell line (A549; Znalesniak, 
2013). TFF1 expression is also strongly up-regulated after treatment with TNFα in in 
vitro models of gastric epithelial inflammation in a dose-dependent manner (Koike et al., 
2007). 
In this study, Tff1 expression was shown to be increased in migratory RGM-1 cells 
during wound healing processes. As a secretory product of terminally differentiated 
gastric surface mucous cells (Kouznetsova et al., 2004), the up-regulated expression 
of Tff1 in migratory cells is unusual, because normally migratory cells lose the markers 
of terminal differentiation (Znalesniak et al., 2009). However, this result has been 
clearly shown on both transcriptional (Figure 14) and protein levels (Figure 15). Of 
note, the antiserum anti-mTff1-1 used here recognized also Tff1 from rat stomach on a 
Western blot analysis and the specificity was demonstrated by competitive inhibition 
with the synthetic peptide used as antigen (Figure 16).  
Furthermore, the expression levels of Tff1 and Gkn2 were not parallel but rather 
contrary in stationary versus migratory RGM-1 cells (Figure 14, Figure 19). The 
co-expression of these two genes was expected, because human TFF1 has been 
reported form disulfide-linked heterodimers with GKN2 (Westley et al., 2005; 
Kouznetsova et al., 2007b). Moreover, as expected, the Tff1-Gkn2 heterodimer was 
detectable in the rat and mouse stomach tissue (data not shown). One explanation for 
the discrepancy would be that in RGM-1 cells Tff1 exists in other, different molecular 
forms (e. g., monomers, homodimers). This assumption is supported by analysis of 
human TFF1 after gel filtration of antral extracts, which gave clear indications for the 
existence of additional forms of TFF1 (e.g., TFF1 monomer, TFF1 dimer) in normal 
human gastric mucosa (Newton et al., 2000) and where the TFF1 was found not only 
as a TFF1-GKN2 heterodimer but also in small amounts as monomers or homodimers 
(Kouznetsova et al., 2007b). 
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The reciprocal regulation of Tff1 and Tff3 expression in stationary and migratory 
RGM-1 cells respectively (Figure 14) might be due to the fact that they are not 
co-expressed in the gastric mucosa in vivo. In human, TFF1 expression is detectable 
in terminally differentiated surface mucous cells of both the corpus and the antrum; 
whereas TFF3 is preferentially expressed in deeper lying surface mucous cells of the 
gastric antrum (i.e. the proliferative zone) and is hardly detectable in the corpus 
(Kouznetsova et al., 2004, 2007a, 2011). This different origin might also explain the 
rather variable expression of Tff3 in RGM-1 cells. Additionally, TFF1 and TFF3 have 
probably different molecular functions. Gastric TFF3 presumably forms TFF3-FCGBP 
heteromers, which are mucus components (Albert et al., 2010; Kouznetsova et al., 
2011), whereas gastric TFF1 is mainly not associated with mucus (Kouznetsova et al., 
2007b).  
Furthermore, TFF1 has been reported to suppress the TNFα–mediated NF-κB 
activation and play an important role in regulating the NF-κB–mediated inflammatory 
response in the multistep gastric tumorigenesis cascades (Koike et al., 2007). 
Moreover, the loss of TFF1 is associated with activation of NF-κB–mediated 
inflammation and gastric neoplasia in mice and humans (Soutto et al., 2011). In this 
study, the migratory RGM-1 cells showed the tendency to induce the expression of 
several inflammation related genes, such as Tgfα, Tgfβ1, Tgfβ2 (data not shown). 
Thus, the up-regulation of TFF1 in migratory RGM-1 cells could indicate a suppressive 
role of TFF1 in inflammatory processes during the restitution/wound healing. 
Additionally, in mammary cells, TFF1 exhibited both in vitro and in vivo 
anti-tumour-effects (Buache et al., 2011). Therefore, the induction of Tff1 during 
restitution in RGM-1 cells might prevent excessive cell invasion as well. 
Several genes (Acta2/α-Sma, Ccna2 and survivin/Birc5) are also significantly 
up-regulated in migratory RGM-1 cells after in vitro wounding (Figure 14). As a 
hallmark of myofibroblast differentiation, α-SMA is essential for connective tissue 
remodelling during wound healing (Tomasek et al., 2002). Generally, the expression of 
α-SMA is typical of migratory cells and is associated with the generation of increased 
contractile forces and stress fibre formation (Masszi et al., 2003; Znalesniak et al., 
2009; Znalesniak & Hoffmann, 2010).  
Cyclin A2 plays a key role in cell cycle regulation by controlling both the S phase (DNA 
replication) and the G2/M transition (cell growth and protein synthesis/mitosis) in 
association with Cdk2 and Cdk1, respectively; furthermore, it also negatively controls 
cell motility by promoting RhoA activation (Arsic et al., 2012). Thus, up-regulation of 
cyclin A2 expression in migratory RGM-1 cells is not expected to enhance cell motility, 
but is rather due to progression of migratory cells through the cell cycle (Watanabe et 
al., 1994; Zahm et al., 1997).  
Survivin is expressed predominantly in gastric surface mucous cells and plays a role in 
mucosal integrity and protection of the gastric mucosa against injury (Chiou et al., 
2003). It is a chromosomal passenger protein (Altieri, 2003) and is shown to inhibit 
apoptosis, to regulate cell division and enhances cell migration and invasion 
(McKenzie et al., 2010; McKenzie & Grossman, 2012). Furthermore, it was reported to 
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be expressed only during mitosis (Waligórska-Stachura et al., 2012) and the 
suppression of survivin in RGM-1 cells was shown to increase the cell damage to injury 
by indomethacin (Chiou et al., 2005). Thus, the up-regulated expression of survivin in 
migratory cells is perfectly in line with its inhibitor function of apoptosis and regulation 
of the cell cycle, because cell migration is coupled to a suppression of apoptosis (Cho 
& Klemke, 2000).  
In contrast, the significant down-regulation of the transcript levels of Pgc (typical of 
mucous neck and antral gland cells; Kouznetsova et al., 2011) and Gkn2 (secretory 
peptide of human gastric surface mucous cells) in migratory RGM-1 cells is typical of 
genes characteristic of terminal differentiation (Znalesniak et al., 2009; Znalesniak & 
Hoffmann, 2010). Of note, many other known gastric differentiation markers, e.g. 
gastric lipase (LipF), lysozyme (Lyz) and Tff2 (Hoffmann, 2012, 2013b) were either not 
detectable or present in trace amounts only (data not shown).  
Moreover, Sdf-1 expression level was also down-regulated in migratory RGM-1 cells. 
This secretory α-chemokine is typically expressed in normal intestinal villus epithelium 
(Agace et al., 2000). It contributes to mucosal wound healing by enhancing restitution 
together with its receptor Cxcr4 (Smith et al., 2005) and is important for the active 
recruitment of stem cells during repair of damaged tissue (Kucia et al., 2005). The 
down-regulation of Sdf-1 in migratory RGM-1 cell is comparable with the situation in 
the non-transformed intestinal epithelial cell lines IEC-18 (Znalesniak et al., 2009) and 
IEC-6 where Sdf-1 promotes restitution (Smith et al., 2005). 
The EMT is a physiological process in which epithelial cells acquire the motile and 
invasive characteristics of mesenchymal cells (Hay, 1995, 2005; Savagner et al., 2005; 
Moreno-Bueno et al., 2008) and has been reported to generate cells with properties of 
stem cells (Mani et al., 2008). As a stem cell marker, Lgr5 is characteristic for the 
population of gastric stem cells that are located mainly at the base of antral glands but 
not fundic glands (Barker et al., 2010; Kouznetsova et al., 2011; Hoffmann, 2012). 
Thus the expression of Lgr5 in RGM-1 cells is indicative of the undifferentiated 
character of this non-transformed cell line and might somehow also be involved in its 
regeneration source. Moreover, the down-regulation of Lgr5 expression in migratory 
cells is reminiscent to the down-regulation of the stem cell marker Musashi-1 in 
migratory IEC-18 cells (Znalesniak et al., 2009), and speaks against the acquisition of 
stem cell characteristics in these migratory cells. As a consequence, this also suggests 
that migratory RGM-1 cells do not undergo the EMT. Furthermore, the typical EMT 
markers, E-cadherin and N-cadherin showed unstable or non-significant alterations in 
migratory cells compared with stationary cells (data not shown), which is in line with the 
reports on the IEC-18 cell line (Znalesniak & Hoffmann, 2010; Znalesniak, 2013). 
Besides, the RGM1 cells show mostly coherent cell migration with few individual 
pioneer cells moving at the migration front (Figure 4). Therefore the down-regulation of 
E-cadherin expression is not expected, as the cells do not loose their cell-cell contacts 
with exception of pioneer cells at the migratory front. This is consistent with previous 
studies, which show that EMT is not complete in the restitution/wound healing process 
(Schäfer & Werner, 2008; Znalesniak et al., 2009). 
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The lack of clear EMT in migratory RGM-1 cells is also supported by the expression of 
vimentin, which is comparable in stationary and migratory cells. Moreover, the elevated 
expression of cyclin A2 in migratory cells is another indication against EMT because 
cyclin A2 is reported to be instrumental in preventing EMT (Bendris et al., 2012). 
However, the significant down-regulation of Muc16 in migratory cells could point 
towards a partial EMT because the knockdown of Muc16 (also known as cancer 
antigen 125 (CA125)) in ovarian cancer cells has been reported to alter epithelial and 
mesenchymal markers, cell motility and migration (Comamala et al., 2011). 
Furthermore, up-regulation of α-SMA, which is a typical mesenchymal marker (Kalluri 
& Weinberg, 2009), could also be a sign for a partial EMT in migratory RGM-1 cells. 
5.1.1.2 Tff1 plays a role in restitution in vitro 
In a functional test of Tff1 during restitution process, RGM-1 cells were transfected with 
the Tff1-siRNA in the scratch wounding assays. As shown in Figure 17, the in vitro 
restitution was impaired by all three siRNA duplexes and this effect increased with the 
concentration of the siRNA duplexes. Tff1 expression was dramatically reduced in 
these cells as expected (Figure 19). The significant down-regulation of α-SMA 
expression in Tff1-siRNA2-transfected cells indicates that the differentiation of RGM-1 
cells into a migratory phenotype was negatively affected by Tff1-siRNA2 (Figure 19). 
Insufficient endogenous Tff1 in RGM-1 cells strongly decreased their migration (Figure 
18). This result is in agreement with that of TFF1 knockdown experiments using 
shRNA analyzing the migration of MCF-7 (human breast adenocarcinoma cell line) and 
ZR75.1 (human breast carcinoma cell line) cells in transwell chambers (Buache et al., 
2011). Therefore, Tff1 is a motogenic factor, which probably has a function in vivo 
during restitution of the gastric mucosa by SMCs and during self-renewal. Particularly, 
a possible up-regulation of TFF1 synthesis in migratory SMCs in vivo would be an ideal 
mechanism to specifically enhance restitution only where topologically needed and to 
minimize eventual negative side effects of TFF1 such as cell scattering and 
invasiveness. 
In summary, the up-regulation of Tff1 expression in migratory RGM-1 cells after the 
wounding indicates that secretory Tff1 directly supports cell migration by an 
autocrine/paracrine mechanism. This is consistent with the observation by Znalesniak 
et al. (2009) that migratory IEC-18 cells up-regulated the expression of genes that 
support cell migration in many ways, such as plasminogen activator inhibitor-1 (Pai-1), 
transforming growth factor α (Tgfα), heparin-binding EGF-like growth factor (Hb-Egf), 
ornithine decarboxylase (Odc), and α-Sma. Moreover, the reduced migration after 
knockdown of Tff1 by RNAi demonstrates the important role of Tff1 during the 
restitution process. In addition, Tff1 may also play a role in regulating the inflammatory 
response through suppression NF-κB–mediated inflammation. 
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5.1.2 Tff3 plays a role in the intestinal immune response in vivo after 
oral T. gondii infection 
There are numerous in vivo studies indicating the protective and healing effects of TFF 
peptides in the GI tract (Hoffmann & Jagla, 2002; Kjellev, 2009; Hoffmann, 2013a). 
Some studies also reported a function in the modulation of the immune response, 
especially for TFF2 (Baus-Loncar et al., 2005a, 2005b). TFF2 and TFF3 are found not 
only in the gastric mucosa, but also in lymphoid tissues and can stimulate the migration 
of monocytes (Cook et al., 1999; Kurt-Jones et al., 2007). Some in vitro studies are 
indicative for a possible function of TFF2 and TFF3 in the recruitment of leukocytes 
during mucosal inflammation (Graness et al., 2002).  
To further test the possible function of TFF3 in the immune responses, a mouse model 
for the T. gondii induced type 1 immunity was used including the Tff3
KO
 and 
corresponding wild type mice. The significant down-regulation of Th1 involved 
cytokines induced by T. gondii parasite, e.g., Ifnγ, Il-12αp35-2, IL-1β, Il-10 and Tnfα in 
the Tff3
KO
 mouse ileum indicates that the absence of Tff3 reduced the immune 
response and the intestinal inflammation in the mouse ileum (Figure 21). Both Ifnγ and 
Il-12, as well as Tnfα, which is essential for the activation of macrophages, are critical 
for the T. gondii induced inflammation and immune response (Denkers & Gazzinelli, 
1998; Stafford et al., 2002). Here, the significantly reduced up-regulation of these 
cytokines clearly demonstrated a depleted immune reaction in the Tff3
KO
 mice ileum 
after T. gondii infection. Moreover, Il-1β is required for the production of Ifn-γ by NK 
cells (Hunter et al., 1995), so it might be speculated that Tff3 could play a role in the 
reaction of NK cells after T. gondii infection based on the down-regulation of both Ifn-γ 
and Il-1β when in the absent of Tff3. 
This conclusion is in line with the hematoxylin and eosin (H&E) staining (Figure 36; 
performed by Dr. I. Dunay (IMMB) and PD Dr. T. Kalinski (IPA), Magdeburg), as well 
as with the CD4 immunostaining (data not shown, performed by PD Dr. T. Kalinski) in 
both infected Tff3
KO
 and corresponding wild type mice ileum. In the ileum of Tff3KO mice, 
the H&E staining revealed a more preserved epithelial structure and a significantly 
increased villi height (Figure 36). Furthermore, a semi-quantitative evaluation of CD4 
immunostaining showed a significant decrease of CD4 expression (data not shown; 
both data were provided by PD Dr. T. Kalinski). 
In summary, this study demonstrates the function of Tff3 as a positive regulator in the 
immune response after T. gondii infection. Interestingly, in contrast, Tff2 peptide was 
reported to antagonize IL-12 release from DCs and macrophages and to negatively 
regulate type 1 immunity against T. gondii in the intestine after the oral infection 
(McBerry et al., 2012). Several groups have also reported that application of 
recombinant TFF peptides, especially TFF2, can reduce inflammatory indices in animal 
models of colitis (Tran et al., 1999; Giraud, 2000; Soriano-Izquierdo et al., 2004). Thus, 
TFF2 and TFF3 might have different roles in the intestinal immune system.  
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Figure 36: H&E staining of mouse ileum after T. gondii infection 
Typical H&E staining of mouse ileum after the oral infection with T. gondii (3 cysts, for 7 days). (A) 
Ileum section of wild type mice, (B) ileum section of Tff3
KO
 mice. The villi height is indicated by 
dashed lines. The histological staining showed here was performed by Dr. I. Dunay. All sections 
were stained and photographed under the same conditions. Scale bars: 50 µm 
TFF3 is typically secreted by intestinal goblet cells (together with MUC2). Recently, 
MUC2 was reported to have an immunoregulatory function in the gut by mitigating the 
inflammatory response in DCs (Belkaid & Grainger, 2013; Shan et al., 2013). Thus, a 
role of TFF3 for the intestinal immune response is within the limits of expectation, i.e., 
by regulating the response of DCs. 
Of note, the different immune responses in the ileum of Tff3
KO
 mice when compared 
with the corresponding wild type mice appeared only in the early stage (7 days) after 
very low-dose (3 cysts) oral infection with T. gondii. In a comparison test (data not 
shown), an extended duration of infection (up to 11 days) and an increased number of 
cysts (up to 10 cysts) eliminated the effect of Tff3 on intestinal inflammation. Moreover, 
infection with different cyst numbers and duration resulted also in different immune 
responses in the mouse brain. The expression of inflammation markers, such as Ifnγ, 
Il-12, IL-1β and Tnfα, was not distinctly changed in the brain 7 days after the oral 
infection with 3 cysts; whereas these markers were significantly up-regulated 11 days 
after the oral infection with a higher dose (10 cysts; data not shown). This is an 
indication for the different extent of T. gondii infection throughout the body under 
different conditions. Furthermore, Tff3 might play a role in the immune response of the 
ileum only at the very early stage of T. gondii infection, before the parasites reach the 
brain.  
Additionally, the expression of Tff2 mRNA was down-regulated in Tff3
KO
 mice (Figure 
21). This is in line with a previous study, which demonstrates reduced Tff2 expression 
in gastric antrum of Tff3
KO
 mice, suggesting a intercalated regulation of the TFF 
transcripts (Taupin et al., 1999).  
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5.2 TFFs in the CNS system 
5.2.1 Cerebral TFF expression in a mouse model of Toxoplasma 
encephalitis 
5.2.1.1 Expression profile of Tffs in the mouse brain after T. gondii 
infection 
Although previous studies showed expression of TFF peptides in the murine brain, the 
precise localization and function of TFF peptides in the CNS is still largely unclear. In 
order to better understand the expression of TFFs in the brain during inflammatory 
conditions, a gene expression analysis was performed using a mouse model of TE. In 
line with previous reports, the transcripts of Tffs, especially Tff1 and Tff3, were found to 
be predominantly expressed in the cerebellum (Figure 25). The immunostaining of 
mouse brain slices (Figure 26) revealed a localization of Tff1 in the cerebellum 
(especially in the granular layer and probably also in Purkinje cells). These results 
indicate a neuronal expression of Tff1 in the mouse brain and are consistent with the 
expression pattern shown in the rat brain (Hirota et al., 1995; Jensen et al., 2013). A 
tendency of decreased staining of Purkinje cells (number, form) was observed in T. 
gondii infected brain slides (Figure 26a-d), which is consistent with a previous study 
demonstrating that the Purkinje cell layer was markedly affected in the form of 
disfiguring and focal loss of cells with apoptotic and necrotic changes after the T. gondii 
infection (El-Sagaff et al., 2005). In line with this, many studies demonstrated a 
decrease in Purkinje cells (number, volume or density) after various infections (Jamroz 
et al., 2009; Shi et al., 2009; Wallace et al., 2010; Sugiura et al., 2011; Campeau et al., 
2013). Moreover, both the results from RT-PCR analysis (Tff1 expressed 
predominately in cerebellum) and immunostaining (increased Tff1 expression in the 
mouse brain after T. gondii infection) were comparable with in situ hybridization studies 
performed by Dr. E. Znalesniak (IMMC, Magdeburg; personal communication). 
Of special note, Tff2 transcription was significantly increased in the brain of Tff1
KO
 mice 
(Figure 25). Here, for the first time, the different expression of Tff2 transcripts has been 
identified in the brain of Tff1
KO
 mice when compared with wild type mice. In contrast, 
the expression of Tff2 in the stomach does not show a significant difference between 
Tff1
KO
 and wild type mice. Conversely, other studies reported that, a lack of TFF1 
induced dramatic inhibition of TFF2 expression in the stomach (Karam et al., 2004; 
Tomasetto & Rio, 2005). The mechanism of how the lack of Tff1 regulates the 
increased expression of Tff2 in the brain is still unclear. As an immediate early gene, 
TFF2 is capable of regulating its own expression through activation of the TFF2 
promoter (Bulitta et al., 2002); the TFF2 promoter can also be activated in response to 
stimulation with both TFF2 and TFF3 peptides (Taupin et al., 1999). Some factors were 
demonstrated to regulate Tff2 expression through the Tff2 promoter. For example, the 
zinc finger transcription factor Sp3, which was reported to be associated with the TFF1 
promoter in MCF-7 cells together with Sp1 (Sun et al., 2005), was also bound to the 
TFF2 promoter and acted as a negative regulator that attenuated the transcriptional 
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activity of the TFF2 gene (Liu et al., 2012). Moreover, the upstream stimulating factor 
(USF) acts as a positive regulator targeted at the Tff2 promoter (Al-azzeh et al., 2002). 
A GAG motif could be responsible for mediating promoter activation in response to 
TFF2 stimulation (Bulitta et al., 2002) and a CCAAT sequence as a cell line-specific 
cis-acting regulatory element may contribute to the high level expression of TFF2 in 
MCF-7 cells (Chi et al., 2004). Additionally, H pylori infection increases DNA 
methylation at the Tff2 promoter, which reduces the antral expression of Tff2 (Peterson 
et al., 2010). Furthermore, administration of aspirin induces activated protein kinase C 
and eventually modifies (directly or indirectly) transcription factors acting on elements 
of the 5’-flanking region of TFF2, resulting in the up-regulation of TFF2 transcription 
(Azarschab et al., 2001). 
To be mentioned, the immunostaining of T. gondii parasites in the untreated control 
brain slides also shows some slight positive signals at the marginal zones, i.e., the 
meninges (Figure 24 A, C, E). This staining is probably non-specific because T. gondii 
was reported to be found predominantly in the grey matter of the mouse brain 
(Ferguson & Hutchison, 1987). Moreover, the location of these slight signals was not 
reproducible on parallel slides. This also points to a non-specific staining of the 
meninges.  
5.2.1.2 Tffs may play a role in the CNS for the immune response 
IBA1, as typical marker for microglia, is particularly elevated in the activated status of 
the microglial cells during the immune response (Ito et al., 1998, 2001). The 
up-regulation of Iba1 in the brain after T. gondii infection (Figure 28, Figure 29) is a 
clear indication for the activation of microglial cells, which are specialized 
macrophages acting as the first and main form of active immune defence to protect 
neurons in the CNS (Brodal, 2010). This result is consistent with previous in vitro 
studies, which indicate that the tachyzoites can invade microglia of the mouse brain 
after the T. gondii infection (Fischer et al., 1997). Interestingly, in the uninfected group, 
the expression level of Iba1 in the cerebellum is significantly higher in Tff2
KO
 mice 
when compared with the wild type (Figure 28, Figure 29). Thus demonstrates that the 
absence of Tff2 positively regulates the inflammation in the cerebellum. This is in line 
with studies that show a higher baseline level of intestinal inflammation markers, e.g., 
Il-1β, in Tff2
KO
 mice (Kurt-Jones et al., 2007). Moreover, there are reports 
demonstrating that TFF2 antagonizes Il-12 release from DCs and macrophages and 
negatively regulates type 1 immunity in the intestine after the oral infection with T. 
gondii (McBerry et al., 2012).  
A significant up-regulation of the IL-12–mediated type 1 inflammatory cytokine Ifnγ as 
well as Cd8 (typical of cytotoxic T-cells and DCs) was observed in the cerebellum of 
Tff2
KO
 mice when compared with wild type mice. This is again an indication for a 
function of Tff2 in the immune response of the CNS as a negative regulator of the type 
1 cytokine release from T lymphocytes and DCs in the T. gondii pathogenesis (Figure 
28). 
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Furthermore, the up-regulated Tff1 expression (on both transcript and protein levels, 
Figure 25, Figure 26) in the mouse brain, particularly in the cerebellum, after T. gondii 
infection is a first hint that Tff1 might also be involved in inflammatory processes of the 
brain. Based on the localization-studies presented in Figure 25 (Tff1) and Figure 28 
(Iba1), no co-expression was detectable off hand. Iba1 is a typical microglial protein 
(Ito et al., 1998), whereas Tff1 is probably of neuronal origin (Lein et al., 2007; Jensen 
et al., 2013).  
In conclusion, the results of this study strengthen the connection between Tff2 and the 
immune system in the CNS and are also consistent with the published data indicating 
that Tff2 acts as a negative regulatory factor of the immune responses. In the CNS, 
Tff2 appears to function as an anti-inflammatory peptide which also plays a role after 
i.p. T. gondii infection. Furthermore, the up-regulation of Tff1 particularly in the 
cerebellum after T. gondii infection is currently enigmatic and might also be an 
indication for a function during inflammatory processes. However, further 
investigations are required to clarify the function of TFF1. For example, an in vitro 
model of inflammation based on primary cell cultures from Tff1-deficient mice brain 
could be established. The examination of inflammatory parameters in the blood and 
liquor cerebrospinalis during the inflammatory processes in wild type and Tff1
KO
 mice 
would also be helpful for the understanding of the function of Tff1 in the immune 
system. 
5.2.2 TFF3 is expressed in primary cell cultures of rat brain 
In the past, TFFs have been demonstrated to be expressed in the CNS and a function 
as neuropeptides has been proposed. However, the precise cellular origin of TFFs in 
the brain has not been determined unambiguously (Hoffmann et al., 2001; Hoffmann & 
Jagla, 2002). In this study, immunofluorescence analysis on rat brain primary cell 
cultures clearly showed the neuronal expression of TFF3 based on the co-localization 
with MAP2 (neuron marker; Figure 30). In contrast, astrocytes, defined by their GFAP 
immune reactivity, clearly did not show any specific staining for TFF3 (Figure 32). As a 
neuropeptide, TFF3 expression revealed changes during postnatal cerebellar 
development (Hinz et al., 2004). Moreover, the neuronal expression of TFF3 could be 
the reason for various functions in the CNS: such as a fear modulating effect, a 
function for hearing, motoric skills and learning and memory. Tff3 showed differential 
dose dependent behavioural effects when injected into the basolateral nucleus of the 
rat amygdala: an anxiolytic effect at a low dose and an anxiogenic effect at a higher 
dose (Schwarzberg et al., 1999). Furthermore, a lack of Tff3 resulted in hearing 
impairment and accelerated presbyacusis (Lubka et al., 2008). TFF3 is also concerned 
with behavioural effect, such as various motoric skills (Blaschke, 2010). Also an effect 
on learning and memory has been described in the mouse after i.p. administration of 
TFF3 (Shi et al., 2012). 
Another major result of this study is that TFF3 is synthesized by microglial cells as well 
(co-localization with IBA1). Microglia is an integral part of the immune system. The 
co-localization of TFF3 probably indicates that TFF3 may act also as a regulator of the 
Discussion 
 81 
immune response in the CNS (Figure 33, Figure 35). This would be related to the 
previous result demonstrating function of Tff3 in the immune response of the intestine 
after T. gondii infection (see chapter 5.1.2). To elucidate a possible role of TFFs in 
immune response, also a Lipopolysaccharides (LPS) administration model for neural 
inflammation was applied. A similar model has been described previously in vivo 
(mouse model) and in vitro (e.g., primary mixed glial cell cultures, microglia cell lines 
N9; Candelario-Jalil et al., 2007; Qin et al., 2007; Lu et al., 2010). The up-regulation of 
Ifnγ, Il-10 and Tnfα was observed 24h after incubation with various concentrations 
(500/1000/1500/2000 ng/mL) of LPS, which is indicative for the inflammatory 
processes in the cells. However, no appreciable change of the Tff3 expression was 
found in all cell cultures after the LPS treatment. Furthermore, the LPS challenge did 
not induce Tff1 or Tff2 (data not shown).  
The dissociated primary neural or glial cell cultures are prevalent and crucial research 
tools allowing access to individual cells for studies. In spite of the advantages, in vitro 
cell culture has also limitations in reproducing the natural environment. Therefore, the 
lack of expression of Tff1 or Tff2 in the primary cultures from cortex or hippocampus 
could result from the absence of adequate dynamic interactions. 
5.3 Future prospects 
The results from this study present the base for future investigations concerning the 
function of TFFs, particularly in the immune system and the CNS. TFF3, as a 
constituent of the mucus, was shown to have a function in regulating the intestinal 
immune response. Thus, it will be interesting to clarify the mechanism of how TFF3 
activates DCs and to test whether TFF3 plays a role in chronic inflammatory diseases 
of the gut. Furthermore, it will be challenging to study the function of TFF3 as a 
secretory product of neurons as well as of microglial cells in the brain. Moreover, to 
analyze the nature of the complementary regulation of TFF1 and TFF2 in the brain and 
the functional consequences are interesting goals. 
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6 Summary / Zusammenfassung 
Summary 
The trefoil factor family peptides (TFF1, -2 and -3) are mainly expressed by mucous 
epithelial cells and are predominantly found in the gastrointestinal (GI) tract as 
exocrine products. TFFs are expressed also in the central nervous system (CNS). 
Previous studies demonstrated protective and healing effects of all three TFF peptides 
after various mucosal damages in the GI tract and also their participation in immune 
responses and inflammatory processes. TFFs show various behavioural effects in the 
CNS as well. Generally, this study was designed to gain more insights into the 
expression and function of TFFs in the GI tract and the CNS considering four different 
aspects:  
(1) The migration of epithelial cells is the major component of mucosal restitution 
occurring in the early phase of mucosal repair. Here, in an in vitro model of gastric 
restitution (scratch wounding of the non-transformed cell line RGM-1), separated 
stationary and migratory cells were compared. Surprisingly, Tff1 (a differentiation 
marker for gastric surface mucous cells) was significantly up-regulated in migratory 
RGM-1 cells. Furthermore a knock-down of Tff1 by the means of RNA interference 
significantly diminished migration of RGM-1 cells. This clearly points to a motogenic 
function of TFF1 during restitution.  
(2) Gene expression was investigated in a mouse model of induced ileitis after 
low-dose oral Toxoplasma gondii (T. gondii) infection. A comparison between Tff3
KO
 
and wild type mice revealed that the inflammatory response is significantly reduced in 
Tff3
KO
 mice. Thus, the mucus constituent Tff3 seems to play an essential role in 
activating dendritic cells after T. gondii infection.  
(3) In order to gain new insights into the expression and role of TFFs in the CNS during 
inflammatory conditions, different Tff
KO
 mice and wild type mice were compared in a 
model of induced encephalitis after i.p. T. gondii infection. Here, Tff1 was significantly 
up-regulated particularly in the cerebellum after T. gondii infection. Of note, the 
up-regulation of Tff1 was even higher in Tff2
KO
 mice. Furthermore, genes typical of 
inflammation showed no different regulation between Tff1
KO
, Tff2
KO
 and wild type mice 
after T. gondii infection implying that Tff1 plays no direct role in this process. However, 
a significant up-regulation of interferon-γ in the cerebellum was higher in Tff2KO mice 
when compared with Tff1
KO
 and wild type mice indicating a function of Tff2 in the 
immune response of the CNS as a negative regulator. 
(4) In order to elucidate which type of cells (neurons, astrocytes and microglial cells) 
express TFFs, primary cell cultures from the rat cortex or hippocampus were 
investigated. Double immunofluorescence analysis together with MAP2 clearly showed 
the neuronal expression of TFF3. In contrast, astrocytes (GFAP positive cells) showed 
no specific TFF3 staining. Furthermore, TFF3 was synthesized by microglial cells as 
well, based on its co-localization with IBA1. Thus, TFF3 is a typical neuropeptide, 
which could also act as a regulator of the immune response in the CNS. 
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Zusammenfassung 
Die Peptide der trefoil factor family  (TFF1, -2 und -3) werden überwiegend von 
mukösen Epithelzellen exprimiert und sind hauptsächlich im gastrointestinalen (GI) 
Trakt als exokrine Produkte zu finden. Außerdem werden TFFs im zentralen 
Nervensystem (ZNS) exprimiert. Frühere Studien haben protektive und heilende 
Effekte von allen drei TFFs nach verschiedenen Schäden an mukösen Epithelien im 
GI-Trakt gezeigt sowie eine Beteiligung von TFFs bei der Immunantwort und 
Entzündungsprozessen nachgewiesen. Außerdem zeigen TFFs verhaltensbiologische 
Effekte nach Applikation in das ZNS. Daher wurde die vorliegende Arbeit darauf 
ausgelegt neue Erkenntnisse über die Expression und Funktion von TFFs im GI-Trakt 
und ZNS unter Berücksichtigung von vier verschiedenen Modellsystemen zu erlangen:  
(1) Die Migration von Epithelzellen ist die Hauptkomponente der mukosalen 
Restitution, die in der frühen Phase der mukosalen Reparatur stattfindet. 
Dementsprechend wurde ein in vitro-Modell für die Restitution des Magens (scratch 
assay von nicht-transformierten gastrischen epithelialen RGM1-Zellen) benutzt, um 
stationäre und migrierenden Zellen zu vergleichen. Dabei zeigte sich eine signifikante 
Hochregulierung von Tff1 (ein Marker für die Differenzierung von 
Oberflächenepithelzellen) in migrierenden RGM1-Zellen. Ferner bewirkte ein 
Knockdown von Tff1 durch RNA-Interferenz eine deutliche Verringerung der Migration 
von RGM1-Zellen, was auf eine motogene Funktion von Tff1 während der Restitution 
hindeutet. 
(2) Ein Maus-Modell für induzierte Ileitis nach gering dosierter oraler Toxoplasma 
gondii-Infektion wurde für Gen-Expressions-Untersuchungen verwendet. Der Vergleich 
von Tff3
KO
-
 
mit Wildtyp-Mäusen ergab eine signifikante Reduzierung der 
Entzündungsantwort. Dies weist darauf hin, dass Tff3 als Bestandteil des Mukus eine 
entscheidende Rolle bei der Aktivierung von dendritischen Zellen nach einer Infektion 
mit T. gondii zukommt. 
(3)  Um die Expression und Funktion von TFFs im ZNS unter entzündlichen Bedingen 
zu analysieren wurden mit Hilfe eines Maus-Modells für induzierte Enzephalitis (nach 
intraperitonealer T. gondii-Infektion) verschiedene Tff
KO
- mit Wildtyp-Mäusen 
verglichen. Es zeigte sich eine signifikante Hochregulierung von Tff1 nach Infektion mit 
T. gondii, insbesondere im Cerebellum, die in Tff2
KO
- Mäusen bemerkenswerterweise 
am höchsten war. Hinzu kommt, dass charakteristische Entzündungensgene keine 
Unterschiede in der Regulation zwischen Tff
KO
-, Tff2
KO
- und Wildtyp-Mäusen nach 
Infektion mit T. gondii aufwiesen. Dies könnte darauf hindeuten, dass Tff1 keinen 
unmittelbaren Einfluss auf die Entzündungsreaktion hat. Dennoch wurde eine 
signifikante Hochregulierung von Interferon-γ im Cerebellum von Tff2KO-Mäusen im 
Vergleich zu Tff1
KO
- und Wildtyp-Mäusen beobachtet, was ein Hinweis für die Aufgabe 
von Tff2 als negativer Regulator bei der Immunantwort des ZNS sein könnte. 
(4) Um aufzuklären, welche Zell-Typen (Neuronen, Astrozyten und Mikrogliazellen) 
TFFs exprimieren, wurden Primärzellkulturen des Ratten-Cortex bzw. Hippocampus 
untersucht. Doppel-Immunofluoreszenz-Analysen mit MAP2 zeigten deutlich die 
neuronale Expression von TFF3, wohingegen Astrozyten (GFAP-positive Zellen) keine 
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spezifische TFF3-Färbung zeigten. Weiterhin wurde nachgewiesen, dass TFF3, 
beruhend auf der Co-Lokalisation mit IBA1, von Mikrogliazellen synthetisiert wird. 
Folglich könnte TFF3 als Neuropeptid außerdem als Regulator bei der Immunantwort 
des ZNS agieren.  
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Appendix  
Appendix I: Body weight of the various mouse strains used in this study  
Body weight analysis of all Tff-deficient mice as well as their corresponding wild types 
was performed. 129/Sv wild type mice (n = 10), Tff1
KO
 mice (n = 26), Tff2
KO
 mice (n = 
14) and wild type mice corresponding to Tff3
KO
 mice with mixed background of 129/Sv 
and C57BL/6 (n = 40, 28 males and 12 females) and Tff3
KO
 mice (n = 31, 21 males and 
10 females) were used for the analysis (12 – 16 weeks old). The results show that 
Tff2
KO
 mice have a significantly reduced body weight (p = 1.56x10
-3
); whereas Tff3
KO
 
mice showed a significantly increased body weight (A). According to a gender analysis, 
the male Tff3
KO
 mice show a greater increase than the female mice (B).   
A: Body weight analysis of all three mouse lines:  
B: Body weight analysis sorted by gender (Tff3
KO
 mice)  
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Appendix II: Pedigree of the Tff3
KO
 mouse strain   
Tff3
KO
 mice used in this study originated from the Tff3-deficient (Tff3
KO
) mice with a 
mixed background of 129/Sv and C57BL/6 (Lubka et al., 2008; Blaschke, 2010). The 
original strain has been described by Mashimo et al. (1996). In order to generate wild 
type (WT) and Tff3
KO
 mice with nearly identical genetic background, mice 
heterozygotes (HT) for Tff3 were crossed for more than 10 generations. The numbers 
refer to the mice used for the breeding. Both mice for each pairing originated from the 
same parents. The generation number of each pairing is indicated in parentheses on 
the right side. Pairings of wild type mice are shown in blue, Tff3
KO
 mice are shown in 
red and the heterozygote mice are shown in black. The yellow background indicates 
the origin of the mice used in this study. 
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Appendix III: Sequencing of Tff1 and Tff2 (RT-PCR products from mouse 
brain) 
This DNA sequencing was performed via commercial sequencing services of Institut 
für Biologie (Abt. Genetik), Humboldt Universität Berlin. The accuracy of the 
sequences was verified by the online software “Pairwise Sequence Alignment” on: 
http://www.ebi.ac.uk/Tools/psa/emboss_needle/nucleotide.html.  
Results are shown as follow: 
primer forward 
primer reverse 
stop codon 
unpaired base 
#======================================= 
# Aligned_sequences: 2            
# 1: RT-PCR product of Tff1 from mouse brain   
# 2: NM_009362.2, Mus musculus trefoil factor 1 (Tff1), mRNA   
#======================================= 
 
 
 
  iv 
#======================================= 
# Aligned_sequences: 2                   
# 1: RT-PCR product of Tff2 from mouse brain      
# 2: NM_009363.3, musculus trefoil factor 2 (Tff2), mRNA   
#======================================= 
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